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ABSTRACT
The steroid/thyroid hormone receptor superfamily is a large class of ligand-
dependent transcription factors that plays a critical role in regulating the expression of
genes involved in a broad range of physiological functions, including development
homeostasis , and reproduction. In the absence of cognate hormone, several receptors are
able to repress transcription below the basa11evel via the recruitment of the nuclear
receptor corepressors SMRT and NCoR. Upon hormone binding by the receptor, the
corepressor complex is dissociated and a coactivator complex is subsequently recruited.
This thesis details the mechanisms by which receptor-associated coactivator 3 (RAC3)
interacts with nuclear receptors , particularly the vitamin D, estrogen, and retinoid
receptors , and modulates their transcriptional activity. It was discovered that these
receptors interact with different a-helical LXXLL motifs ofRAC3 in vitro. Mutation of
specific motifs differentially impairs the ability ofRAC3 to enhance transcription by the
receptors in vivo. In addition , the intrinsic transcriptional activation function ofRAC3
was also characterized. Here , a single LXXLL motif, NR box v , was found to be
essential to activation by serving as a binding surface for the general transcriptional
integrator CBP/p300. Finally, the cofactor binding pocket of retinoid receptors 
was
characterized. It was demonstrated that, to a large extent, the coactivator pocket of
RAa overlaps with the corepressor pocket, with the exception of helix 12 , which is
required for coactivator, but not corepressor binding. Recruitment ofRAC3 or SMRT
also correlates directly with the ability ofRAa to activate or repress transcription
respectively. Intriguingly, it was discovered that the AF-2 domain ofRXa inhibited
cofactor binding to RXRa heterodimers, for deletion of this domain dramatically
enhanced RAC3 and SMRT binding. In addition, it was demonstrated that the 
RXa
cofactor binding pocket contributed minimally to recruitment of cofactors. Conversely,
the AF-2 domain of the partnering monomer and its cofactor pocket were required for
these interactions. These findings suggest that the partner of RXa is the primary
docking point for co factors at RXa heterodimeric complexes. Taken together, this
work contributes significantly to the field of nuclear receptor function in detailing the
mechanisms by which the coactivator RAC3 is recruited to nuclear receptors and
regulates their transcriptional activity.
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ACTR activator of thyroid receptor
activation domain
AF- 1/AF- activation function 1/2
AIBI amplified in breast cancer
androgen receptor
bHLH basic helix-loop-helix
CARI coactivator-associated arginine
methyltransferase 1
CBP cAMP response element binding protein
DBD DNA binding domain
direct repeat
DRIP VD R - interacting proteins
ERp estrogen receptor beta
ERE estrogen response element
glucocorticoid receptor
GRIP 1 glucocorticoid receptor-interacting
protein 1
GST gl utathione-S- transferase
HAT histone acetyltransferase
HDAC histone deacetylase
LBD ligand binding domain
mineralcorticoid receptor
NCoA nuclear receptor coactivator
NCoR nuclear receptor corepressor
NR box nuclear receptor binding box
PAS Per-ART-Sim domain
PCAF p300/CBP associated factor
pCIP p300/CBP co integrator-associated protein
PGC- peroxisome proliferator activated
receptor coactivator 1
PPAR peroxisome proliferator activated receptor
progesterone receptor
RAC3 receptor-associated coactivator 3
RAa retinoic acid receptor alpha
RID receptor-interacting domain
RXRa retinoid X receptor alpha
SMRT silencing mediator for retinoic acid
and thyroid hormone receptors
SRA steroid receptor RNA activator
SRC steroid receptor coactivator
TIF2 transcription intermediary factor 2
thyroid hormone receptor
TRA TR -associated proteins
VDR vitamin D receptor
VDRE vitamin D response element
CHAPTER I
BACKGROUND
A. Steroid/Nuclear Receptors and Hormone Action
Steroid hormones are small lipophilic molecules that elicit a wide range of
biological responses through interaction with the steroid/nuclear hormone receptor
superfamily, whose members act as ligand-dependent transcription factors that regulate
the expression of hormone target genes. The process by which these molecules carr out
their physiological activity is a multi-step one that begins with the arrval of the steroid 
its target cell via a plasma transport protein. Upon dissociation from the plasma protein
the hormone is able to diffuse through the cell membrane due to its lipophilic character
where it wil bind to the receptor in the cytoplasm or continue through the nuclear
membrane to interact with a receptor in the nucleus (1). Cytoplasmic receptors are then
able to translocate to the nucleus, where they bind specifically to cognate hormone
response elements (HREs) in the promoters of target genes. It is believed that those
receptors that are located primarily in the nucleus are constitutively bound to their
response elements , for they are able to repress transcription below the basal level in the
absence of ligand. Hormone binding by all of these receptors converts them into
transcriptional activators that enhance the expression of target genes by mechanisms that
include the recruitment of co activator molecules , which wil be discussed in detail in this
work.
The steroid/nuclear receptor superfamily can be further subdivided into three
classes of nuclear receptors. Type I or steroid receptors include those for estrogens (ER),
progestins (PR), androgens (AR), glucocorticoids (GR), and mineralcorticoids (MR).
Type I receptors are coupled to heat shock proteins and sequestered to the cytoplasm in
the absence of ligand (1). Upon hormone binding, they dissociate from the heat shock
proteins , homodimerize, and trans10cate to the nucleus , where they bind response
elements consisting of palindromic repeats (2). The ER recognizes a half-site with the
sequence AGGTCA while the GR, MR, PR, and AR all recognize the same element
which contains the sequence AGAACA as the half-site. This observation raises the
question of specificity, which may be explained by differential expression ofthe
receptors themselves. It is also possible that residues flanking the half-site contribute to
the recruitment of specific receptors to target gene promoters. Type II receptors include
those for all-trans retinoic acid (RA), thyroid hormone (TR), and vitamin D (VDR).
These receptors are strictly nuclear and form heterodimers with the retinoid X receptor
for 9-cis retinoic acid (RXR). They also bind constitutively to response elements
consisting of direct repeats. Intriguingly, all ofthese Type II receptors recognize the
same half-site , which contains the sequence AGGTCA (3). Specificity is determined by
the I-to-5 rule , in which the spacing between each half-site determines which
heterodimer will bind (4). For example, the HREs for the VDR, TR, and RA are
composed of direct repeats spaced by 3 , 4 , or 5 nucleotides respectively. A third class of
nuclear' receptors is the orphan receptors , so-called because endogenous ligands for these
proteins are currently unkown.
The target genes that are regulated by these receptors are involved in a wide array
of biological activities including cell proliferation, differentiation, development
reproduction, and homeostasis (5 , 6). For example , studies on vitamin A-deficient
(V AD) animals have demonstrated that retinoids are required during pre- and postnatal
development and in adult life (7). They are indispensable for growth, reproduction, and
for the maintenance of numerous tissues. These studies were confirmed upon
examination ofRA null mutant mice. Mice lacking RAa or RAy displayed similar
defects as V AD animals , including poor viability, growth deficiency, and male sterility
(8- 10). RA double knockout mice had a much more severe phenotype, as evidenced by
a dramatic reduction in viability (9). These studies demonstrated that retinoic acid is the
active vitamin A derivative and that the effects of vitamin A in vivo are mediated by
RAs.
The physiological functions of vitamin D and the VDR are also fairly extensive
(11). The traditional action of vitamin D , as carred out via its metabolite 1 25-
dihydroxy-vitamin D , is to effect calcium and phosphate homeostasis to ensure the
deposition of bone mineral. Vitamin D stimulates calcium and phosphate absorption in
the intestine and reabsorption in the kidney and bone as to increase the concentration of
these ions in the blood. These responses are elicited through target genes that include
osteocalcin, osteopontin, and vitamin D hydroxylase (11). Insensitivity to vitamin D
known as hereditary hypocalcemic vitamin D-resistant rickets (HVDRR), results in a
failure to achieve normal bone density and has been linked to mutation of the VDR in
virtually all cases (12). This strongly suggests that the biological effects of vitamin Dare
mediated by the VDR, as with retinoids and RAs. Furthermore , VDR knockout mice
displayed a phenotype very similar to HVDRR (13 , 14). At various intervals after birth
the mice acquired low bone mass , hypocalcemia, and elevated 1 25-dihydroxy-vitamin D
levels. These effects could be partially rescued with a diet of high levels of calcium and
phosphate. Consistent with the broad biological roles for nuclear receptors , other targets
for vitamin D action have been revealed. For example, vitamin D is thought to be critical
to the differentiation of hematopoietic cells such as HL-60 cells , which are a human
leukemia cell line that differentiates into macrophage-like cells upon hormone treatment
(15 , 16). Similarly, vitamin D appears to affect the maturation and proliferation of
various normal and neoplastic epithelial cells found in several tissues including the
mamary gland, colon, and prostate (11).
The primary actions of estrogens occur in the female reproductive tract. These
responses are elicited through target genes that include the progesterone receptor
prolactin, and c- fos , each of which contains an estrogen response element in their
promoters and whose expression levels are increased by estrogen (6). In ERa knockout
mice (ERKO), female reproductive organs such as the uterus , ovary, and mammary gland
developed fairly normally during the pre- and neonatal stages (17). However
development was severely impaired after puberty, indicating insensitivity to estrogen in
these tissues. Somewhat surprisingly, male mice showed abnormalities in
spermatogenesis and sexual behavior, suggesting an important role for ERa even in male
animals (18). More recently, ERp null animals (BERKO) were generated (19). Female
mice were fertile , but showed reduced ovarian function and decreased litter size. Male
mice were normal until old age, when hyperplasia of the prostate was noted. These
observations are supported by the increased ERp versus ERa levels in prostate and ovary
while increased ERa levels were found in the uterus , vagina, and mamary gland (20).
Furthermore , the a and p knockout mice display opposite responses to estrogen in the
uterus. The ERKO mouse lost responsiveness while the BERKO mouse demonstrated
increased response to estrogen as evidenced by increased cell proliferation (21).
Therefore , ERp may play an antiproliferative role in the uterus and possible function to
counteract the activity of ERa.
Most members of the nuclear receptor superfamily share a common domain
structure (Fig. 1). The N-terminus contains the variable AlB region, which also includes
the ligand-independent activation function- 1 (AF- l) domain. The C region represents the
highly conserved DNA-binding domain (DBD) and is followed by the hinge region (D)
and the C-terminalligand-binding domain (LBD) (E). The LBD consists of 12 a-helices
with helix 12 representing the ligand-dependent activation function-2 (AF-2) domain.
The LBD also mediates dimerization of nuclear receptors. In the absence of ligand
several nuclear receptors are able to repress basal transcription via recruitment of the
nuclear receptor corepressors SMRT and NCoR (Fig. 2) (22 23). SMRT and NCoR are
found in complexes with the corepressor mSin3 and histone deacetylases (HDACs),
suggesting that transcriptional repression by nuclear receptors may involve histone
deacetylation (24-26). Ligand binding triggers the release of these corepressors and
subsequent recruitment of co activators through a drastic conformational change in the
AF-2 domain of the receptor. Structural studies have demonstrated that helix 12 within
the AF-2 domain projects away from the LBD in the unliganded structure (27-30). This
helix rotates nearly 180 to pack tightly against the LBD upon hormone binding in the
, TR, and ER crystal structures. This conformational change, together with ligand-
induced changes in helices 3- , is believed to facilitate interactions of the receptor with
co activators (31-34). Subsequently, co activators are able to enhance transcriptional
activation by the receptor via mechanisms that include recruitment of the general
coactivator CBP/p300 and histone acetylation.
B. Steroid/Nuclear Receptor Coactivators
One of earliest indications that suggested the existence of co activators for
steroid/nuclear receptors was the phenomenon of squelching, in which the presence of a
given, activated nuclear receptor interfered with or inhibited transcriptional activation by
a second, activated receptor in transient transfection assays. These observations led to
the hypothesis that a limiting pool of cellular factors regulated the overall activity of
receptors (35). Subsequent biochemical and expression cloning approaches identified a
large number of factors that were capable of interacting with steroid/nuclear receptors in
a ligand-dependent maner. Many of these factors were also demonstrated to enhance
the transcriptional activation function of the receptors as well, and thus were termed
coactivators. Prominent among these co activators was a class of homologous proteins of
160 kilodaltons , the steroid receptor coactivator (SRC) family (36).
The first member of the SRC family, steroid receptor coactivator- 1 (SRC- l), was
cloned by using the PR-LBD as bait in a yeast-two-hybrid screen of a human B-cell
cDNA library (37). SRC- l interacts in a ligand-dependent maner with and enhances
AF-2 transcriptional activation by a broad range of nuclear receptors , including PR, ER
, RXR, GR, and PP AR. Recent data also detail the enhancement of ER (38) and AR
(39-41) AF - 1 activities by SRC- 1. In addition, SRC- l has been demonstrated to interact
with the general transcription factors TBP and TFIIB , although the functional
consequences of these interactions are unkown (42 , 43). Furthermore, SRC- 1 is able to
enhance transcriptional activation mediated by NF-KB , SMAD3 , and AP- 1 (44-46),
supporting a role for nuclear receptor co activators in multiple intracellular signaling
pathways. Subsequent studies have identified two functionally distinct SRC- 1 isoforms
SRC- la and SRC- , which contain unique C-termini , suggesting that alternative splicing
may regulate SRC- l function(47).
The identification of transcription intermediar factor 2 (TIF2) and GR-interacting
protein 1 (GRIP1) established the SRC family of co activators (48 , 49). TIF2 was isolated
in a Far-western screen as an ER- and RA-interacting factor while GRIPI was isolated
:1,
using the GR-LBD as bait in a yeast-two-hybrid screen. TIF2 and GRIP 1 share 94%
amino acid identity, thus represent the human and murine orthologs , respectively. TIF2
and GRIP 1 associate in vivo with hormone-bound RA, ER, and PR and coactivate
ligand-dependent transactivation. Like SRC- , GRIPI has been demonstrated to enhance
receptor AF- l activity in addition to that of the AF-2 domain (41). A biological role for
GRIPI has been outlined in terms of muscle cell-specific gene expression and
differentiation (50). GRIP1 is overexpressed during muscle cell differentiation and is
required for induction and activation ofthe transcription factors myogenin and MEF-
GRIP1 interacts with these two factors directly and enhances their transcriptional
activation function. Intriguingly, the inv(8)(p 11q 13) chromosomal translocation results
in a fusion between TIF2 and the MOZ gene, which contributes to the pathogenesis of
acute myeloid leukemia (AML), suggesting a role for transcriptional regulation by
nuclear receptor co activators in these leukemias (51).
The third member of the SRC family was reported simultaneously by several groups
as an RA-interacting protein (RAC3), a CBP-interacting protein (p/CIP), a hRp-
stimulatory protein (ACTR), a gene amplified in breast cancer (AIB- l), and a TR-
interacting protein (TRA- I) (52-56). p/CIP represents the mouse homolog while
RAC3/ ACTR/ AIB- lITRA are human isoforms. In addition to co activating many
nuclear receptors , pCIP has also been demonstrated to enhance the activity of interferon-
a and cAMP regulatory element binding protein (CREB), suggesting that this coactivator
may be involved in multiple signaling pathways (53). Furthermore, RAC3/TRA-
expression can be upregulated by hormone treatment, which represents another possible
mechanism by which co activators may potentiate hormone action (57 58). The 26S
proteosome also has been demonstrated to regulate RAC3 expression, in addition to the
levels of SRC- , TIF2 , and CBP (59). The proteosome inhibitor MG 132 enhanced
coactivator levels in HeLa cells , suggesting that co activators may be the target 
ubiquitin-mediated degradation and that protein turnover may contribute to their
transcriptional activity.
Although many other steroid/nuclear receptor co activators have been cloned (see
Discussion), the SRC family has been the focus of the most intense analysis in recent
years. Much evidence exists that supports the role of these cofactors in mediating the
transcriptional activation function of the receptors. Furthermore, a biological role for
SRC members in hormone action has been revealed with the generation of SRC- l and
RAC3 null mutant mice (60 61). Since RAC3/AIB- l is also amplified in breast and
pancreatic cancers , these co activators are likely critical to cell growth and differentiation.
Therefore, understanding the precise mechanisms by which these co factors interact with
receptors and modulate their function will contribute greatly to our knowledge of
hormone-related human diseases and also serve as a potential target for novel
therapeutics.
C. Mechanisms of Nuclear Receptor Interactions with Cofactors
The SRC family of co activators also shares a common domain structure, with the
most highly conserved region being the N-terminal bHLH-PAS domain (Fig. 3A). The
..,
bHLH region functions as a DNA-binding or dimerization surface in many transcription
factors , including the MyoD family of proteins (62 63). The PAS motif is also found in
several transcriptional regulators, including Period (Per), Arl hydrocarbon receptor
(Ah), and single-minded (Sim). Similar to the bHLH domain, the PAS domain also
plays a role in protein-protein interactions and dimerization. However, the function of
the bHLH-PAS domains ofSRC co activators remains unkown, though it is likely to
mediate intra- or intermolecular interactions. This bHLH-PAS domain is followed by a
centrally located receptor-interacting domain (RID) andC-terminal transcriptional
activation domain (AD).
The RID of SRC co activators mediates ligand-dependent , direct interactions with
nuclear receptors (57 , 64 , 65). Detailed analysis of the sequence of the RID identified a
conserved motif, LXXLL, where L is leucine and X is any amino acid, that is termed the
NR box (66). Three such motifs are found in the RID ofSRC co activators with an
additional, non-conserved NR box also present at the C-terminus of the SRC- l isoform
SRC- l a (Fig. 3B). Site-directed mutagenesis and peptide competition experiments have
provided strong evidence for the requirement of these motifs for mediating interactions
between co activators and liganded nuclear receptors (53, 66-68). Furher support for the
role of these motifs in mediating agonist-dependent interactions with nuclear receptors is
found in a study in which phage-displayed peptide libraries were screened for peptides
that interact specifically with agonist or antagonist bound estrogen receptor (69). Many
peptides isolated with estradiol-bound ERa contained the LXXLL motif, while those
isolated with tamoxifen-bound receptor did not. These findings suggest that the
activation of the ERa by tamoxifen that is observed in some tissues might occur via a
different mechanism than estradiol-induced activation, such as through the recruitment of
non-LXXLL containing co activators to tamoxifen-specific surfaces of the ER.
Crystallographic and protein structure prediction analyses have indicated that these
motifs form amphipathic a-helices with the leucine residues comprising a hydrophobic
surface on one face of the helix. The helix is able to interact with the AF-2 domain of the
liganded receptor via a hydrophobic groove made up of residues from receptor helices 3
, and 12 that is the result of the conformational change induced by hormone binding
(Fig. 4) (31- , 53).
The most interesting aspect ofNR box function is the revelation that a receptor-
specific code exists , where different nuclear receptors prefer different NR boxes of the
RID for interaction with co activators (32 , 67 , 68 , 70 , 71). For example , a 13-aa peptide
encompassing GRIP1 motifii efficiently blocked interaction between GRIPI and the
TRp- LBD in vitro while a peptide comprising motif iii was a more potent competitor for
GR binding (32). Similarly, yeast two-hybrid assays demonstrate that mutation ofTIF2
motif ii is most deleterious to interactions with PP ARa while a motif i mutation has the
greatest effect on the TIF2-RXp interaction (70). In most cases , however, mutation of a
single motif does not completely abolish coactivator interaction with nuclear receptors
suggesting that multiple NR boxes contribute to the overall, high-affnity binding to the
receptor. It is likely that the precise arrangement of multiple motifs and structural
nuances of each receptor determine the relative contribution of each NR box to the
interaction.
Other determinants that contribute to NR box selectivity by different nuclear
receptors include residues flanking each NR box. For instance, a chimeric peptide
containing the GRIP 1 NR box iii motif in the context of the flaning sequences ofNR
box ii competed for TR-LBD binding with a similar potency as the peptide comprising
NR box ii (32). Also , using phage-displayed libraries enrched for LXXLL-containing
peptides , it was demonstrated that several subclasses of these peptides exist which
" .
contain different flaning residues and which vary in their abilities to interact with
different ER mutants and other receptors (72). Furthermore, it has been shown that the
flanking N-terminal amino acids are not essential, while the eight residues C-terminal to
the NR box are required for SRC- l mediated coactivation ofRA, TR, and ER (71).
These studies also revealed additional preferences ofER and RA for different NR box ii
terminal amino acids. Intact residues + 12 and + 13 (where L ofLXXLL is + 1) are
two intact NR boxes of co activator for interaction, the spacing between the motifs also
:1,
required for SRC- l rescue of ER activity while residues at +6 , +7 , + 11 , and + 13 are
necessary for rescue ofRA function. Finally, because most nuclear receptors require
can serve as a determinant for recognition. Deletion of 30 of the 50 amino acids between
NR boxes ii and iii abolished the ability of SRC- l to rescue IgG-mediated inhibition of
Interestingly, more recent studies have detailed a similar mechanism of
RA activity (71). In contrast, proper spacing between NR boxes i and ii was required
for coactivation of PP ARy, consistent with the requirement of intact motifs i and ii for
maximal PP ARy transactivation.
interaction for the corepressors SMRT and NCoR with nuclear receptors (73-75). Both
proteins contain LXXLL-like motifs , termed CoRN boxes , in the respective receptor-
. 1 
interacting domains. These motifs have a consensus sequence of LXXI/HIXXXI/L and
also form an a-helix. Mutation ofthese motifs blocked interaction with unliganded 
or TR while peptides corresponding to these motifs were able to compete away the
corepressor-receptor interaction in vitro , implicating the CoRN box as being required
for bipding. In vivo , those mutations that blocked interaction with corepressor also
abolished transcriptional repression by TR. Furthermore, using receptor mutational
analysis and molecular modeling, this domain appears to contact the receptor via the
same hydrophobic pocket that accomodates the NR box of co activators (73). However
due to the extended nature of the CoRNR box, the charge clamp formed by the conserved
glutamate from helix 12 and the lysine from helix 3 may not be required to position this
motif, but rather would inhibit corepressor binding. These observations support previous
studies that demonstrate that helix 12 is not required for corepressor binding (23 , 76).
Overall , it suggests that the coactivator and corepressor binding sites on nuclear receptors
overlap to a large degree and that helix 12 acts as the determining factor that
discriminates between the binding of coactivator or corepressor in the presence or
absence of ligand, respectively.
D. X-ray Crystal Structures
The biochemical studies outlined above clearly implicate the LXXLL motifs of
SRC co activators as being critical to the interaction with and coactivation of nuclear
receptors. Further insight into the molecular basis of these interactions can be found in
the recently solved crystal structures of several nuclear receptor LBDs with coactivator
fragments containing NR boxes. In the structure of TRp- LBD complexed with T3 and a
13-aa peptide encompassing NR box ii of GRIP 1 (32), the leucines of the a-helical NR
box make contacts with a hydrophobic groove consisting of residues from helices 3 , 4
and 12 ofTRp. A single LXXLL peptide interacts with each monomer of the TRp dimer.
Mutagenesis confirms the importance of these receptor residues for in vitro binding of
GRIPI to TRp. A very similar structure is observed with agonist-bound ERa-LBD
complexed with a peptide comprising NR box ii of GRIP 1 (Fig. 4) (31). However, in the
antagonist-bound ERa-LBD structure , helix 12 of the ERa is occluding the coactivator-
binding site, consistent with the inability of SRC co activators to bind antagonist-bound
nuclear receptors. Most strikingly, a region of helix 12 contains an NR box-like sequence
(LXXML) and functions as an intramolecular mimic of the LXXLL motif by making
contact with the hydrophobic groove. Similar results were obtained in the crystal
structure of the heterodimer of the RAa and RXa ligand binding domains complexed
with the RA-specific antagonist BMS614 (77). The extended ring structure of the
ligand prevents helix 12 from adapting the active conformation, but instead positions it in
the coactivator groove where it makes contacts with residues involved in LXXLL motif
binding. Therefore , the coactivator-binding site is not generated. These observations
provide a molecular basis of antagonist function via conformational changes of helix 12
and inhibition of coactivator binding. The structure of the 
PP ARy-LBD homodimer
bound to rosiglitazone and an 88-aa fragment of SRC- l containing NR boxes i and ii has
also been described (34). This study details the function of a "charge clamp" consisting
of a conserved glutamate from helix 12 and lysine from helix 3 of the LBD that positions
the LXXLL motif into the hydrophobic groove of the receptor. In addition, the two NR
boxes of the SRC- l fragment are observed to contact simultaneously the PP ARy dimer
providing further support for the role of multiple motifs in mediating coactivator-receptor
int ractions. Although the biological relevance of the PPARy homodimer is unkown
the coactivator fragment makes similar contacts as those found in the structure ofthe
PP ARy/RXRa ligand binding domains crystallized with an SRC- l peptide, 9-cis retinoic
acid, and the PP ARy ligands rosiglitazone or GI262570 (78). However, in contrast to the
structures of the PPARy homodimer and RARa/RXRa heterodimers , this heterodimer is
asymmetrical at the dimer interface and helix 12 ofPPARy makes contacts with helix 7
ofRXRa. These differences may account for the permissive nature ofPPARRX
heterodimers versus other RXR heterodimers. In the instances ofVDR/, TR/RXR
and RARXR heterodimers , the hormone induced transcriptional activation function of
RXR is suppressed and RXR ligand is actually prevented from binding upon heterodimer
formation. Therefore , RXR is a silent parner and these heterodimers are considered
non-permissive" to RX ligands. However, in the case ofPPAR, both receptors
are individually responsive, or "permissive , to their respective ligands. The additional
contacts between PP AR and RXR noted above may explain these observations since
helix 12 of PP AR may be stabilized by interaction with RX in a position that permits
coactivator binding even in the absence ofPPAR ligand.
E. Mechanisms of Transcriptional Activation by SRC Coactivators
The SRC co activators also contain an intrinsic transcriptional activation function
which is evident upon tethering coactivator to DNA via a heterologous DNA-binding
domain. All three members are able to effciently activate transcription when fused to the
Ga14 DNA-binding domain in both yeast and mammalian cells (48 65). Detailed
deletional analysis has subsequently mapped the activation domain (AD) as being located
terminal to the receptor-interacting domain. Interestingly, this AD also contains 3
additional LXXLL motifs representing NR boxes iv, v , and vi , that have been linked to
interaction with the general transcriptional activators CBP/p300 (Fig. 3). CBP/p300 has
been demonstrated to interact with SRC proteins in vitro and in vivo and mutation of one
or more of the AD NR boxes markedly impairs these interactions, as well as the
,:j.
activation function ofthe coactivator (64 , 71 , 79). Furthermore , microinjection studies
::s'
have shown that anti-CBP antibodies abolish the ability of SRC- l to coactivate RA
suggesting that CBP/p300 is required for the coactivation function ofSRC- l (71). ",n
However, it is worthy to note that additional, CBP-independent transcriptional activation :1.
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domains have also been attributed to members ofthe SRC family, supporting the
existence of multiple mechanisms of transcriptional activation by co activators (41 , 43
64). The contribution of these multiple activation domains to overall coactivator fuction
':!.
is not completely clear, but several studies suggest that co activators may preferentially
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utilize specific ADs depending on the receptor or activation function (AF- l vs. AF-2) that
is mediating the response to hormone (41). In particular, the N-terminal AF- l activation
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domain seems to be most critical to transcriptional activation by the androgen receptor
(AR). SRC- l and GRIPI have been demonstrated to bind and coactivate the AF-
domain ofthe AR (39-41). These interactions are mediated by the C-terminus of the
SRC coactivator, rather than the centrally located domain containing NR boxes i/ii/iii.
Consistent with this observation, mutation of these motifs does not inhibit the ability of
the coactivator to enhance transcriptional activation by the full-length AR, but only the
isolated AF-2 domain (39 , 40). This AF- l interacting domain also lacks the CBP-
interacting domain of the coactivator, thus coactivation of AF - 1 likely occurs via
mechanisms other than CBP recruitment , but through additional coactivators , such as
CARI (see below), which also binds the C-terminus of GRIP 1 (80). Interestingly, the
terminus of the AR also can interact with the C-terminal AF-2 domain and is required
for both AF-2 induced transcription and SRC coactivation of AF-2 activity (39). These
studies suggest that the AF- l and AF-2 domains may synergize for complete AR activity
and that the interaction of the two activation domains may result in recruitment of
coactivator to the AR. Finally, SRC co activators have also been demonstrated to enhance
the AF- l activity of the ERa in the presence of both estradiol and tamoxifen, suggesting
that the partial agonism of tamoxifen occurs by coactivator recruitment to the AF-
domain (38).
Another potential mechanism of transcriptional activation by SRC co activators is
histone acetylation. Hyperacetylated histones have long been linked to transcriptionally
active chromatin, for acetylation leads to an unpacking of the condensed chromatin
network, thereby facilitating the access of transcription factors to target gene promoters.
Accordingly, both CBP/p300 and the CBP/p300-associated factor P/CAF have been
demonstrated to possess potent histone acetyltransferase (HAT) activity (81-83), which is
required for transcriptional activation by CBP (84). Both factors interact with SRC
coactivators , as well as with nuclear receptors themselves, and enhance receptor
transcriptional activation (85-87). Therefore , recruitment of HAT-containing
' '
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co activators by the receptor may lead to a modulation of chromatin structure , thereby
facilitating the access of either additional transcriptional activators , such as the
DRIP/TRA complex (see below), or the assembly of the pre-initiation complex
ultimately leading to transcriptional activation. Interactions between co activators and the
RA versus CREB via microinjection analysis (91). Whereas P/CAF HAT activity was
...
basal transcription machinery may also playa role in transcriptional activation, for both
CBP/p300 (88 89) and SRC- l (42 43) have been reported to interact with TBP and
TFIIB. Interestingly, moderate HAT activity has also been attributed to SRC- l and
ACTR, suggesting that liganded nuclear receptors recruit a coactivator complex
containing multiple enzymatic activities (54, 90). The apparent redundancy of HAT
activities among the coactivator complex remains to be resolved completely. However
transcription factor-specific differences in HAT requirements have been established for
required for transcriptional activation by RA, CBP HAT activity was required for
CREB function. Additionally, cell-type and promoter-specifi differences may also
account for the existence of numerous HAT-containing coactivators. Finally, multiple
HAT activities may be required if non-histone proteins also serve as substrates for these
enzymes. In support ofthis , p300 has been demonstrated to acetylate p53 , increasing its .;111
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DNA binding activity (92). Also , CBP and P/CAF can acetylate TFIIE and TFIIF in
vitro , which again links the basal transcription machinery to transcriptional activation by
nuclear receptor co activators (93). Furthermore, a recent study reports that ACTR itself
can be acetylated by CBP/p300 (94). In this paper, hormone treatment results in
enhanced histone acetylation at ER, RA, and VDR target gene promoters and increased
recruitment of coactivators, including ACTR and CBP/p300. However, this effect is
transient in nature and is strongly downregulated after prolonged hormone treatment.
Surprisingly, acetylation of ACTR by CBP/p300 at specific lysine residues causes the
dissociation of ACTR from the DNA-bound ER homodimer. These results suggest that
the mechanism of downregulation of receptor activity involves release ofthe coactivator
complex from the receptor via acetylation of the coactivator itself.
Finally, ligand-independent mechanisms of coactivator recruitment have also
been reported. Zwijsen and colleagues demonstrated that cyc1in Dl can function as a
coactivator for ERa through the recruitment ofSRC- l in the absence of hormone (95).
This coactivation was observed even in the context of AF-2 mutated receptors
suggesting that cyc1in D 1 can mediate transcriptional activation by ERa mutants that
cannot bind hormone or directly recruit SRC coactivators. Interestingly, cyclin Dl bound
SRC- l directly via the domain containing the three LXXLL motifs. Peptide competition
experiments revealed that NR box ii of SRC- l was preferred by ERa while NR box iii
was preferred by cyclin Dl , suggesting a specificity of the NR boxes for distinct protein-
protein interactions. Cyc1in D 1 also bound ERa directly and was required for
recruitment of SRC- l to ERa in the absence of estradiol, indicating that cyclin D 1 can
act as a bridging factor between ERa and SRC-
In another study, Tremblay, et al demonstrated that phosphorylation of the AF-
domain ofERp led to the recruitment ofSRC- l in the absence of hormone (96). SRC-
interacted directly with the AF- l domain ofERp via a region that contained two
consensus proline-directed kinase sites. Serine 106 ofERp was readily phosphorylated
by MAPK in vitro , which subsequently enhanced the interaction with SRC- l. In vivo
treatment of transfected cells with MAPK inhibitors impaired the interaction of SRC-
with ERp and abolished the ability of SRC- l to enhance transcriptional activation by the
unliganded ERp, suggesting that phosphorylation-dependent recruitment of coactivator
by ERp is required for maximum AF - 1 activity. Interestingly, SRC- l and AIB 1
themselves can also be phosphorylated by Erk-2 (97 , 98). This phosphorylation results in
an enhancement of AIB 1 transcriptional activation and stimulates the recruitment ofp300
and its associated HAT activity (97). Taken together, these studies reveal alternative
routes for coactivator recruitment to nuclear receptors that may underlie the multiple
mechanisms of transcriptional activation by receptors and contribute to the specificity of
receptor function.
The focus of this thesis project was a detailed analysis ofRAC3 regulation 
nuclear receptor function. RAC3 is a polymorphic variant of ACTRI 
AIB- l that was
independently isolated in our laboratory (52). It was demonstrated that the LXXLL
motifs of RAC3 are key contributors to RAC3 interactions with nuclear receptors, in
particular VDR, ERp, and RAa , and also the general transcriptional coactivator CBP.
Specifically, receptor-specific preferences of these nuclear receptors for the three NR
boxes of the RAC3 receptor-interacting domain were uncovered. These motifs
differentially regulate interactions between the coactivator and each receptor both in
solution and when bound to DNA. Consequently, they also differentially participate in
RAC3 enhancement of transcriptional activation in vivo. Furthermore, the NR boxes of
RAC3 activation domain, particularly NR box v , are critical to coactivator interaction
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with CBP. This recruitment ofCBP was found to be the major mechanism ofRAC3
coactivation ofRAa activity, but apparently was dispensable for stimulation ofERp
activity. This finding suggested that RAC3 can activate transcription by multiple
mechanisms. Finally, the cofactor-binding pocket ofRAa and RXRa was also
characterized. Recent structural data have demonstrated that this hydrophobic pocket is
comprised of helices 3 , 4, 5 , and 12 of the receptor ligand-binding domain. This work
receptors in vitro , and therefore , also required for transcriptional activation by the
reveals that these intact helices are required for RAC3 recruitment to liganded retinoid
receptor in vivo. Thus , coactivator recruitment to the receptor is essential for
transactivation. Interestingly, helices 3 , 4 , and 5 are also required for unliganded receptor
',I
interactions with the corepressor SMRT and therefore, transcriptional repression. These
findings indicate that the coactivator and corepressor binding pockets of retinoid
receptors overlap to a great extent and that helix 12 plays a key regulatory role in cofactor
binding to the receptor. Overall , this project has uncovered several novel points
significantly to the field of transcriptional regulation by these receptors and cofactors.
;111
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concerning RAC3 regulation of nuclear receptor function and has contributed
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CHAPTER II
THESIS GOALS AND SPECIFIC AIMS
In the past few years , the field of nuclear receptor research has witnessed an
explosion in data, be it biochemical , genetic , or crystallographic , concerning the
mechanisms of transcriptional regulation by steroid/nuclear receptors. While the
biological responses to hormones have been studied for quite some time, it has only been
in recent times that we are beginning to understand the cellular factors that mediate these
responses. It has become clear that nuclear receptors recruit co factors termed
corepressors and co activators in order to regulate the expression of their respective target
genes. In the case of co activators , much work has been done in detailing the mechanisms
by which the first known nuclear receptor coactivator, SRC- , regulates receptor
function. These studies include the discovery of the LXXLL motif or NR box , an a-
helical domain that has been demonstrated to be critical to the ability of SRC- l to interact
with liganded receptors and activate transcription. However, little is known about the
regulation of receptor function, particularly ofRAa , VDR, or ERp, by RAC3 , the third
member of the SRC family of co activators that was previously cloned in our laboratory.
Therefore , the major goal of my thesis research was to characterize in detail the
mechanisms by which the coactivator RAC3 modulates the activity of these members of
the steroid/thyroid hormone receptor superfamily. The specific aims of the project were
as follows.
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The first aim of the proj ect was to characterize the mechanisms by which RAC3
regulates the activity ofnuc1ear receptors. In paricular, the role of the LXXLL motifs of
the RAC3 receptor-interacting domain (NR boxes i- iii) were investigated in order to
determine if different nuclear receptors preferred different NR boxes for interaction with
RAC3. To accomplish this , site-directed mutagenesis and peptide-competition
experiments were performed to map RAC3 interactions with nuclear receptors in vitro.
Further insight into these interactions was gained by studying the recruitment of RAC3 to
DNA-bound nuclear receptors. In order to provide functional evidence for RAC3
regulation of receptor function in vivo , the ability ofRAC3 to enhance transcriptional
activation by these receptors and the NR box requirements of this coactivation activity
were also determined.
Since RAC3 contains a domain that is able to activate reporter expression when
fused to the Ga14 DNA-binding domain , the transcriptional activation function of the
coactivator was also characterized in the second aim of the project. The role that the C-
terminal LXXLL motifs (NR boxes iv-vi), which are found in the RAC3 activation
domain, play in this activation were determined by site-directed mutagenesis.
Furthermore , the mechanism of transcriptional activation was studied by analyzing RAC3
interactions with the general transcriptional cointegrator CBP/p300. Finally, the
contribution of CBP/p300 interaction to the coactivation of nuclear receptor activity by
RAC3 was assayed in vivo by transient transfection.
The third aim of this work investigated the receptor requirements for interaction
with the coactivator RAC3 , as well as with the corepressor SMRT. Based on structural
studies , it has been hypothesized that both co activators and corepressors interact with a
hydrophobic pocket in the receptor ligand-binding domain that consists of helices 3 , 4, 5
and 12. To test this , the cofactor-binding pocket of retinoid receptors was characterized.
The effects of mutation of the above a-helices on receptor interactions with RAC3 and
SMRT were determined in vitro. In addition, the relative contribution of the cofactor-
binding pocket of each monomer in a DNA-bound receptor dimer to cofactor recruitment
was examined. These analyses were then correlated with the transcriptional activity of
retinoid receptors in vivo.
It is the goal ofthis project to contribute significantly to the understanding of
steroid/nuclear receptor regulation of gene expression. Although receptor function has
been studied intensely in recent years, the precise mechanisms by which hormone action
is mediated are still not clear. Therefore, during my thesis research, I attempted to gain
insights into the maner in which steroid/nuclear receptors are modulated by the
coactivator RAC3 and the corepressor SMRT. Ifwe understand the details of cofactor
recruitment to receptors and how , in turn, the transcriptional activity of the receptor is
regulated, it wil allow us to better comprehend the overall pathway that begins with the
arrival of hormone at a target cell and ends with the physiological response that is elicited
by the body.
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CHAPTER III
EXPERIMENTAL PROCEDURES
A. Recombinant Protein Expression and Purifcation
Plasmids encoding GST fusion proteins were transformed into E. coli BL21
competent cells and subsequently grown up in 100 mL LB broth containing 1 00 g/mL
ampicilin to 6oo=OA- 55. Protein expression was then induced for 3-4 hours with
ImM IPTG and cells were harvested and washed in 10 mM Tris, pH=8/150 mM NaCl/l
mM EDTA (STE). Cells were then resuspended in STE , and 5 mM DTT, 1 mM PMSF
and 1. 5% Sarkosyl were added. Cells were sonicated and centrifuged at 8000 rpm for 30
minutes to remove cell debris. To the supernatant, 2% Triton X- I00 and 100 L of a
50% slurr of Glutathione-sepharose beads were added and rotated for 30 minutes at 4
The beads were then collected by centrifugation and washed 4-5 times with cold PBS
before final resuspension in storage buffer containing 50 mM Hepes/150 mM NaCl, 5
mM DTT , and 10% glycerol.
B. Far-Western Analysis
Purified GST fusion proteins were separated by SDS-PAGE and electroblotted onto a
nitrocellulose membrane. After blocking overnight at 4 in HBB (25 mM Hepes-KOH
pH=7.7125 mM NaCl/5 mM MgCh) plus 5% nonfat milk/l mM DTT/0.05% NP-
proteins were denatured with 6 M guanidine hydrochloride (GnHCl) in HBB and
subsequently renatured in stepwise dilution of GnHCl at concentrations of 3 M, 1.5 M
75 M , 0. 375 M, and 0.187 M. Membranes were then blocked again for 1 hour at room
temperature in the above blocking buffer followed by 30 minutes at room temperature in
the above buffer substituted with 1 % nonfat milk and 0. 1 mM methionine. Membranes
were subsequently hybridized overnight at 4 with S-methionine labelled protein diluted
in hybridization buffer (20 mM Hepes , 75 mM KCl, 0.1 mM EDTA, 2. 5 mM MgClz,
05% NP- , 1 mM DTT , 0. 1 mM methionine). The membrane was washed three times
at room temperature in hybridization buffer and bound probe detected by
autoradiography. labelled probes were generated by Quick-coupled in vitro
transcription/translation (Promega). For peptide competition experiments , the given
concentration of peptide was added to the probe 10 minutes prior to hybridization with
the membrane. Peptides were synthesized by the University of Massachusetts Medical
School peptide facility with sequences as follows: NR box i peptide
(LESKGHKKLQLLTLSSDDRGHSSL), NR box ii peptide
(LQEKHRILHKLLQNGNSP), NR box iii peptide (KKNNALLRYLLDRDD),
control peptide (GSGSATATLYENKRPPYIL). Radioactive bands were quantified by
PhosphorImager using the ImageQuant software (Molecular Dynamics). Far-Western
experiments were repeated three times and peptide competition data are representative of
duplicate experiments.
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C. GST pull- down assay
Approximately 5 Ilg of purified GST fusion protein was incubated with 5 ilL of 
methionine labelled protein with moderate shaking at 4 overnight in binding buffer (20
mM HEPES/pH 7. , 75 mM KCl , 0. 1 mM EDTA, 2. 5 mM MgClz, 0.05% NP40 , 1 mM
DTT , 1 mg/mL BSA). The bound protein was washed three times with binding buffer
and beads collected by centrifugation. The bound protein was eluted in SDS sample
buffer, subjected to SDS-P AGE , and detected by autoradiography. GST pull-down
experiments were repeated at least twice.
D. Site-directed mutagenesis
NR box mutants were generated with the Quick-change site-directed mutagenesis
system (Stratagene). Mutagenesis utilizes a supercoiled, double stranded DNA template
with the insert of interest and two , synthetic , complementary oligonucleotide primers
containing the desired mutation. The primers extend during temperature cycling by
means of PfuTurbo DNA polymerase. Then, the parental DNA template is digested away
with DpnI , which is specific for methylated DNA, thus selecting for mutation-containing
synthesized DNA. The sequences of all mutant constructs were confirmed by
dideoxynucleotide chain-termination reactions using the T7 Sequenase protocol (USB).
. "
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E. Gel electrophoresis mobilty shift assay
The sequence ofthe DR3 element used for VDR/RXR gel shift assays is
AGCTTAAGAGGTCAGAAAGGTCACTCGCAT. The sequence of the DR5 element
used for RARX assays is AGCTT AAGAGGTCACCGAAGGTCACTCGCA T.
The sequence of the DRI element for RXRX assays is
AGCTT AAGAGGTCAAGGTCACTCGCA T. The double-stranded oligonucleotide
probe was end- labeled with dCTP by standard Klenow fill-in reaction.
Unincorporated nuc1eotides were subsequently removed by purifying the probe with the
Micro Bio-Spin P-30 column (Bio-Rad). The purified probe was incubated within vitro
transcribed/translated receptors in binding buffer containing 7.5% glycerol , 20 mM
HEPES/pH 7. , 2 mM DTT, 0. 1 %NP40, 1 flg poly-dIdC and 100 mM KCl. Wild-type or
mutant GST-RAC3-RID was eluted from glutathione agarose beads with 10 mM reduced
glutathione and added to the binding reaction. The DNA-protein complex was formed on
ice for one hour and resolved on a 5% native polyacrylamide gel, which was
subsequently dried and subjected to autoradiography. Experiments were repeated at least
twice with a representative result shown.
F. Cell Culture and Transient Transfection
HEK293 and CV- l cells were maintained in Dulbecco s modified Eagle s medium
supplemented with 10% fetal bovine serum and 5 flg/flL gentamycin at 37 /5%CO
Cells were plated for transfection in DMEM supplemented with 10% resin-charcoal
stripped fetal bovine serum in 12- or 6-well plates one day prior to transfection. HEK293
cells were transfected using the standard calcium phosphate method while CV - 1 cells
were transfected using Lipofectamine according to manufacturer s protocol (Gibco.
Twelve hours after transfection, cells were washed with PBS and refed fresh media
containing the indicated concentration of ligand. After 24 hours , cells were harvested for
galactosidase and luciferase activities in lysis buffer containing 25 mM Tris-
/pH=7. , 15% glycerol , 2% CHAPS , 1 % Lecithin, 1 % BSA, 4 mM EGTA, 8 mM
MgClz, 1 mM DTT , and 0.4 mM PM SF as described (76). Luciferase activity was
determined with a MLX plate luminometer (Dynex) using 50 flL of cell lysate and 100
flL each of buffer A (0. 1 M KP0 /5 mM ATPIlO mM MgClz) and buffer B (0.09 M
KP0 1l mM Luciferin). Luciferase activity was then normalized to p-galactosidase
activity in order to account for differences in transfection effciency between samples.
Transient transfections were performed in triplicate and each experiment was repeated at
least twice.
CHAPTER IV
RESULTS
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CHAPTER IV-
DIFFERENTIAL UTILIZATION OF RAC3 LXXL MOTIFS BY RECEPTORS
A. VDR and ERp interact with multiple surfaces ofRAC3
Our laboratory has previously defined the minimal receptor interacting domain
(RID) ofRAC3 to be amino acids 613-752 , which contains the first three LXXLL motifs
(52). I wished to further determine if different receptors were capable of binding to the
same regions ofRAC3. To accomplish this , a panel of GST-RAC3 fusion proteins , in
total comprising the full- length RAC3 , was purified and probed with S-methionine
labeled VDR and ERp in a Far-Western assay (Fig. 5). The VDR, as expected, interacted
in a ligand-dependent manner with GST-RAC3 613-752 in this assay (Fig. 5B). It also
bound GST-RAC3 723- 1034, which only contains NR box iii , in a ligand-dependent
manner. No interactions were evident in the absence of vitamin D. The VDR did not
interact with any other GST-RAC3 fragment , including GST-RAC3 342-646 , which
contains NR box i. It also appeared that the VDR interacted more strongly with GST-
RAC3 723- 1034 than with GST-RAC3 613-752 , suggesting a more important role for
NR box iii in the RAC3-VDR interaction. However, a different pattern was evident upon
repeating this assay with ERp, for in addition to ligand-dependent interactions with
GST-RAC3 613-752 and 723- 1034 , ERp also bound the 342-646 fragment, which
contains only NR box i (Fig. 5C). These interactions were of approximately equal
intensity. There was also a weak, ligand-independent interaction with GST-RAC3 1-407.
Identical results were obtained for ERa (data not shown). A Coomassie Blue-stained
polyacrylamide gel of the GST-RAC3 fusion protein confirmed the identity of each GST-
RAC3 fusion protein and approximately equal protein concentrations in each lane (data
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not shown). Therefore , the VDR and ERp display different binding patterns for RAC3
fragments , with the VDR interacting preferentially with regions containing NR box iii
and the ERp interacting equally well with regions containing any of the three NR boxes
and the N-terminal bHLH-PAS domain.
B. NR Box peptides diffefentially compete with nuclear receptofs fOf RAC3 binding
. '
We then wanted to investigate the relative importance of individual NR boxes
within the RAC3-RID in mediating the interactions between RAC3 and the VDR or ERp.
Peptides were synthesized corresponding to NR boxes i , ii , and iii , which were then
tested for their relative abilities to compete with the RAC3-RID for VDR or ERp
binding. To do this, peptide at concentrations of 0 , 2. , 5 , 12. , or 25 M were incubated
with labeled receptor and l M ligand prior to probing the GST-RAC3 613-752
, .
fragment in the Far-Western assay. With the VDR, peptides corresponding to the second
and third LXXLL motif were able to compete away the RAC3-RID interaction with VDR
in a dose-dependent manner (Fig. 6A). However, peptide iii was much more potent, for
as little as 2. M peptide abolished nearly all of the GST-RID interaction with VDR.
This observation was confirmed upon quantifying the data, for the of peptide iii was
rr.
several fold lower than that of peptide ii (Fig. 6B). The peptide comprising NR box i had
little , if any, effect on the VDR-RlD interaction. A control experiment demonstrated that
the effects of these peptides were specific, for a random peptide did not alter the
interaction between the VDR and GST-RAC3-RID (Fig. 6C). We again identified a
different pattern when the same experiment was done with the ERp (Fig. 7). Here, all
three peptides were able to compete effciently for ERp binding with the RAC3-RID
with peptide ii being the most potent. Thus , these data reveal receptor-specific
preferences for interactions between RAC3 and different nuclear receptors, for the VDR
and ERp have different affnities for the NR boxes ofRAC3. Residues flanking each
LXXLL motif likely contribute to this specificity, for the motifs themselves are so highly
conserved that surrounding amino acids may influence the affnity of a paricular receptor
for the particular NR box.
C. NR box mutations can impair RAC3 interactions with nuclear receptors in vitro
In order to assess the integrity of the LXXLL motif itself in mediating the
interaction between the RAC3-RID and nuclear receptors , we used site-directed
mutagenesis to switch the leucine residues of each motif to alanines (Fig. 8A). The
mutants were made using the GST-RAC3-RID fusion as the template , confirmed by
DNA sequencing and tested for their ability to interact with the 
VDR RAa
RXa or ERP in GST-pulldown assays (Fig. 8B). The wild-type GST-RAC3-RID
was able to pull down a significant amount of S- VDR in the presence of 1 flM Vitamin
D. This interaction was specific, for GST alone pulled down much less VDR.
Mutations in NR boxes i or ii displayed wild-type binding. However, when NR box iii
was mutated, the RID- VDR interaction was greatly reduced to a level only slightly higher
than background binding to GST alone. GST-RAC3 342-646 , which contains only NR
box i , also had minimal binding to the VDR, consistent with the Far-Western assay.
Equal protein concentrations of each GST fusion confirmed the specificity of these
findings (data not shown). Thus , these data support the above observations in implicating
NR box iii as being most critical to RAC3 interaction with the VDR in vitro.
We also assessed the NR box requirements of retinoid receptors. Wild-type GST-
RAC3 RID effciently precipitated RAa in the presence of 1 flM all-trans retinoic acid.
In contrast to the VDR, mutation ofNR box iii had little effect on this interaction.
However, mutation ofNR box i reduced binding significantly while the NR box ii
mutation abolished the RAa-RID interaction altogether. These observations imply that
RAC3 NR box ii is most important for interactions with RAa. Similar results were also
obtained with RXa , with NR boxes i and ii mediating the interaction with the RAC3-
RID. However, unlike RAa , mutation of either NR box i or ii had about the same
effect on the interaction, reducing it to only slightly above background binding.
Therefore , motifi may be more important to coactivator interactions with RXa while
motif ii is critical to interactions with RAa.
Finally, the wild-type RID was also able to pull down significant amounts Of
ERp in the GST -pulldown assay while the GST only control demonstrated minimal
interaction. In contrast to the other receptors , alanine substitution for leucine in any of
the three NR boxes weakened the interaction of the RAC3-RID with ERp, with the
mutation ofNR box ii being the most deleterious, again supporting the results of LXXLL
peptide competition experiments. However, with each mutation, significant binding
above background between the RAC3-RID and ERp was still observed.
Furthermore , the GST-RAC3 342-646 fragment, with only NR box i , was able to interact
effciently with ERp as in the Far-Western assay. These data suggest that although all
three motifs are capable of interacting with ERp separately, none of them is absolutely
required for the interaction. In contrast , NR box iii of RAC3 appears to be essential for
the interaction with the VDR and NR box ii essential for interaction with RAa. These
subtle , but precise differences in NR box requirements also suggest potential differences
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in the coactivator binding pocket on each receptor.
D. RAC3-RID interactions with DNA-bound nuclear receptors
Cij
The above data provide compelling evidence that the VDR and RAa interact
specifically with RAC3 in solution via the LXXLL motifs of the RAC3 RID , particularly
NR box iii for VDR and NR box ii for RAa. To gain further insight into the function of
, :J
NR boxes in coactivator-receptor interactions on a heterodimeric complex bound to
DNA, we performed gel-shift assays with VDR/RX and RARX heterodimers on a
DR3 or DR5 element, respectively, in the presence of wild-type or mutant RAC3-RID.
The DR3 element consists of two half-sites, in a direct repeat, with the sequence
AGGTCA. These two half-sites are separated by 3 nucleotides, which makes this
element specific for the VDR/RX heterodimer versus other RXR heterodimers. The
DR5 element contains the same half-site, but separated by 5 nuc1eotides. These probes
were labeled with dCTP using the Klenow fragment of DNA polymerase and
incubated with in vitro transcribed/translated receptors and the indicated GST fusion
protein, which was eluted from the glutathione-sepharose beads with excess glutathione.
The VDR/RXR heterodimer bound strongly to the labelled DR3 probe and was
unaffected by addition ofGST alone (Fig. 9, lanes 1 2). Addition ofthe RAC3-RID
resulted in a shift of the heterodimeric complex to a slower migrating form only in the
presence of 1 J.M vitamin D (arrow, lanes 3 and 4), consistent with the ligand-dependent
interaction between the RAC3-RID observed in the Far-western assay. Mutation ofNR
box i had little effect on the ability of the RID to shift the complex (lane 5). However
mutating NR box ii diminished the formation of the RID- VDR/ complex , while
mutating NR box iii nearly abolished the formation completely (lanes 6 and 7).
Consistently, GST-RAC3 342-646 , with only NR box i , was unable to shift the
VDR/RXR complex (lane 8). These results differ slightly from the GST - pull down, in
which only the NR box iii mutation inhibited interaction with VDR alone. However, they
are consistent with the hypothesis that suggests that two motifs may contribute to the
interaction with DNA-bound nuclear receptor heterodimers, with one LXXLL motif per
monomer.
Many studies have demonstrated that helix 12 of nuclear receptors , which
comprises the ligand-dependent AF-2 domain, is critical to coactivator binding (99). As
detailed above , it is believed that high-affinity interactions between receptors and SRC
coactivators requires a ligand-induced repositioning ofthis helix. However, the role of
each helix 12 of a DNA-bound nuclear receptor heterodimer in recruiting co activators is
not completely understood. In order to gain insight into this , we analyzed the
involvement of nuclear receptor AF-2 domains in regulating the interaction between the
RAC3-RID and the VDR/RXR heterodimer. Using the gel-shift assay, we compared the
ability of the RID to bind the wild-type heterodimer versus the VDR/R443 and I I
a much stronger shift ofthe heterodimeric complex by the RAC3-RID (lane 6) without
VDR402/R heterodimers , in which the AF-2 domain ofRX or VDR had been
deleted , respectively (Fig. 10). As demonstrated above, the RID was able to bind the
DNA-bound, wild-type VDRI complex (Fig. 10 , lane 2). This shift appears weaker
than that in the previous experiment due to underexposure of the autoradiograph in order
to clearly see the other bands on the gel. Deletion of the VDR AF-2 domain did not
affect the formation of the heterodimer-DNA complex (lane 3), but resulted in the loss of
the RID-shifted complex (lane 4). This suggests that the VDR AF-2 domain is required
for interaction ofRAC3 with the heterodimer, and that RX AF-2 domain alone is not
sufficient for the interaction. Interestingly, deletion of the RX AF-2 domain resulted in
affecting heterodimer formation (lane 5), suggesting that the RXR AF-2 domain can
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inhibit the interaction between RAC3 and VDR/RXR. The strong interaction was
abolished upon deletion ofthe VDR AF-2 domain (lane 8), further supporting a
requirement ofVDR AF-2 helix 12 for RAC3 binding to the DNA-bound heterodimer.
These findings are consistent with a model of allosteric inhibition of coactivator binding
to the RARX heterodimer by the RXR AF-2 domain (100).
Additionally, we compared the RAC3 NR box preferences ofVDRlRX versus
VDRlRXR443 (Fig. lIA). Intriguingly, the VDRlRX443 heterodimer displayed
different NR box preferences. Mutation ofNR box i or iii greatly reduced the shift by 
the
RAC3-RID (lanes 3 and 5), while mutation ofNR box ii only slightly weakened the
binding (lane 4). Thus deletion of the RXR AF-2 domain resulted in a switch in the NR
box requirements , with NR boxes i and iii being most important for VDR/443
expression levels of each 
labeled receptor (Fig. IIB). This finding supports the
compared to NR boxes ii and iii for VDRlRX. An autoradiograph confirmed equal
hypothesis that multiple LXXLL motifs provide RAC3 with the flexibility to adapt to
different configurations of a nuclear receptor dimer. It also suggests that the RXR AF-
1 '
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domain may be involved in the positioning of specific NR boxes within the VDRlRXR
heterodimer.
In the analysis ofRAa-RXa, the heterodimer specifically bound to the 32
labeled DR5 probe in the presence of all-trans retinoic acid (Fig. 12 , lane 2). Addition of
GST alone had no effect on the complex while the wild-type RAC3-RID shifted a portion
of the complex to a slower migrating form (lanes 3,4). However, mutating NR box i of
the RAC3-RID inhibited somewhat the interaction with RAa-RXa , while mutating
NR box ii abolished it \)omp1etely (lanes 5 6). Mutation ofNR box iii had no effect on
the RID-induced shift (lane 7). These observations correlate completely with the results
of the GST pull down experiments. Thus , the RAa-RXRa heterodimer has different
NR box requirements than the VDR-RXRa heterodimer, which required an intact NR
box ii and iii for interaction with the RAC3-RID. In analyzing the role of helix 12 of
!I 
each receptor, it was evident that, similar to VDR-RXa , helix 12 ofRXRa inhibited the
interaction with RAC3 , for deletion of this helix resulted in a complete shift ofthe
RAa-RXRa complex (lane 9). Conversely, helix 12 ofRAa is absolutely required
for coactivator interaction, for deletion of helix 12 ofRAa blocks the interaction with
the RAC3-RID (lane 11). In summary, it is evident that the different RXR heterodimers
have different RAC3 NR box preferences for coactivator binding, but share the
requirement of helix 12 of the RX partner and are inhibited by helix 12 ofRX itself.
Finally, we determined the NR box requirements of the RXa/Ra
homodimer, which is able to bind at a DRI response element (Fig. 13). No interaction
with RAC3 was evident in the absence of9-cis retinoic acid or upon addition of purified
GST alone (lanes 2 3). However, the wild-type RID specifically shifted a portion of the
homodimer to a slower migrating form in a ligand-dependent manner (lane 4). Mutation
ofNR boxes i or ii completely abolished this interaction, while mutation ofNR box iii
had minimal effect, consistent with the GST pulldown data (Fig. 8).
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E. Effects of NR box mutations on RAC3 coactivation function in vivo
RAC3 haspreviously been shown to enhance the transcriptional activity of the
retinoic acid receptor (RA) and progesterone receptor (PR) (52). However, its effect on
VDR and ERp function in vivo has not been demonstrated. To address this, we
performed transient transfection assays in HEK293 and CV - 1 cells using luciferase
reporters harboring either two copies of the VDRE of the osteopontin gene for VDR
studies or a consensus ERE element for ERp studies (Fig. 14). The reporter construct
was transfected into cells with expression plasmids for the receptor, wild-type or mutant
RAC3 , and beta-galactosidase. Cells were treated with hormone or solvent control and
subsequently harvested. Luciferase activity was then measured and normalized to beta-
galactosidase activity, thus accounting for differences in transfection efficiency between
samples. Transfection of the VDR into CV- I cells minimally activated the VDRE-driven
We then analyzed the role of the NR boxes in mediating the ability ofRAC3 to
reporter. However, treating these cells with 40 nM vitamin D strongly stimulated its
activity. Cotransfection of wild-type RAC3 further enhanced VDR transcriptional
activation by approximately 50%, consistent with the coactivation function ofRAC3 for
RAR and PR (Fig. l4A).
potentiate VDR activity (Fig. 14A). Mutations of each NR box of the RAC3-RID were
made in the context of the full-length RAC3 expression plasmid and confirmed by DNA
sequencing. They were then tested for their ability to coactivate the VDR in transient
transfection assays. Mutation ofNR box i did not inhibit RAC3 enhancement ofVDR
transactivation, consistent with its inability to block the interaction ofRAC3 with VDR in
vitro. However, the RAC3 NR box ii or iii mutations abolished the function ofRAC3 in :iI
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enhancing VDR activity, reducing VDR activity to that observed in the absence of
transfected RAC3. Therefore , these in vivo data are consistent with the above in vitro
gel-shift data demonstrating that NR boxes ii and iii ofRAC3 are critical to VDR
interaction in the context of the DNA-bound VDR/RX heterodimer. Taken together, it
is clear that NR boxes ii and iii are both involved in RAC3 regulation ofVDR/RX
function, while the role ofNR box i appears minimal.
We then repeated these experiments with the ERp (Fig. 14B). Estradiol treatment
of CV - 1 cells transfected with the ERp and the ERE- Luciferase reporter activated
reporter expression approximately 8-fold. Cotransfection of wild-type RAC3 resulted in
a strong, 6-fold enhancement ofERp activity. It is evident from these data that RAC3 is
a more potent coactivator for the ERp than for the VDR. Cotransfection ofRAC3
expression plasmids containing mutations in NR boxes i , ii , or iii all suppressed the
ability ofRAC3 to coactivate the ERp, with the NR box ii mutant having the greatest and
NR box iii mutant having more modest effects on RAC3 function. However, all three
ability of the GST-RAC3-RID protein harboring a single NR box mutation to still bind
mutant RAC3 constructs still retained some coactivation function, consistent with the
ERp in vitro. Thus , these in vivo data correlate with the in vitro data in implicating all
three NR boxes of the RAC3-RID as being involved in RAC3 regulation of
ERp function, with none of the motifs being absolutely required. These data suggest that
ERp has greater flexibility than VDR in selecting different RAC3 NR boxes.
Finally, we d cided to assess the functional consequences of the antagonism of :.1:
RAC3 interaction 'Nith DNA-bound VDR/R by the RXR AF-2 domain observed in
gel-shift assays. To do this , we compared the ability ofRAC3 to coactivate VDR/
versus VDR/RX443 activities by transient transfection assays (Fig. 15). When wild-
type VDR and RXR were expressed in HEK293 cells , RAC3 was able to enhance
transcriptional activation of the VDRE-driven reporter by approximately 50% (left).
However, when VDR was coexpressed with RXR443 , RAC3 displayed a 2. fold
enhancement of receptor activity, likely via increased interaction with RAC3 (center). As
expected, the VDR402 mutant was transcriptionally inactive and RAC3 could not
modulate its activity (right). Thus , these in vivo data are consistent with the gel-shift data
in demonstrating that the RXR AF-2 domain can inhibit RAC3 modulation of the
VDR/RXR heterodimer while the VDR AF-2 domain is absolutely required for this
regulation.
Overall , the above data clearly reveal receptor-specific preferences for the a-
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helical NR boxes of the RAC3 receptor-interacting domain. Motifs ii or iii were
absolutely essential to RAC3 interactions with the VDR or RAa , respectively, while
motifs i and ii made equal contributions to interaction with RXRa. Interestingly, all
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three NR boxes appeared to be involved in interactions with ERp, but none were
individually required for this interaction. This suggests that coactivator interactions with
the steroid receptors such as ERp may be more flexible than those with non-steroid
receptors. Furthermore, two motifs were essential to RAC3 recruitment to a DNA-bound
;;j
VDR/R or RARXR heterodimer, which is consistent with the hypothesis that a
single coactivator molecule binds to a receptor dimer using one NR box per monomer.
Finally, the same NR boxes that mediated interactions with receptors in vitro were also
demonstrated to mediate RAC3 enhancement of transcriptional activation by these
receptors in vivo.
CHAPTER IV-
CHARACTERIZATION OF RAC3 TRANSACTIV ATION FUNCTION
One mechanism by which nuclear receptor co activators activate transcription may
be via recruitment of the general transcriptional activators CBP/p300 (53 , 64, 85 , 101).
Our laboratory has previously demonstrated that RAC3 is able to interact with two
fragments ofCBP in vitro , CBP-C (1921-2120) and CBP-D (2041-2240) (57).
Interestingly, RAC3 contains three additional LXXLL motifs, termed NR boxes iv, v, and
, in the previously defined activation domain (Fig. 3). In light ofthese findings, we
decided to determine if these NR boxes mediated the interaction with CBP and were
involved in transcriptional activation by RAC3 invivo. NR boxes iv, v, and vi were
mutated by leucine to alanine substitution via site-directed mutagenesis (Fig. 16A). The
template for this mutagenesis was a Ga14-DNA-binding domain fusion to RAC3 401-
1204 , which contains the functional regions ofRAC3. The wild-type or mutant
constructs were cotransfected into HEK293 cells with a reporter containing four tandem
copies of Ga14-DBD binding sites. Wild-type Gal-RAC3 401- 1204 activated this
reporter 3- fold comp3red to the activity of the Ga14-DBD alone (Fig. 16B). Mutation of
NR boxes iv or vi had little effect on the ability of Gal-RAC3 401- 1204 to activate
transcription. However, mutation ofNR box v completely inhibited this transcriptional
activation function, reducing the activation level to the basal level ofthe Ga14-DBD
alone. To determine if this observation was a result of the inability ofRAC3 401- 1204
(mut v) to bind CBP , we labeled each Ga14-RAC3 401- 1204 construct with 
methionine by in vitro transcription/translation and probed the RAC3-interacting
fragments of CBP in a Far-western assay (Fig. 17). Each construct expressed at an equal
level in the transcription/translation reaction and, consistent with its lack of
transactivation function, mutation ofNR box v drastically reduced RAC3 401- 1204
binding to both CBP-C and CBP-D fragments (Fig. 17 A). Upon quantifying the data, it
was determined that Ga1-RAC3 401- 1204(mut v) displayed a 50- and 100-fo1d lower
affinity for CBP-C and CBP- , respectively, compared to the wild-type probe (Fig. 17B).
Mutation ofNR boxes iv or vi had minimal effects on CBP interaction. Therefore, these
in vitro and in vivo data correlate perfectly in implicating NR box v ofRAC3 as being
critical to transcriptional activation through CBP recruitment.
In order to determine the role of CBP recruitment in RAC3 enhancement of
nuclear receptor transcriptional activation, we tested the ability of these mutants to
coactivate both RAa and ERp by transient transfection assays (Fig. 18). Each
activation domain mutant was first sub cloned into the full-length RAC3 expression
vector that lacks the Ga14-DBD fusion. The wild-type or mutant RAC3 was then
cotransfected into 293 cells with receptor expression plasmids and RA- or ERE-driven
luciferase reporter constructs. In the RAa analysis , wild-type RAC3 enhanced RAa
activity by 85% in the presence of 10 nM all-trans retinoic acid (Fig. 18A). Mutation of
RAC3 NR boxes iv or vi had no effect on this stimulation of transcription. However
mutation ofNR box v did slightly reduce the ability ofRAC3 to coactivate RAa
consistent with the above results that demonstrate that mutation ofRAC3 NR box v
till
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reduces its intrinsic transactivation function and reduces CBP binding. Nevertheless
, it is
worthy to note that RAC3-mut v still retained the capacity to enhance RAa activity,
suggesting a CBP- independent mechanism of activation by the coactivator.
Surprisingly, a much different result was observed when the same experiment was
done with ERp (Fig. 18B). Wild-type RAC3 again strongly enhanced estrogen receptor
activity in the presence of 15 nM estradiol. However, unlike RAa , mutation of neither
NR boxes iv, v , nor vi had any inhibitory effect on the ability ofRAC3 to coactivate
ERp. This indicates that CBP recruitment is dispensable for RAC3 enhancement ofERp
activity and suggests that other mechanisms ofRAC3 transcriptional activation
, such as
interaction with CARl , the DRIP/TRA complex , or the general transcription
machinery also contribute to RAC3 transcriptional activation.
Finally, we wished to compare the coactivation function ofRAC3 with that of the
other two members of the SRC family of coactivators , namely SRC- l and TIF2
, in order
to determine if functional differences existed between these proteins (Fig. 19). For ERp,
RAC3 potently enhanced estradiol-induced transcriptional activation several fold
consistent with the above data. Intriguingly, transfection of TIF2 resulted in a similar
enhancement ofERp activity, while SRC- l appeared to have no effect on receptor
function in our hands (Fig. 19A). This experiment was also performed with the RAa
(Fig. 19B). Here , only RAC3 was capable of stimulating RAa activity in the presence
ofretinoic acid, demonstrating about a 70% increase in activity. These findings suggest
that SRC co activators possess receptor-specific coactivation functions , with RAC3
possibly being a more flexible coactivator for multiple nuclear receptors.
In this chapter, it has been demonstrated that the C-terminal NR boxes
particularly NR box v , are critical to the intrinsic transcriptional activation function of
RAC3. Mutation of this motif inhibited the ability of a Ga14-DNA binding domain
fusion of RAC3 to enhance the expression of a repOlier containing Ga14 binding sites.
This effect correlated with the inability ofRAC3 (mut v) to bind the general
transcriptional activator, CBP , thereby elucidating a mechanism of activation by RAC3.
However, other mechanisms do clearly exist, for this mutant was still able to strongly
potentiate transcription by the ERp. RAa coactivation was slightly reduced by
expression ofRAC3 (mut v), thus CBP binding may contribute to RAC3 enhancement of
RAa activity. Additionally, it was evident that functional differences exist between the
members of the SRC family of co activators , for RAC3 and TIF2 , but not SRC- l were
able to enhance ERp activity while only RAC3 could coactivate RAa.
CHAPTER IV-
THE COFACTOR BINDING POCKET OF RETINOID RECEPTORS
A. Receptor residues required for cofactor interaction in vitro
It has been clear for some time that the AF-2 domain of nuclear receptors
undergoes a drastic conformational change upon ligand binding that facilitates the
binding of co activators (102). This change is characterized by a folding back of helix 12
of AF-2 in which it packs against the LBD and is absolutely required for coactivator
interaction. More recent crystallographic evidence has detailed the formation of a
hydrophobic groove consisting of residues from helices 3 , 4, 5 , and 12 that
accommodates the a-helical LXXLL motif of SRC co activators (31-34). In addition, a
charge clamp consisting of a highly conserved glutamate from helix 12 and a conserved
lysine from helix 3 serves to position the LXXLL motif in this hydrophobic groove
based on the structure of the PPARy homodimer with an SRC- l fragment containing two
LXXLL motifs (34). In light of these findings, we decided to investigate the involvement
of specific residues within these critical helices in cofactor binding by retinoid receptors.
Upon aligning several nuclear receptor LBD sequences , highly conserved residues that
are part of the cofactor binding pocket and contact the LXXLL motif based on structural
data were selected and mutated by site-directed point mutation in the context of a full-
length RAa expression vector (Fig. 20). The mutations were: V240R from helix 3
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F249R from helix 4 , L261R from helix 5, and E412K, which represents the charge clamp
glutamate in helix 12. Each RAa construct was then labeled with S-methionine by in
vitro transcription/translation reaction. Wild-type and mutant receptors expressed at
equal levels in the reaction as determined by autoradiography (Fig. 21 C). They were then
tested for interaction with RAC3 by GST-pulldown assay using a GST fusion of the
RAC3 receptor-interacting domain (RID) in the presence of 1 flM all-trans retinoic acid
(Fig. 21A, left). GST-RID pulled down a significant amount of wild- type RAa
compared with only minimal binding to GST alone. However, mutation of any of the
cofactor pocket residues drastically reduced this interaction. RAa V240R, L261R, or
E412K, from helices 3 , 5 , and 12 respectively, each abolished RID-receptor binding such
:1'
that only a minimal background signal remained. RAa F249R from helix 4 retained
some interaction with GST-RID , but at a very low level compared to wild-type receptor.
Equal amounts of GST-RID were used in each reaction, as determined by Coomassie
Blue staining (data not shown). Therefore, these results clearly indicate that specific
Since it is unclear how RX, the commonheterodimeric partner of non-steroid 'el
conserved residues within the predicted RAa cofactor-binding pocket and an intact
charge clamp are required for receptor interaction with the RAC3-RID.
nuclear receptors , interacts with co activators , we next analyzed the binding ofRXa 
the RAC3-RID and characterized the RXRa residues required for this interaction. Here
double mutants were made in the proposed cofactor-binding pocket of full-length RXa
(Fig. 20). The mutations were: L276A1V280A from helix 3 (ml) and V298A1L301A
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from helix 5 (m2). Wild-type and mutant receptors were then labeled with 
methionine and tested for interaction with the RAC3-RID by GST-pulldown assay in the
presence of 9-cis retinoic acid (Fig. 2IB). Similarly to RARa , either mutant receptor was
impeded in its interaction with the RAC3-RID , with RXa L276A1V280A abolishing the
interaction and RXRa V298A1L30lA retaining some minimal , but detectable binding.
Intriguingly, several recent studies have determined that the nuclear receptor
corepressors SMRT and NCoR contain an LXXLL-like motif, termed the CoRN box
that is required for interaction with unliganded TR and RA (34 , 73-75). This domain
consists of the consensus sequence LXXVHIXXXVL and also forms an a-helix. The
motif also appears to bind to the same hydrophobic pocket in the receptor as coactivators
but may not require the charge clamp formed by residues from helices 3 and 12 , for the
CoRN box is longer than the LXXLL motif and would not fit in the clamped pocket
conformation (73). Therefore , we wished to determine if the same residues within the
RAa hydrophobic groove that were required for RAC3 binding were also critical to the
binding of the corepressor SMRT. A similar GST-pulldown assay using a GST fusion of
SMR T 982- 1291 , which has previously been demonstrated to be suffcient for binding to
RAa , was used to assess the effects of the RAa mutations on corepressor binding in
the absence of ligand (Fig. 21A, right) (103). GST-SMRT 982- 1291 pulled down
significant amounts of wild-type RAa compared to GST alone. The V240R, F249R
and L261R mutations each inhibited the interaction, with F249R and L261R more or less
abolishing the binding to the receptor, while V240R had a slightly more modest effect.
As expected , mutation ofE412 in helix 12 did not alter the SMRT-RAa interaction
consistent with observations that helix 12 is not required and actually inhibits corepressor
interactions with nuclear receptors (23). This also suggests that an intact charge clamp is
not required for corepressor binding. Similar results were obtained with NCoR (data not
shown). Therefore, the above data demonstrate that RAa uses a similar surface for
interaction wlth coactivators and corepressors with the exception of helix 12, which is
required for binding of coactivators , but not corepressors. However, since mutation of
helix 4 retains some interaction with RAC3 while mutation of helix 3 retains some SMRT
binding, it also appears that the components ofthe cofactor binding pocket do make
slightly different contributions to binding different classes of cofactors. :: I
B. RAC3 recruitment to DNA-bound Retinoid Receptors
We have demonstrated above that RAC3 NR boxes ii and iii are critical for
interaction with the VDR-RX heterodimer bound to a DR3 response element while NR
boxes i and ii control the interaction with RA-RX bound to a DR5 element.
Furthermore , we found that helix 12 ofRX inhibits RAC3 binding to VDR-RXR or
:: I
RA-RXR, for deletion of this domain strongly enhances the shift of these heterodimers
by the Ri\C3-RID. We wished to extend these studies in order to investigate the relative
contributions ofth,::tcspective cofactor binding pockets ofRAa and RXRa to RAC3
interaction with DNA-bound RAa-RXRa. To do this , we first performed
electromobility shift assays with the mutant RAs heterodimerized with wild-type RXa
and tested their abilities to recruit RAC3 to the DR5 in the presence ofretinoic acid
(Fig. 22). Again, we observed a significant shift of wild-type RAa-RXa by the
RAC3-RID on a DR5 element (Fig. 22 , lane 2). However, mutation of each of the helices
making up the cofactor binding pocket ofRAa more or less completely inhibited this
interaction, without significantly affecting heterodimer formation (lanes 3- 10). To
confirm these observations , this experiment was repeated using the helix l2-truncated
RXRa-443 , for de1etion ofRXRa helix 12 enhances coactivator binding to the
heterodimer (Fig. 23 , lane 3). Indeed, mutation of helices 3 , 5 , or 12 abolishes
recruitment of the RAC3-RID while mutation of helix 5 (F249R) significantly reduces
this binding (Fig. 23 , lanes 5 , 7, 9 , 11). To extend this analysis to corepressor recruitment . I.
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by retinoid receptors , similar gel-shift assays were performed using a purified GST-
SMRT 982- 1495 fusion protein in the absence of hormone (Fig. 24). This SMRT
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fragment shifted a portion of the receptor complex to a slower migrating form, while the
entire complex was shifted in the presence ofRXRa-443 (Fig. 24 , lanes 2 , 4). Therefore
the AF-2 domain ofRXR can also inhibit corepressor binding to DNA-bound nuclear
receptors in the absence of hormone , similar to its effects on coactivator binding in the
presence of hormone (Fig. 10). Again consistent with GST-pulldown data (Fig. 21),
mutation of helices 3 , 4 , or 5 strongly inhibited SMRT interaction, with the V240R
mutant still binding weakly (Fig. 24, lanes 6 , 8 , to). Mutation of helix 12 (E412K) , I
expectedly had no effect on recruitment of SMRT (lane 12) compared to wild-type
RAa. Finally, the same result was obtained when this experiment was repeated with
RXRa-443 , except that the residual binding ofSMRT to RAa V240R/RXa-443 was
more evident (Fig. 25). Therefore , these studies support the hypothesis that RAa uses
an overlapping, but not identical surface to bind co activators and corepressors. They also
,.f.
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reveal that the AF-2 domain ofRXa is antagonistic to SMRTrecruitment to
RAa/RXa in the absence of hormone , similar to its effects onRAC3 recruitment in
the presence of hormone.
Although RXRa was able to bind the RAC3-RID in GST-pulldown assays (Fig.
21), it is not currently known ifRXRa makes contacts with co activators in the context of
DNA-bound heterodimeric nuclear receptor complexes. To address this question, the
and the RAC3-RID (Fig. 26). As a positive control, the RID significantly shifted the
1, I
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cofactor pocket mutants ofRXRa were used in gel-shift assays with wild-type RAa
wild-type heterodimer (lane 2) while inclusion ofRAa V240R abolished recruitment of
coactivator completely (lane 4). In contrast, the RXRa mutations had a more modest
effect on coactivator binding. RXa ml or m2 decreased the interaction, but a
detectable shift by the RAC3-RID was still observed (lane 6 8). As expected, the
heterodimer in which both receptors were mutated failed to bind the RAC3-RID (lane
1 0). In order to confinn these observations, we repeated the experiment using RXRa-
:1'
443 instead of wild-type RXRa (Fig. 27). As demonstrated previously, the RAC3-RID
strongly shifts the RARa /RXRa-443 heterodimer compared to the wild-type
heterodimer (lanes 2 .md 4). When RXa-443 harboring the V298A1L301A mutation is
::!,
dimerized with wild-type RAa , this shift is reduced somewhat but a strong interaction
with the RAC3-RTD is still evident (lane 6). Therefore, it can be concluded that the
RAa cofactor binding pocket is required for the recruitment of coactivator while the
RXRa pocket contributes , but is not essential to this interaction. It is likely that the 
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portion of the heterodimer serves as the primary docking point for coactivator and that
any interaction between RXRa and coactivator is secondary and not essential.
As demonstrated above, the contribution of RXRa to coactivator binding by the
RAa-RXRa heterodimer appeared minimal. However, mutation of the RXRa cofactor
binding pocket did severely diminish the interaction with the RACJ-RID in solution, as
evident from the GST-pulldown assay (Fig. 21). In order to investigate these differences
further, we analyzed the interactions between the RAC3-RID and a DNA-bound RXa ;' I
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using a Iabeled DRI element, which has been demonstrated to support binding by
RXRa-RXRa homodimer. In vitro translated wild-type RXRa bound the DRI probe in
the presence of 9-cis retinoic acid and the homodimer was shifted to a slower migrating
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form upon addition of the RAC3-RID (Fig. 28, lanes 1 2). In contrast, when the RXa
L276A1V280A or V298A1L301A mutants were used in the binding reaction, they were
unable to bind to the RID (lanes 4 6). However, the L276A1V280A mutant homodimer
displayed considerably weaker DNA binding, thus this mutation may affect
homodimerization or the overall structure of the protein to a greater extent than the
V298A1L301A mutation, which bound DNA as well as wild-type RXRa. These results
indicate that the RXRq cofactor binding pocket is critical to coactivator binding to the
1;,,
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RXR homodimer, but plays a minimal role in coactivator binding to a RAa-RXa
Ir'
heterodimer.
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C. Effect of RARa mutations on transcriptional activity in vivo
In order to understand the functional consequences of mutating the cofactor
binding site ofRAa in vivo , we performed transient transfection assays to investigate
the transcriptional activity of these mutants compared to wild-type RAa (Fig. 29). As a
control, an additional mutant RAa, RAa-403 , was also tested for transcriptional
activity. RAa-403 , in which helix 12 has been deleted entirely, has previously been
demonstrated to constitutively repress transcription due to enhanced corepressor binding
and failure to recruit coactivator upon hormone binding (23). HEK293 cells were co-
transfected with the expression plasmid for each receptor along with a luciferase reporter
containing the RA response element from the RAp promoter and a beta-galactosidase
plasmid that allows normalization of luciferase activity. Transfected cells were also
treated with 50 nM all-trans retinoic acid or solvent only for 24 hours before harvesting.
In the absence of hormone RAa had little activity compared to the empty vector alone
while RAa-403 repressed transcription below the basal level as expected. In addition
the RAa V240R, F249R, and L261R mutants all had no effect on reporter expression.
However, the helix 12 point mutant, RAa E412K, did decrease basal expression
somewhat , although not to the extent of the helix 12 truncation, RAa-403 , consistent
with the ability ofRARa E412K to retain corepressor binding in vitro.
In the presence of hormone , the reporter alone was stimulated 2-fold, likely due to
the activation of endogenous retinoid receptors. Transfection of wild-type RAa
resulted in an additiona14-fold enhancement in reporter expression. As expected
RAa-403 retained the ability to repress transcription even in the presence of ligand
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while each of the point mutations strikingly inhibited transcriptional activation by RAa.
RAa F249R retained the most activity, consistent with its ability to still bind the RAC3-
RID weakly in vitro. However, RARa V240R, L261R, and E412K actually displayed a
slight dominant negative effect on the RARE-driven reporter. This finding can likely be
attributed to the formation of inactive heterodimers with endogenous RX, thereby
titrating away the formation of active, endogenous RA-RX heterodimers in 293 cells.
Therefore, these observations correlate with the above in vitro data in implicating specific
residues in the cofactor binding pocket of RAa as being critical to both the interaction
with RAC3 and transcriptional activation upon hormone binding. It also suggests that
recruitment of co activators such as RAC3 is required for transcriptional activation by
RAa in vivo.
In order to more clearly investigate the role of the RAa cofactor binding pocket
in transcriptional repression in vivo , the V240R, F249R, and L261R point mutants were
sub cloned into the RAa-403 expression plasmid. Since RAa-403 represses
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transcription more strongly than the full- length receptor, the effects of these mutations on
this repression activity should be more evident in the context of the truncated RAa.
Co-transfection ofRAfa-403 with the RA-driven reporter resulted in a significant
repression of basal activity in the absence of hormone (Fig. 30). However, expression of
either RAa-403 V240R, F249R , or L261R each abolished the ability ofRAa-403 to
repress transcription, consistent with the reduction in interaction with the corepressor
SMRT in vitro. This suggests that recruitment of nuclear receptor corepressors such as
I,'
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SMRT is required for RAa to repress transcription in vivo , for mutations that abolish
corepressor interaction also abolish repressor activity.
D. Effects of RXRcx mutations on transcriptional activity in vivo
We next performed experiments to characterize transcriptional activation by :11
RXRa in vivo by co-transfecting 293 cells with the wild-type receptor or cofactor pocket
mutants with a luciferase reporter driven by a DRI-containing promoter (Fig. 31A).
Treatment of cells transfected with empty vector with 9-cis retinoicacid had little effect
on reporter activity while transfection of wild-type RXa strongly stimulated expression
approximately 22-fold. RXRa L276A1V280A and V298A1L301A were much less
effcient in transcriptional activation, consistent with their impaired abilities in binding
coactivator in vitro. However, in contrast to the mutated RAa , the mutated RXa was
still able to activate transcription to some extent. Several possibilities may explain this
observation. First, RXRa V298A1L301A retained some RAC3 binding in vitro , albeit
very weak. Secondly, RAC3-independent mechanisms of transcriptional activation may
also contribute to R)Ra activity. This hypothesis contrasts with RAa, in which
co activator binding appeared to be required for activation. It is also possible that
hormone treatment is activating endogenous retinoid receptors at the DRI-driven
reporter.
A much different result was obtained when a similar experiment was performed to
analyze the RAa/RXRa heterodimer. RAa was cotransfected with wild-type or
mutant RXRa and a reporter under the control of a DR5 response element (Fig. 31B).
All-trans retinoic acid, which is specific for RAa , stimulated this reporter without
overexpression of receptors , likely by activating endogenous retinoid receptors.
Overexpression of wild-type RAa/RXRa fm1her enhanced reporter expression nearly
fold. Interestingly, wild-type RAa coexpressed with RXRa V298A1L301A also did
not alter receptor activation of the DR5 reporter, in contrast to its fuction at the DRl- Ilil
driven reporter, where it was 4-fold less active than the wild-type receptor. These
findings are consistent with our gel-shift data, which demonstrated that the RXRa
cofactor binding pocket was critical to RAC3 interaction with the RXa-RXRa
homodimer at a DRI element, but only made minor contributions to coactivator binding
to the RAa-RXRa heterodimer at a DR5 element. However, the RXa L276A/280A
In summary, several novel aspects have been uncovered concerning the structural
mutation did slightly reduce transcriptional activation. This may be due to the more
serious effects on overall RXRa structure that occur upon mutating these residues , as
described above. It is also possible that helix 3 may be more important to RXa activity
relative to helix 5.
requirements of retinoid receptors in the recruitment of co activators and corepressors.
First , the binding pocket ofRAa for these co factors does overlap to a significant extent.
Nuances do exist , however, for an intact helix 12 is required for RAC3 interactions in the
presence of hormone but not for SMRT interactions in the absence of hormone.
Furthermore , although mutation of helices 3 , 4 , and 5 does significantly inhibit binding to
both cofactors , it appeared that intact helix 4 was slightly less critical to recruitment of
;kl.
RAC3 while intact helix 3 was less important to the recruitment of SMRT. However, one
cannot rule out the possibility that the effects of these mutations were due to more global
conformational changes in the receptor s structure rather than the inhibition of
interactions with a specific domain within the receptor. Second , recmitment of these
co factors in vitro correlates perfectly with the transcriptional activity of the receptors in
vivo , since RAC3 interaction was required for activation while SMRT binding was
essential to repression. Third, the coactivator pocket ofRXa contributes differently to
RAC3 binding depending on the receptor complex. It is required for coactivator
regulation of the RXa homodimer, but contributes minimally to the RAa/RXa
heterodimer. Lastly, the AF-2 domain ofRXa is clearly a vital regulatory domain in
governing interactions between cofactors and the RAa/Ra heterodimer, for as in the
case of the liganded heterodimer and RAC3 binding, this region also inhibits SMRT
binding to the unliganded heterodimer.
CHAPTER V
CONCLUSIONS AND DISCUSSION
A. Conclusions
In this thesis , I have characterized in detail the mechanism by which the
coactivator RAC3 regulates the function of nuclear receptors. The centrally located NR
boxes , which are comprised of a-helical LXXLL motifs , have been demonstrated to be
absolutely critical to the interactions between RAC3 and the various receptors, namely
the vitamin D , estrogen, and retinoid receptors. Furthermore, these receptors also had a
preference for specific RAC3 NR boxes. It was discovered that NR box iii is required for
VDR binding, while NR box ii is essential for RAa binding, and NR boxes i , ii, and iii
are involved, but not individually required for ERp interaction. Consequently, the
specific motifs were also crucial to the ability of RAC3 to enhance transcriptional
activation by these receptors in vivo. The C-terminal NR boxes ofRAC3 were also
analyzed in terms of the transcriptional activation fuction of the coactivator. A single
NR box in the RAC3-AD proved to be necessary for activation by RAC3. Mutation of
this motif not only abolished the activity ofRAC3 , but also severely impaired its
interaction with the general transcriptional coactivator CBP. However, multiple
mechanisms of activation by RAC3 were uncovered, for this mutation slightly reduced
RAC3 coactivation ofRAa , but not ERp. In terms of the receptors themselves , it was
covered that the coactivator and corepressor binding pockets overlap to a large extent
with subtle structural differences being evident, however. Recruitment ofthese co factors
was also found to be essential to the transcriptional activity of the receptor in vivo.
Finally, it was demonstrated that the AF-2 domain ofRXa was a key regulatory module
goveming the interaction of both RAC3 and SMRT to retinoid receptors.
B. RAC3 NR boxes Regulate Interactions with Nuclear Receptors and CBP
The NR boxes are highly conserved among the SRC family of co activators (104).
Our data and that of others clearly reveal that multiple motifs are necessary for high
affinity interactions with nuclear receptors (64, 67, 70, 71). Furthermore , this work has
uncovered receptor-specific preferences for the different NR boxes of the RAC3
receptor-interacting domain. NR box iii was required for VDR binding, while NR box ii
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was essential for RAa binding, and NR boxes i , ii , and iii were involved, but not
individually required for ERp interaction. Peptides corresponding to these motifs were
able to compete with the RAC3-RID for receptor binding. The integrity of the motifs
themselves was also important, for mutations in specific NR boxes inhibited RAC3
interactions with these receptors in vitro. With the DNA-bound VDR/RXRa heterodimer
we found that mutation ofNR boxes ii or iii ofRAC3 weakens the interaction with the
RAC3-RID. In contrast, NR box iii ofRAC3 is the only critical motif for interaction
with VDR in solution. Therefore , it is likely that each motif binds to each monomer of
the receptor heterodimer, consistent with the structure of a PP ARy- LBD dimer co
crystallized with a fragment of SRCI containing two NR boxes (34). Biochemical data
receptor (106). TRA 220 contains two consensus NR boxes , with RXR preferrng box 
supporting this hypothesis is evident in a study of TRA220 interactions with nuclear
receptors (105). TRA220 links certain receptors to the TRA complex , a large group of
polypeptides initially demonstrated to be required for the activity of the thyroid hormone
and its partner (VDR, TR, or PP AR) having a clear preference for NR box 2 , as shown by
in vitro binding assays. Both motifs are required for effcient interaction ofTRA220
with DNA-bound TR/RXR or VDR/RXR and optimal coactivation ofVDR-mediated
the DRIP complex , DRIP205 (107). Mutation ofNR box i ofRAC3 also drastically
transcriptional activation. Similar results were reported with the TRA220 homolog of
reduced interaction with RXRa , while having much weaker effects on RAC3 interactions
with VDR or RAa. Therefore , for RXa heterodimers, motifi ofRAC3 likely
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contacts RXa and motifs ii and iii are utilized by the partnering monomer. The above
data on ERp suggest that all three NR boxes of the RAC3-RID are involved for a wild-
type interaction while the presence of two motifs is suffcient for a strong interaction
motif ii being most important. In light of this finding, RAC3 may utilize motif ii in
combination with motif i or iii for effcient interaction with the ERp homodimer. The
integrity of the other motif may be critical to the overall conformation of the coactivator
or potentially make :1/ additional contact with another region of the receptor. Support for
the latter possibility can be found in recent studies detailing the enhancement of the N-
terminal AF- l activation function of nuclear receptors by SRC co activators (38 , 41). The
presence of multiple NR boxes also likely provides co activators the flexibility to interact
with a proad range of nuclear receptors, resulting in the different preferences that are
observed between nuclear receptors and distinct motifs , depending on the precise
structural nuances of each receptor-coactivator interface. This is evident upon comparing
the NR box requirements of the VDR/RXRa heterodimer versus those of VDR/RXRa-
443. Deletion of the AF-2 helix ofRXRa not only enhances RAC3-RID binding to the
heterodimer, but also switches the NR box preferences from motifs ii/iii to motifs i/iii.
Finally, amino acids flanking the NR boxes also likely contribute to the specificity of
interaction (71 108), for, despite the high homology between the RAC3 NR boxes
peptides comprising each motif and surrounding residues displayed different affnities for
VDR or ERp binding. Thus , it is clear that the multiple NR boxes do not serve merely
redundant functions.
Importantly, this receptor-specific code has also been analyzed in vivo in terms of
transcriptional coactivation of nuclear receptors by RAC3 via transient transfection
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assays. Consistent with the in vitro interaction data, mutation ofNR box ii or iii blocked
the ability ofRAC3 to enhance the activityofVDR in CV- l cells. In contrast, mutation
ofNR boxes i , ii , or iii reduced, but did not abolish RAC3 coactivation ofERp. Similar
studies have been performed with SRC- l using site-directed mutagenesis and antibody
microinjection ass.lXS (71). The requirement of specific NR boxes for transactivation of
reporter genes by different receptors was determined by injecting anti-SRC- l antibodies
into cells along with rescuing plasmids for wild-type or NRbox; mutants of SRC- l. Anti-
SRC- l IgG completely abolishes transcriptional activation by ER, PR, RA. TR, and
PPARy, while coinjection of wild- type SRC- l rescues receptor function. Mutation ofNR
box ii ,prevented rescue of ER function in SRC- l immunodepleted cells while NR boxes
ii and iii were required for rescue ofRA and TR activity and boxes i and ii for PR
activity. Furthermore , in the case ofPP ARy, different ligands elicited different NR box
requirements for SRC- l coactivation. Troglitazone-bound PP ARy preferred NR box ii
over box i while the opposite was observed in indomethacin treated cells. Together, these
data support receptor-specific LXXLL motif requirements for coactivation function and
receptor interactions that account for the presence of multiple NR boxes within SRC
coactivators.
A role also has been revealed for the C-terminal NR boxes ofRAC3 in the
transcriptional activation function of the coactivator, for RAC3 can activate transcription
when fused to the Ga14 DNA-binding domain. NR box v ofRAC3 proved to be required
for wild-type trans-activation by RAC3. Mutation of this motif not only abolished the
activity ofRAC3 , but also nearly abolished the ability ofRAC3 to interact with the
general transcriptional coactivator CBP. This observation suggests that one mechanism
by which RAC3 is able to activate transcription is via recruitment ofCBP. However
other, CBP-independent mechanisms of activation by SRC members clearly exist (41 , 43
64). In support of this , we found that mutation ofNR box v had no effect on the ability
ofRAC3 to coactivate ERp. RAC3 may recruit other factors such as CARI or the
DRIP/TRA complex , or target the general transcription machinery in order to enhance
ERp activity. In contrast, the NR box v mutation did slightly reduce coactivation of
RAa , indicating that CBP recruitment may be contributing factor to RAC3 coactivation
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of RAa.
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C. Mechanisms of Cofactor Recruitment by Retinoid Receptors
The residues required for cofactor interaction and the contribution of these amino
acids to the transcriptional activity of the receptor were also investigated. Recent
crystallographic evidence has detailed the formation of a hydrophobic pocket, induced by
ligand binding to nuclear receptors , which serves as the docking surface for the LXXLL
motif of co activators (31-34). This pocket consists of helices 3 , 4 , and 12 of the
ligand-binding domain and also includes the charge clamp, a conserved glutamate from
helix 12 and lysine from helix 3 , which positions the motif within the pocket. Based on
the corresponding residues interaction with the LXXLL motif in the crystal structures of
hERa , hTRp, or hPP ARy complexed with SRC fragments , a highly conserved amino
acid from each ofthese helices of human RAa was selected for analysis. We found that
mutation of valine 240 , phenylalanine 249 , or lysine 261 , from helices 3 , 4 , and 5,
respectively, each strikingly inhibited RAa interactions with RAC3 in vitro and
transcriptional activation by the receptor in vivo. Mutation of the charge clamp
glutamate, E412 , had the same effect. We concluded from these findings that coactivator
interaction is required for transcriptional activation function ofRAa. This also
suggests that any contribution ofthe RAa AF- l domain to the overall activity of the
receptor is minimal. Interestingly, the V240 , F249 , or L261 mutations also impaired the
interaction ofRAa with the nuclear receptor corepressor SMRT. In the context of
RARa 403 a helix 12 truncated receptor that constitutively represses transcription, these
mutations also blocked this repressor activity. Thus , corepressor recruitment is required
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for transcriptional repression by RAa. This data is consistent with recent studies that
describe an LXXLL-like motif, termed the CoRN box , which is required for corepressor
interaction with unliganded nuclear receptors and may also bind to the same hydrophobic
pocket on the receptor as co activators (73-75). However, unlike co activators , the charge
clamp and helix 12 are likely not involved in the binding of corepressors , based on the
length of the CoRN box. Our finding that mutation of glutamate 412 from helix 12 has I',
no effect on the RAa-SMRT interaction support this hypothesis.
Finally, we have investigated the ability ofRXRa , the common heterodimeric partner
for non-steroid nuclear receptors , to interact with RAC3. In solution RXa was able to
bind the RAC3-RID , and mutation of specific cofactor-pocket amino acids inhibited this
interaction. Intriguingly, however, the contribution of the RXa cofactor pocket
contributed differently to coactivator recruitment to DNA-bound nuclear receptors
depending on the paricular dimer examined. In the case of the RXa/RXa
homodimer bound to a DRI element, the cofactor pocket was required in order to bind
the RAC3-RID. Consistently, mutation ofthis pocket drastically reduced the ability of
RXRa to activate transcription in vivo from a DRI-driven reporter. A different pattern
was evident upon examining the RAa/RXa heterodimer. Here, the RXa cofactor
pocket only contributed somewhat to coactivator binding at a DR5 element , while the
RAa pocket was absolutely required. In support of this in vitro data, the RXa mutant
had only slight effects on RAa/RXa transcriptional activity at a DR5-driven reporter
II V1VO. In summary, these observations suggest that RAa is the primary docking point
for coactivator binding to the RAa/RXRa heterodimer, but that RXa can also recruit
RAC3 to the RXRa/RXRa homodimer. In both cases , an intact cofactor binding pocket
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is essential to the recruitment ofRAC3.
D. The AF-2 domain is a Critical Regulator of Cofactor Recruitment
The finding that the AF-2 domain ofRXa can interfere with RAC3-RID binding to
a DNA-bound VDR/RXRa or RAa/Ra heterodimet is consistent with studies
suggesting allosteric inhibition of co activator binding to RAR by the RX AF-
domain (100). This inhibition may be the result of competition between the AF-2 domain
ofRXR and the LXXLL motif for the coactivator binding site on the other receptor. In
the antagonist-bound ERa-LBD and RARXR-LBD crystal structures , the AF-2 domain
occupies the coactivator binding groove, mimicking the hydrophobic interactions of the
NR box peptide with this domain in the agonist-NR box peptide-receptor complex (31
77). Biochemical studies with RARXR and SRCI support these observations , for
binding ofRA- and RXR-specific ligands enhance SRCI interaction with the receptor
dimer relative to the interaction in the presence of either ligand alone (100). Presumably,
one ligand binding fecruits a single NR box to the receptor dimer, which displaces the
AF-2 domain from the coactivator binding site and relieves allosteric inhibition, allowing
the second ligand to bind the other receptor monomer. This , in turn, enhances the
interaction with coactivator by recruiting a second NR box (100). In the case of wild-
type receptors , hormone does stimulate RAC3-RID binding to the heterodimer, but only
weakly compared to the VDR/RXa-443 or RAa/RXRa-443 dimers , where a very
strong, ligand-dependent interaction is observed. These observations are confirmed by in
vivo studies demonstrating that RAC3 can coactivate VDR/RXa-443 activity to a
greater extent than VDR/RXRa activity. Hormone binding and RID recruitment must
not be able to displace every RXa AF-2 domain from the coactivator binding site of the
partnering receptor, thus fewer RID molecules are able to bind in the presence of the
RXRa AF-2 domain. This suggests that the AF-2 domain ofRXRa plays a critical role
in regulating RAC3 modulation of receptor function. However, other possibilities may
explain this finding, foremost being the hypothesis that deletion of the AF-2 domain of
RXRa results in a conformational change of the VDR/RXa-443 dimer that enhances its
affnity for the RAC3-RID. Our data demonstrating that the coactivator and corepressor
binding sites ofRAa overlap to a large extent further support the critical role of the AF-
2 domain in regulating cofactor interactions with nuclear receptors. Intact helices 3 , 4
and 5 are required for both RAC3 binding to liganded RAa and SMRT binding to
unliganded RAa. However, helix 12 , which comprises the AF-2 domain is only
required for coactivator binding. Therefore , these studies suggest that co activators
corepressors , and the RXR AF-2 domaip all can interact with a similar surface on the
partnering monc.mer. Corepressor may displace the AF-2 domain ofRX and bind to the
DNA-bound heterodimer in the absence of hormone. Thus , helix 12 is not required for
corepressor-receptor interactions. Our data demonstrating that mutation of the highly
conserved glutamate in RAa helix 12 has no effect on the RAa-SMRT interaction
support this hypothesis. Subsequent ligand binding by the receptor induces a
conformational change in helix 12 that may displace corepressor, thereby facilitating
coactivator binding. This indicates that helix 12 is essential for coactivator binding.
However, it does appear evident from the data presented here that slight structural
differences do exist between the coactivator and corepressor pockets in addition to the
contribution of helix 12. Specifically, RAC3 retained some residual binding to RAa
F249R while RAa V240R had somewhat weaker effect on interaction with SMRT.
Therefore , it is possible that helix 4 may be less important to coactivator binding while
helix 3 is not as critical to the binding of corepressors.
E. Functional Differences between Members of the SRC Family
Our data demonstrates for the first time that RAC3 can enhance the transcriptional
activation function of the VDR and ERp, and that this coactivation activity depends on
different NR box requirements. Several other co factors have been found to stimulate
VDR activity, including SRCl , GRIPl/TIF2 , NCoA- , and the DRIP complex (109-
112) while SRCI can coactivate the ERp (113). The role of multiple co activators in the
function of nuclea; h ceptors in vivo is one of the most important remaining questions to
be answered concuning the function of the SRC family. Although all three members do
possess similar properties in terms of interactions with nuclear receptors and
enhancement of transcriptional activation, several reports suggest that their activities are
not completely overlapping and particularly outline a division between SRC- l and
TIF2/GRIPl versus RAC3/ACTR/pCIPiAIBl functions. For example, microinjection of
expression plasmids for SRC- l or NCoA- , but not pCIP , were able to rescue RA-
dependent activation in SRC- l immunodepleted cells (53). Also , the relative contrbution
of each coactivator may depend on cell or tissue type and/or coactivator levels in these
relative to TIF2 and SRC- , thus it may serve a more prominent role in nuclear receptor
cells. RAC3/ ACTR/ AIB- l is expressed at high levels in placenta, heart, and HeLa cells
expressed at relatively low levels in these cell lines , suggesting that AIB- l is specifically
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function in these cells (57). In addition, AIB- l was cloned as a gene that is amplified in
ER-positive BT-474 , MCF- , and ZR75 breast cancer cell lines (55). AIB- l mRA and
protein levels are expectedly higher in these cells as well. SRC- l and TIF2/GRIPl are
involved in the pathogenesis of these tumors. Our data demonstrating that RAC3 can
coactivate both RAa and ERp while TIF2 co activates only ERp and SRC- l does not
coactivate either receptor support the hypothesis of distinct roles in receptor regulation by
the three members of the SRC family of coactivators. Consistently, RAC3 and TIF2 NR
box peptides have been demonstrated to have a higher affnity than those of SRC- l for
ERp (114).
However, perhaps the most conclusive evidence for unique functions of SRC
co activators can be found in studies from the O' Malley laboratory detailing SRC- l and
RAC3 knockout mice (60 , 61). In the SRC- l -/- animal, the mice had no external
phenotype compared with the wild-type control mice (61). Both males and females
displayed normal growth rates and were fertile. However, upon analysis of steroid
hormone responses in reproductive tissuesi female mice did show decreased estrogen-
induced uterine growth while males exhibited decreased testosterone-induced prostate
growth. Females were also inhibited in terms of mammary ductal elongation and alveolar
development. An additional study demonstrated that the SRC- l null mice also displayed
a resistance to thyroid hormone (115). These findings suggest that SRC- l is required for
maximal response to hormone in vivo. Interestingly, the coactivator TIF2 was
overexpressed by two- fold in these animals while the expression level ofRAC3 was
unaffected, indicating that TIF2 may compensate for the loss ofSRC- l and that RAC3
may serve a different functional role in steroid receptor activity. This was confirmed in
the report of the RAC3 knockout mouse (60). These mice displayed a much more severe
phenotype. Males and females had reduced growth rates , likely due to decreased levels
of insulin-like growth factor (IGF- l). Furthermore, females were delayed in the onset of
puberty and had abnormal reproductive function, as measured by decreased ovulation
decreased pregnancy rates , and decreased litter sizes. Finally, as in the SRC- l knockout
female RAC3 -/- mice also were impaired in the development of the mammary gland.
These two studies clearly outline a distinct biological role for RAC3 versus SRC- l and
TIF2 , with RAC3 likely being more critical to overall growth and sexual maturation.
F. SRC.associated Coactivators
In addition to the SRC family of co activators, many other co factors have been
identified which stimulate the activity ofnuc1ear receptors (116). For the sake of brevity,
only those associated with SRC family members will be discussed here.
SRA
Recently, in a search for nuclear receptor cofactors , a novel steroid receptor RNA
activator (SRA), was isolated in a yeast-two-hybrid screen using the AF- l domain of the
PR as the bait (117). This coactivator is selective for the N- tern1inal AF- l activation
domain of nuclear receptors and can reverse estrogen-induced squelching ofPR-driven
gene expression. Interestingly, SRA is also selective for steroid receptors versus RXR
heterodimers , for it enhances only PR, GR, AR, and ER activities while having no effect
on the activities of the TRp, RAy, RXRy, or PPARy. However, maybe the most
surprising characteristic of SRA is that it apparently fuctions as an RNA transcript
which is evident from several observations. First, efforts to generate SRA-encoded
protein in vitro or in vivo were not successful. Second, several mutant constructs of SRA
that disrupt translational start sites or open reading frames were still able to potentiate 
activity. Third, SRA retained coactivation activity in the absence of protein synthesis via
cyclohexamide treatment. Finally, SRA transcripts were identified as components of an
SRC- l complex in vivo via whole cell fractionation followed by gel filtration
chromatography. SRA, detected by RT-PCR, specifically copurified with SRC- l in the
same fractions. SRA rnA was also efficiently coimmunoprecipitated with SRC-
antibodies , further supporting the existence of a complex containing SRA and SRC-
This study suggests that SRA is a novel RNA coactivator that forms a complex with
SRC- l in vivo and selectively enhances the activity of steroid hormone receptors via the
AF - 1 domain.
CARMI
A novel enzymatic activity was attributed to nuclear receptor co activators with
the cloning of CARI (Coactivator-associated arginine methyltransferase 1) via a yeast-
two-hybrid screen using the C-terminal amino acids 1121- 1462 of GRIP 1 (80). This
region represents a second, CBP-independent activation domain of GRIP 1 (41). CARI
showed extensive homology to the PRMT (protein methyltransferase) family of arginine-
specific methyltransferases and interacted with all three members of the SRC coactivator
family in vitro. Furthermore, CARI contained potent histone methyltransferase
activity in vitro , with a preference for histone H3. In vivo, CARI enhanced
transcription by a Ga14-DBD fusion of GRIP 1 1121-1462 and further stimulated GRIPI
coactivation of AR, TR, and ER activities. This coactivation function was dependent
upon three amino acids located in the region critical to methyltransferase activity,
suggesting that this enzymatic activity is required for CARl' s ability to enhance
receptor function. In the absence of GRIP 1 , CARI had no effect on receptor function
thus SRC coactivators are likely required in order to recruit CARI to the receptor
complex. Overall , the cloning of CARI contributes to the mechanism by which SRC
co activators activate transcription through multiple domains. One activation domain may
be required in ordeqo recruit CBP/p300 and histone acetylation activity, while the
second activation domain recruits CARI and histone methylation activity. These
multiple nzymatic functions may be promoter specific or cooperate to remodel
chromatin and facilitate transcriptional activation.
- - -- 
PGC-
The cloning and characterization ofPGC- l (PPAR Gamma Coactivator- l) was a
critical finding to the field of nuclear receptor co activators , for it linked coactivator
function to the regulation of a specific physiological process , namely adaptive
thermogenesis. PGC- l was isolated in a yeast-two-hybrid screen using PP ARy 183-505
as the bait and was demonstrated to interact with several members of the nuclear receptor
superfamily (118). It also possesses potent coactivation function for PP ARy and TR
activities at the UCP- l (uncoupling protein- I) promoter, inducing the expression of this
mitochondrial protein involved in heat generation in brown fat cells. Consistently, PGC-
1 is also upregulated in muscle and brown fat cells upon exposure to cold temperatures.
Further studies have demonstrated that PGC- l enhances mitochondrial biogenesis and
oxygen consumption in muscle cells via the induction ofUCP-2 and the regulation of
NRs (nuclear respiratory factors), which are transcription factors that regulate genes
involved in mitochondrial DNA replication and transcription (119). Finally, a very recent
study reports the functional association between PGC- l and SRC- l (120). SRC- , as
well as CBP/p300 , interacts with PGC- l in vitro and in vivo and enhances transcriptional
activation by a Ga14DBD fusion ofPGC- l in transient transfection assays. These
interactions are mediated by SRC- l 782- 1139 and p300 1805-2441. Intriguingly,
expression ofPPARy or NR- 1 also enhanced Gal-PGC- l activity while cotransfection
ofPPARyincreased the interaction between PGC- l and SRC- l or CBP/p300 in vitro and
in vivo. These data support a model ofPGC- l activation in which the interaction with a
transcription factor such as PP ARy stimulates PGC- l activity by inducing SRC-
recruitment (120). This recruitment likely is the result of a confonnational change in
PGC- l that occurs upon binding to the transcription factor. This study also suggests the
SRC coactivator function may be essential to adaptive thermogenesis, for it may be
required for transcriptional activation by PGC-
G. Co activator Complexes
Much effort has been made recently to isolate and purify an entire complex of
polypeptides that functions to coactivate nuclear receptor function. However, the few
studies that have been reported concerning the existence of an SRC coactivator-
containing complex are unclear and even contradictory. Xu, et al identified one such
complex by incubating T47D cell extracts with purified, histidine-tagged PR immobilized
on a Ni affnity column (121). Upon elution, SRC- l and CBP were found in the PR-
containing fraction only in the presence of progesterone. Furthermore, this complex co-
immunoprecipitated in the presence of hormone using an anti-CBP antibody and was
prevented from assembling upon expression ofEIA. However, using gel filtration
fractionation ofT47D or HeLa celllysates , McKenna, et al found that SRC- l and CBP
eluted in distinct fractions, implying that these proteins exist in different preformed
complexes (122). CBP copurified with the p300/CBP-associated factor PCAF while
SRC- l copurified with TIF2. Therefore, from these studies, it is diffcult to get a clear
picture of the existence of an SRC complex in vivo.
DRIP/TRAP Complex
Several groups also have identified virtually identical complexes that appear
distinct from the SRC coactivator complex. Using the VDR-LBD as an affnity matrix , a
complex was purified from Namalwa cell extracts tern1ed DRIP (VDR- interacting
proteins) that specifically interacts with ligand-bound VDR-LBD (111). The same
complex was also purified using affnity chromatography from HeLa cells that
constitutively express Flag-tagged TR and named TRA (TR-associated proteins) (106).
Subsequently, this complex was identified as ARC (activator-recruited cofactor) (123)
and SMCC (Srb/Mediator coactivator complex) (124). The DRIP/TRA complex lacks
CBP/p300 or SRC proteins (125) and is recruited to the receptor AF-2 domain by the
DRIP205/TRA220 subunit via a single LXXLL motif(125 , 126). Additional contacts
between the DRIP150 subunit and the AF- l domain of the glucocorticoid receptor have
also been reported , which together with DRIP205 , may functionally link the GR AF-
and AF-2 domains to maximally enhance GR activity (127). Unlike SRC co activators
the DRIPs/TRAs have been demonstrated to be required for transcriptional activation by
nuclear receptors in cell-free in vitro transcription assays (106, 111). The DRIPs also
enhance VDR activity on chromatin-organized templates despite a lack of HAT activity,
suggesting a potential unidentified chromatin remodeling function (125). Furthermore, it
is evident that thIS complex plays a more global role in transcriptional activation rather
than being specific to nuclear receptors, for ARC was identified as a coactivator for VP16
and p65 (123), while SMCC enhances p53 activity (124).
Swi/Snf complex
The Swi/Snf complex, which contains ATP-dependent chromatin remodeling
activity, has also been implicated in nuclear receptor function (128). Initially identified
by yeast genetics as a group of gene products which reduced expression of the SUC2 and
HO genes involved in sucrose fermentation and mating-type switching, homologs were
later cloned from Drosophila (Brahma) and mammalian cells (hbrm and BRG- l). The
first link to receptor function was revealed by the loss of steroid-induced transcriptional
activation by the GR and ER in Swi/Snfmutant yeast strains (129). Additional work on
the GR demonstrated that hbrm and BRG- l could enhance GR activity in mammalian
cells and that GR transactivation of chromatin organized templates required the BRG-
complex (130 , 131). This interaction between GR and the Swi/Snf complex was
subsequently shown to be mediated by the AF- l domain of the receptor, suggesting the
possibility that the Swi/Snf and SRC complexes may cooperatively enhance receptor
function via recruitment to the AF- 1 and AF-2 domains , respectively (132). Finally,
hbrm and BRG- l have also been demonstrated to potentiate transcription by the ER and
RA (133).
H. Model of SRC Function
In order to integrate the wealth of data collected on the mechanism of action of
SRC co activators , the following model of SRC fuction in the regulation of nuclear
receptor activity can be proposed (Fig. 32). Hormone binding triggers nuclear
translocation of Type I steroid receptors and the release of the corepressor complex from
Type II non-steroid receptors and subsequent recruitment of an SRC coactivator to the
target gene promoter. SRC is able to interact with the AF-2 domain of each monomer of
the dimer via multiple, a-helical NR boxes located in the receptor-interacting domajn.
SRC is likely complexed with the RNA coactivator SRA, which enhances AF- l activity.
After initial SRC docking to the receptor, it is able to recruit additional co activators to the
complex. These include CBP/p300 , which uses the NR boxes of the SRC transcriptional
activation domain for interaction with coactivator, and the CBP/p300-associated factor
P/CAF. Additional, direct interactions between CBP/p300 and nuclear receptors and
between P/CAF and SRC have also been reported, which may enhance complex
formation. Furthermore , SRC is also able to recruit CARI to the target gene via a
different domain than that required for CBP/p300 binding. Once this complex is
assembled, the histone acetylase activities of CBP/p300 , P/CAF, and possibly SRC itself
together with the histone methyltransferase activity ofCARl , serve to modify
chromatin, thus facilitating the access of additional transcription factors , co activators
such as the DRIP/TRA complex , and/or the basal transcription machinery to the target
gene promoter to activate transcription. Of course , caveats to this model likely exist. For
example, the coac 1ivator complex may be comprised of different components depending
on the specific nuclear receptor, cell type, or target gene. Different co actIvator complex
components may create a level of specificity among different receptors that answers the
questions surrounding the potential redundancy among the members of the SRC family.
Also , with the intense focus on hormone action and plethora of receptor co factors being
cloned in recent years , it is likely that additional members of the coactivat6r complex
have yet to be identified. In addition, non-histone substrates for the enzymatically active
co factors may be involved , for as described above, CBP/p300 can acety1ate non histone
proteins such as ACTR, p53 , and TFIIE/TFIIF. Finally, it is possible that the receptor is
able to recruit single , pre-formed coactivator complex to the target gene upon hormone
binding. However, though the precise details of transcriptional activation by nuclear
receptors are stil not clear, it is evident that the SRC family of co activators is critical to
receptor function and will continue to warrant investigation into its role in intracellular
signaling pathways.
Models of Multiple Coactivator Complexes in Nuclear Receptor Function
One of the most important questions remaining to be answered concerning the
transcriptional activation function of nuclear receptors is how these coactivators
including the SRC family, CBP/p300 , the DRIP/TRAs , and Swi/Snf, all contribute to
receptor function. Several models have been proposed (Fig. 33) (99):
1) Sequential: In this model , each coactivator complex is recruited to a given promoter
by the receptor in sequence. For example, Swi/Snfmay be recruited first in order to
remodel the chromatin architecture by nucleosomal disruption/displacement, thereby
facilitating the access of subsequent activators. Upon completion of this activity, this
pF.
complex leaves the promoter and is replaced by the SRC complex, which contains
histone acetylation and methylation activities. The SRC complex may then be
dissociated by acetylation of SRC by CBP (94) and exchanged for the DRIP/TRA
complex , which likely targets RNA polymerase and the basal transcription machinery
(134). It is unclear whether a given complex actively recruits the next complex or if
other signaling events , such as phosphorylation, lead to the exhange of complexes.
2) Cooperative: Here , different coactivator complexes may be recruited at the same time
to distinct hormone response elements at a given promoter. The SRC and
DRIPITRA complexes may bind separate receptors at the target gene promoter and
together synergize for maximal transcriptional activation. It is possible that the
sequences flanking a given response element may contribute to the specificity of
coactivator recruitment or that the different complexes can compete for receptor
binding.
3) Parallel: Finally, it is also possible that different coactivator complexes are recruited
to the same target gene in a signal specific manner. For example, signal A, be it a
phosphorylation event or the binding of another transcription factor, may result in the
recruitment of the SRC complex to a given receptor. On the other hand, signal B may
stimulate the recruitment of the DRIP/TRA complex. This model would allow for
different responses to specific signaling pathways that may account for the amazing
aray of biological functions cared out by nuclear receptors.
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Ligand-dependent transcription factors
Bind specific hormone response elements
Steroid Receptors
homodimers
Non-steroid receptors
RAR VDR PP AR
heterodimerize with RXR
Figure 1. Nuclear Receptor Domain Structure. Most members of the steroid/thyroid
hormone receptor superfamly share a common domain strcture. The N-termnus con-
tains the higWy varable AI domain and the ligand-independent activation function-
(AF- l) domain. This is followed by the higWy conserved DNA-binding domain (DBD).
The C-termnus includes the ligand-binding domain (LBD), which also mediates
dimerization and cofactor binding. The LBD also contains the ligand-dependent AF-
transcriptional activation domain.
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Figure 2. Model of Nuclear Receptor Function. In the absence of honnone
receptors actively repress transcription via interactions with corepressors by
mechanisms including histone deacetylation. Ligand binding trggers the
release of the corepressor complex and subsequent recruitment of a coactivator
complex, which enhances transcriptional activation by the receptor by mecha-
nisms that include histone acetylation.
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Figure 3. SRC family domain structure. (A) Schematic representation of the
structural domains of SRC coactivators. RID=receptor-interacting domain,
AD=activation domain, HAT=histone acetyltransferase domain. (B) Sequence
alignment of the SRC LXXLL motifs.
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Figure 4. Crystal strcture of ERa-LBD complexed with (A) agonist (DES)
and GRI1 NR box ii versus (B) antagonist (OHT). The LXXL motif is in
orange and helix 12 is in purle. In the agonist-bound strcture, helices 3,
and 12 fonn a hydrophobic pocket that serves as the docking point for the
LXXL motif of coactivator. However, in the antagonist-bound structure , helix
12 mimics the LXXL motif, thereby preventing coactivator binding. Adapted
from Shiau, et al. Cell 95;927. DES=diethylstilbestrol, OHT=hydroxy-
tamoxifen.
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Figure 5. The VDR and ERp interact with different fragments of
RAC3. (A) A schematic ilustration of RAC3 and its functional domains
as well as the purified GST-RAC3 fragments used for Far-Western assays.
RID=receptor-interacting domain, AD=activation domain, i-vi=RAC3
LXXL NR boxes. (B) Far-western assay using 35S- VDR to probe GST-
RAC3 fusion proteins in the presence or absence of l M 1 25-dihydroxy-
vitamn D3. (C) Far-western assay using 35S- to probe GST-RAC3
fusion proteins in the presence or absence of I M 17 -estradiol.
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Figure 6. Peptides corresponding to the NR boxes of the RAC3-RI can
compete for VDR binding.(A) Far-western assay using 35S- VDR to probe
GST-RAC3-RID in the presence of IJlM vitamin D and given concentration of
peptide. (B) PhosphorImager quantitation of the data from (A) plotted as per-
cent GST-RAC3-RID binding to 35S-VDR versus peptide concentration. (C) A
control peptide has no effect on the GST-RAC3-RID interaction with VDR.
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Figure 7. Peptides corresponding to the NR boxes of the RAC3-RID can
compete for ERp binding.(A) Far-western assay using 35S- to probe GST-
RAC3-RID in the presence of If.M 17 -estradio1 and given concentration of pep-
tide. (B) PhosphorImager quantitation of the data from (A) plotted as percent
GST-RAC3-RI binding to 35S- versus peptide concentration.
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Figure 8. Mutation of RAC3 NR boxes reveal diferent LXXLL motif
preferences for nuclear receptor binding.
(A) Alanine substitution for leucine in each of the RAC3-RID NR boxes.
(B) GST -pull down assay of indicated nuclear receptors and GST fusion
proteins in the presence of IJlM hormone.
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Figure 9. Mutation of RAC3 NR boxes inhibits RAC3-RI binding to
DNA-bound VDRlXRa heterodimer. Gel-shift assay using 1.5flL of in
vitro translated VDR and RXRa, IflM vitamin D3' indicated GST fusion
protein, and 32p-DR3 probe. The arow indicates the RID-receptor com-
plex.
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RAC3-RID
32p-DR3
Figure 10. The RXRa AF -2 domain can interfere with RI binding
to VDRlRa while the VDR AF -2 domain is required for the inter-
action. Gel-shift assay using 1.SJlL of the indicated in vitro translated
receptors 1JlM vitamin 03' and 32 DR3 probe in presence or absence
of GST -RAC3-RID. The arrow indicates the RID-receptor complex.
=non-specific band from lysate.
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Figure 11. Distinct NR box requirements for the VDRlRaa443
heterodimer. (A) Gel-shift assay using 1.5JlL of in vitro translated VDR
and RXa-443 1JlM vitamn D3, 32 DR3 probe, and indicated GST
fusion protein. *=non-specific band from lysate. (B) Autoradiograph con-
firmng equal expression of 35 beled receptors.
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Figure 12. The RARa/Ra heterodimer has different NR box
requirements than the VDRlRa heterodimer. Gel-shift assay using
SJlL of in vitro translated receptors, indicated GST fusion protein, 1JlM
all-trans retinoic acid, and 32p-DRS probe. The AF-2 domain of RXRa also
can interfere with RID binding to RARalRa while the RARa AF-
domain is required for this interaction. The arow indicates the RI-
receptor complex. *=non-specific band from lysate.
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Figure 13. RAC3 NR box preferences of the RXRalRXRa;
homodimer. Gel-shift assay using RXRa, DRI probe , and indicated
GST fusion protein in the absence or presence of 1JlM cis retinoic acid.
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Figure 14. NR box mutation inhibits RAC3 coactivation function in
vivo. (A) Transient transfection assay in CV- l cells using VDR , VDRE-
driven reporter, and indicated RAC3 construct in the absence or presence
of 40nM vitamn D3' (B) Transient transfection assay in CV- l cells
using ER , ERE-driven reporter, and indicated RAC3 construct in the
absence or presence of lOnM 17 -estradiol.
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Figure 15. Comparison of RAC3 coactivation of VDRlRa ver-
sus VDRlRa-443 versus VDR-402IRRa. Transient
transfection assay in HEK293 cells using indicated receptors, a VDRE-
driven reporter, and wild-type RAC3 in the absence or presence of
lOnM vitamn D3' Deletion of the RXRa AF- 2 domain increases
RAC3 coactivation activity while deletion of the VDR AF-2 domain
abolishes transcriptional activation by the receptor.
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Figure 16. Mutation of NR box v inhibits RAC3 transcriptional
activation. (A) Site-directed mutations of LXXL motifs in RAC3-
AD. Mutations were made in context of the Gal4-RAC3(401- 1204)
fusion. (B) Effect of mutations on transcriptional activation of Gal4-
RAC3(401- 1204) by transient transfection in HEK293 cells transfected
with indicated Gal4-DBD fusion and luciferase reporter containing 4
Ga14 binding sites.
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Figure 17. Mutation ofRAC3 NR box v reduces interaction with CBP.
(A) Autoradiograph of 35 Gal-RAC3(401- 1204) probes (top) and Far-western
assay (bottom) using these probes to test for interaction with CBP-C and CBP-
fragments. (B) PhosphorImager quantitation of the data in (A). CBP-C=1921-
2120 and CBP-D=2041-2240.
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Figure 18. CBP interaction correlates with RAC3
coactivation of RARa, but not . (A) Mutation on NR
box v reduces RAC3 coactivation of RARa. Transient
transfection assays in HEK293 cells. (B) Mutation of the NR
boxes of the RAC3 activation domain does not affect
coactivation of ER
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Figure 19. Receptor-specific transcriptional enhancement by
SRC coactivators. (A) RAC3 and TIF2 , but not SRC- 1 can
coactivate ER activity. (B) Only RAC3 can coactivate RARa
activity. Transient transfection assays in HEK293 cells using ERE- or
RAE-driven luciferase reporters.
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Sequence Alignment of Coactivator Binding Pockets
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Figure 20. Sequence alignment of the cofactor binding pocket
of nuclear receptors. LXXL contact residues are based on
the crystal structures of hERa, hTR , and hPP ARy complexed
with SRC fragments.
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Figure 21. Mutation of the cofactor binding pocket of RARa and
RXRa inhibit interactions with co activators and core pressors. (A)
GST pulldown assay ofRARa with GST-RAC3 and GST-SMRT inter-
acting domains. (B) GST pulldown assay ofRXRa with GST-RAC3
interacting domain. (C) Autoradiograph of probes used in GST
pull down assays.
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Figure 22. Mutation of the RARa cofactor binding pocket inhibits
RAC3 recruitment to the RARalRa heterodimer. Gel-shift
assay using 1.5f.L of indicated in vitro translated receptors, 32p-DR5
probe, and If.M atRA in the presence or absence of the RAC3-RID.
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Figure 23. Mutation of the RARa. cofactor binding pocket inhibits
RAC3 recruitment to the RARa/Ra.-443 heterodimer. Gel-shift
assay using l.SJ.L of indicated in vitro translated receptors, 32p-DRS
probe, and 1J.M atRA in the presence or absence of the RAC3-RID.
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Figure 24. Mutation of the RARa cofactor binding pocket inhibits
recrutment of SMRT to the RARa/Ra heterodimer in the
absence of hormone. Gel-shift assay using 1. 1 of each of the indi-
cated in vitro translated receptors and a 32 DR5 probe in a binding
reaction in the absence or presence of purified GST-SMRT-ID (982-
1495).
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Figure 25. Mutation of the RARa cofactor binding pocket inhibits SMRT
recruitment to the unliganded RARa/Ra-443 heterodimer. Gel-shift assay
using 1.5f.L of each indicated in vitro translated receptor and a 32p-DR5 probe in
the presence or absence of GST-SMRT-ID (982- 1495).
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Figure 26. Effect of RXRa cofactor binding pocket mutation
on RAC3 recruitment to RARalRa heterodimer at DR5
element. Gel-shift assay using 1.5JlL of each indicated in vitro
translated receptor IJlM all-trans retinoic acid, and a 32 DR5
probe in the presence or absence of the RAC3-RID.
ml=L276AN280A, m2=V298A1301A
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Figure 27. Mutation of the RXRa cofactor binding pocket has little
effect on RAC3 binding to the RARaJRa or RARaJXRa-443
heterodimers. Gel shift assay using I.SJ.L of each indicated in vitro
translated receptor, a 32p-DRS probe, and 1J.M all-trans RA in the pres-
ence or absence of the RAC3-RID. rn=V298AJ301A
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Figure 28. Mutation of the cofactor binding pocket of RXRa
abolishes recruitment of RAC3 to the RXa homodimer. Gel-
shift assay using 1.5JlL of in vitro translated wild-type or mutant
RXRa, 1JlM cis retinoic acid, and a 32 DRI probe in presence or
absence of the RAC3-RI. The arrow indicates the RID-receptor
complex.
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Figure 29. Transcriptional activity of RARa cofactor
binding pocket mutants. Transient transfection assay in HEK293
cells of wild-type or mutant RAa and RARE-driven luciferase
reporter in absence (left) or presence (right) of 50nM all-trans
retinoic acid.
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Figure 30. Mutation of the cofactor binding pocket abolishes
transcriptional repression by RARa-403. Transient transfection
assay in HEK293 cells of indicated receptor and RA-driven
luciferase reporter.
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Figure 31. Mutation of the RXRa cofactor binding pocket has different effects on
transcriptional activity at a DR1- versus DRS-driven reporter. (A) Transient
transfection assay in HEK293 cells of indicated receptor and DRI-driven luciferase
reporter in absence (left) or presence(right) of 100nM 9cis retinoic acid. (B) The same
assay was repeated using a DR5-driven reporter and hRRa in absence (left) or
presence(right) of 100nM all-trans acid. mut- l=L276AN280A, mut-2=V298A/301A
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Figure 32. Model of SRC coactivator function. An SRC coactivator is recruited to
a DNA-bound nuclear receptor dimer via the LXXLL motifs. Subsequently, SRC is
able to enhance transcriptional activation by the receptor by recruiting additional
coactivators such as CBP/p300, PCAF , SRA, and/or CAR1 , which modify chromatin
via histone acetylation and histone methylation.
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Figure 33. Models of Multiple Coactivator Complexes. One of the
unanswered questions concerning nuclear receptor function is the mecha-
nism by which multiple coactivator complexes are coordinated into tran-
scriptional activation by the receptor. The above models, which are
described in the text, provide several hypotheses.
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Steroid and nuclear receptor coactivators (NCoAs)
have been implicated in the regulation of nuclear recep-
tor fuction by enhancing ligand-dependent transcrip-
tional activation of target gene expression. We have pre-
viously isolated receptor-associated coactivator 3(RAC3), which belongs to the steroid receptor coactiva-
tor family. In this study, we investigated the differential
mechanisms by which RAC3 interacts with and modu-
lates the transcriptional activity of different nuclear
receptors. We found that the vitamin D receptor (VR)
and estrogen receptor /3 interact with different a-helicalLXL motifs of RAC3. Pep tides corresponding to these
motifs have diverse afnities for the VDR and estrogen
receptor /3, and mutation of specific motifs differentially
impairs the abilty of RAC3 to interact with these recep-
tors in vitro. Consequently, these mutations inhibit the
enhancement of transcriptional activation by these re-
ceptors in vivo. Fuhermore, we found that the activa-
tion fuction-2 (AF -2) domain of the retinoid X receptor
interferes with RAC3 binding to a DNA-bound VDRlret-
inoid X receptor (RX) heterodimer, whereas the VDR
AF-2 domain is required for this interaction. These re-
sults suggest a receptor-specific binding preference for
the different LXL motifs of RAC3, which may provide
flexibilty for RAC3 to differentialy reguate the fuc-
tion of different nuclear receptors.
The vitamin D receptor (VDR)l and estrogen receptor 
(ERf3) belong to the steroid/thyroid hormone receptor super-
family, which is a large class ofligand-dependent transcription
factors that plays critical roles in regulating genes involved in
a wide aray of biological processes, including development and
homeostasis (1) This superfamily can be divided into three
subgroups. The ERf3 is a Type I receptor, which also includes
receptors for steroids such as progestins , androgens , glucocor-
ticoids, and mineralcorticoids. These receptors are coupled to
* Ths work was supported by National Institutes of Health Grant 1
ROI DK52888-0I (to J. D. C. ) and a U. S. Ary Medical Research and
Material Command pre-doctoral fellowship (to C. 1.). The costs of pub-
lication of this aricle were defrayed in par by the payment of page
charges. Ths aricle must therefore be hereby marked advertisement"
in accordance with 18 U. C. Section 1734 solely to indicate this fact.
* To whom correspondence should be addressed: Dept. ofPharmacol-
ogy and Molecular Toxicology, University of Massachusetts Medical
School, 55 Lake Ave. North, Worcester, MA 01655. Tel.: 508-856-1481;
Fax: 508-856-1225; E-mail: don.chen assmed.edu.1 The abbreviations used are: VDR
, vitamin D receptor; RX, retinoid
X receptor; RA, retinoic acid receptor; ERI3, estrogen receptor 13;
RAC3 , receptor-associated coactivator 3; SRC , steroid receptor coacti-
vator; RID, receptor-interacting domain; AF- activation fuction-
domain; NR box, nuclear receptor interacting box: DR, direct repeat;
LBD , ligand binding domain; GST, glutathione S-transferase; NCoA
nuclear receptor coactivator; PAS , Per-Arnt-Sim domain; CBP, CREB-
binding protein; PCAF, p300/CBP-associated factor: ERE , estrogen re-
sponse element: TR, thyroid hormone.
heat shock proteins and sequestered to the cytoplasm in the
absence ofligand. Upon hormone binding, they dissociate from
the heat shock proteins , homodimerize, and trans locate to the
nucleus where they bind to cognate response elements consist-
ing of palindromic repeats. The VDR is a Tye II receptor like
those for thyroid hormone (TR) and all-trans retinoic acid
(RA). These receptors are strictly nuclear and form het-
erodimers with the receptor for 9-ds retinoic acid (RX). They
also bind constitutively to response elements consisting of di-
rect repeats (DRs). A third class of nuclear receptors is the
orphan receptors , so-called because endogenous ligands for
these proteins are currently unkown.
Most members of the nuclear receptor superfamily share a
common domain structure. The N terminus contains the vari-
able AJ region, which also includes the ligand-independent
AF-1 activation domain. The highly conserved DNA binding
domain and the C-terminalligand binding domain (LBD) fol-
low this region. The LBD contains the ligand-dependent AF-
activation domain and also mediates dimerization of nuclear
receptors. In the absence of ligand, nuclear receptors are able
to repress basal transcription via fuctional interactions with
the nuclear receptor corepressors SMRT and NCoR (2, 3).
SMRT and NCoR are found in complexes with the corepressor
mSin3 and the histone deacetylase HDACI, suggesting that
transcriptional repression by nuclear receptors may involve
histone de acetylation (4-6). Ligand binding triggers the re-
lease of these corepressors and subsequent recruitment of co-
activators through a drastic conformational change in the AF-
domain of the receptor. Structural studies have demonstrated
that helix 12 , which contains the AF -2 domain, projects away
from the LBD in the unbound RX structure, but rotates
nearly 180 to pack tightly against the LBD upon hormone
binding in the RA, TR, and ER (7-10). This conformational
change, together with induced changes in helices 3- , is be-
lieved to facilitate interactions of the receptor with co activators
(11-16).
Coactivators recruited by ligand-bound nuclear receptors in-
clude members ofthe SRC family of co activators such as SRCI
(also known as NCoA- l), TIF2!GRIPI (also known as SRC2 or
NCoA-2), and RAC3/ACTRlpCIP/AIBl (also known as SRC3 or
NCoA-3) (reviewed in Refs. 17 and 18). SRC family members
share an N-terminal basic helix-loop-helixAS-A/AS-B do-
main of unkown function, centrally located receptor interac-
tion domain, and C-terminal transcriptional activation domain.
These cofactors interact with receptors in a hormone- and
AF- dependent manner and enhance transcriptional activa-
tion by nuclear receptors. Both coactivators and receptors also
have been demonstrated to interact with the general transcrip-
tional activators CBP/p300 and PCAF (19-26), suggesting that
a large multi-protein complex is assembled at the target gene
promoter to activate transcription. Furthermore , several coac-
tivators , including SRCl , ACTR, PCAF , and CBP/p300 , possess
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intrinsic histone acetylation activity, which disrupts nucleo-
somes (21 , 27-30). Therefore, the mechanism by which nuclear
receptors activate transcription may entail the recruitment of a
coactivator complex via the AF-2 domain that can modifY chro-
matin structure, thereby facilitating access to the promoter by
the general transcription machinery.
Intriguingly, members ofthe SRC family of co activators have
been found to contain several conserved motifs, termed NR
boxes, with the consensus sequence LXL, where X is any
amino acid (31). Motifs within the receptor-interacting domain
and transcriptional activation domains of SRC1 and TIF2 have
been demonstrated to mediate interactions with liganded nu-
clear receptors and CBP/p300 , respectively (23 , 32). Crystallo-
graphic and protein structure prediction analyses have indi-
cated that these motifs form amphipathic a-helices with the
leucine residues comprising a hydrophobic surface on one face
ofthe helix (11 , 12 , 14 24). The helical motif is able to interact
with the AF -2 domain of the liganded receptor via a hydropho-
bic groove made up of residues from receptor helices 3 , 4 , 5 , and
12 that is the result of the conformational change induced by
hormone bindig (11 , 14, 16). Mutational analyses of the NR
boxes ofSRCl and TIF2/GRIP1 have also uncovered a receptor-
specific code of interaction, where different nuclear receptors
require different NR boxes to interact with the coactivator
(32-34). These studies indicate that flankg residues outside
the NR box may also be important to nuclear receptor-coacti-
vator interactions.
In this study, we investigate the mechanisms by which RAC3
regulates the fuction of the VDR and ER,B, for little is known
concerning the regulation of these receptors by SRC coactiva-
tors, particularly RAC3. These analyses reveal receptor-spe-
cific interactions in which the VDR and ER,B interact with
different surfaces of RAC3. We demonstrate different prefer-
ences ofthese receptors for specific NR boxes ofRAC3 and that
single mutations in these LXL motifs are able to severely
impair the abilty of RAC3 to interact with and, thus, coacti-
vate the VDR and ER,B. In analyzing the requirement of nu-
clear receptor AF-2 domains , we observe that the AF-2 domain
ofRX can inibit RAC3-RID binding to the DNA-bound VDRJ
RXheterodimer, whereas the AF -2 domain ofVDR is required
for this interaction. These data add a new level of complexity to
the regulation of nuclear receptor activity by SRC coactivators
and suggest that different classes of nuclear receptors may be
regulated by RAC3 via different mechanisms.
EXPERIMENTAL PROCEDURES
Far Western Analysis-Far Western assays were carred out as de-
scribed (20). Briefly, GST fusion proteins were expressed in DH5a cells
and purified with glutathione-agarose beads (Amersham Pharmacia
Biotech). Purfied proteins were then separated by SDS-polyacrylamide
gel electrophoresis and electroblotted onto a nitrocellulose membrane.
Proteins were denatured with 6 M guanidine hydrocWoride and rena-
tured by the stepwise dilution of guandine hydrocWoride. Membranes
were then blocked and hybridized overnght with labeled protein.
The membrane was washed , and bound probe was detected by autora-
diography. Labeled probes were generated by Quick-coupled in vitro
transcription/translation (Promega). For peptide competition experi-
ments , the given concentration of peptide was added to the probe 10 min
before hybridization with' the membrane. Peptide sequences were as
follows: NR box i peptide (LESKGHKLQLLTLSSDDRGHSSL), NR
box ii peptide (LQEKHRILHKLLQNGNSP), NR box iii peptide
(KKNNALLRYLLDRDD), control peptide (GSGSATATL YENKRP-
PYIL). Radioactive bands were quantified by PhosphorImager using the
ImageQuant software (Molecular Dynamics).
GST Pull-down Assay-Approximately ILg of purified GST fusion
protein was incubated with 5 ILl of labeled protein with moderate
shakg at 4 oC overnght in binding buffer (20 mM HEPES, pH 7.
mM KC1, 0.1 mM EDTA, 2.5 mM MgCl , 0.05% Nonidet P- , 1 mM
dithiothreitol, I mg/ml BSA). The bound protein was washed three
ties with bindig bufer, and beads were collectd by centration. The
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bound protein was eluted in SDS sample bufer, subject to SDS-polyacrl-
amde gel electphoresis, and detectd by autoradiography.
Site-directed Mutagenesis-NR box mutants were generated with the
Quick-change site-directed mutagenesis system (Stratagene). The se-
quences of all mutant constructs were confrmed by dideoxyucleotide
chai termination reactions using the T7 Sequenase protocol (U. S.
Biochemical Corp.
Gel Electrophoresis Mobility Shift Assay-The sequence of the DR3
element used for VDRJ gel-shift assays is AGCTTAAGAGGTCA-
GAAGGTCACTCGCAT. The double-stranded DR3 was end-labeled
with ( PJdCTP by standard Klenow fill-in reaction. The purfied probe
was incubated with labeled receptors in bindig buffer containig
5% glycerol, 20 mM. HEPES , pH 7. , 2 mM dithiothreitol, 0. 1% Nonidet
1ILg ofpoly(dI-dC) and 100 mM KCl. Wild-type or mutant GST-
RAC3-RID was eluted from glutathione-agarose beads with 10 mM
reduced glutathione and added to the bindig reaction. The DNA-
protein complex was formed on ice for I h and resolved on a 5% native
polyacrylamide gel, which was subsequently dred and subjected to
autoradiography.
Cell Culture and Transient Transfection-HEK293 and CV- I cells
were maintaied in Dulbecco s modified Eagle s medium supplemented
with 10% fetal bovie serum and 5 1Lg/1L1 gentamycin at 37 o , 5% CO
Cells were plated for transfection in Dulbecco s modified Eagle s me-
dium supplemented with 10% resin charcoal-stripped fetal bovine se-
rum in 12- or 6-well plates I day before transfection. HEK293 cells were
transfected using the standard calcium phosphate method, whereas
CV-1 cells were transfected using LipofectAINE accordig to the
manufacturer s protocol (Life Technologies, Inc.) Twelve hours after
transfection, cells were washed with phosphate-buffered saline and
refed fresh medium containig the indicated concentration of ligand.
Afer 24 h, cells were harested for l3-galactosidase and luciferase
activities as described (35). Luciferase activity was determned with a:
MLX plate luminometer (Dynex) and normalized relative to l3-galacto-
sidase activity.
RESULTS
VDR and ER,B Interact with Multiple Surfaces of RAC3-
have previously defined the minimal receptor interacting do-
main (RID) ofRAC3 to be amino acids 613-752 , which contains
the first three LXL motifs (Fig. lA) (20). We wished to
further determine if different receptors were capable of binding
to the same regions of RAC3. To accomplish this , we purfied a
panel of GST-RAC3 fusion proteins, in total comprising the
full-length RAC3 (Fig. lA), and probed these fusions with
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"S.ERpSJmethionine-labeled VDR and ERf3 in a Far Westem assay.
The VDR, as expected, interacted in a ligand-dependent man-
ner with GST-RAC3 613-752 in this assay (Fig. IE). It also
bound GST-RAC3 723-1034, which only contained NR box iii
in a ligand-dependent manner. The VDR did not interact with
any other GST-RAC3 fragment, including GST-RAC3 342-646
which contained NR box i. It also appeared that the VDR
interacted more strongly with GST-RAC3 723-1034 than with
GST-RAC3 613-752 , suggesting a more important role for NR
box iii in the RAC3-VDR interaction. However, a different
pattem was evident upon repeating this assay with ERf3,
for in addition to ligand-dependent interactions with GST-
RAC3 613-752 and 723-1034 , ERf3 also bound the 342-646
fragment, which contained only NR box i (Fig. lC). These
interactions were of approximately equal intensity. There was
also a weak, ligand-independent interaction with GST-RAC3
407. Identical results were obtained for ERa (data not
shown). A Coomassie Blue-stained polyacrylamide gel of the
GST-RAC3 fusion protein confirmed the identity of each GST-
RAC3 fusion protein and approximately equal protein concen-
trations in each lane (data not shown). Thus , the VDR and ERf3
display different binding pattems for RAC3 fragments, with
the VDR interacting preferentially with regions containing NR
box iii and the ERf3 interacting equally well with regions con-
taining any of the three NR boxes and the N-terminal basic
helix-loop-helix-PAS domain.
NR Box Peptides Differentially Compete with Nuclear Recep-
tors for RAC3 Binding-We then wanted to investigate the
relative importance of individual NR boxes within the RAC3-
RID in mediating the interactions between RAC3 and the VDR
or ERf3. Peptides were synthesized corresponding to NR boxes
, ii, and iii, which were incubated with labeled receptor
and 1 JLM ligand before probing the GST-RAC3 613-752 frag-
ment in the Far Westem assay. With the VDR, peptides corre-
sponding to the second and third LXL motif were able to
compete away the RAC3-RID interaction with VDR in a dose-
dependent manner (Fig. 2A). Upon quantifyng the data , it was
evident that peptide iii was a more potent inhibitor than pep-
tide ii, whereas the peptide comprising NR box i had little, if
any, effect on the VDR-RID interaction (Fig. 2B). A control
experiment demonstrated that the effects of these peptides
were specific, for a random peptide did not alter the interaction
between the VDR and GST-RAC3-RID (Fig. 2C). We again
identified a different pattern when the same experiment was
done with the ERf3 (Fig. 2D). Here, all three peptides were able
to compete efficiently for ERf3 binding with the RAC3-RID
with peptide ii being the most potent (Fig. 2E). Thus , these
data reveal receptor-specific preferences for interactions be-
tween RAC3 and different nuclear receptors , for the VDR and
ERf3 have different affnities for the NR boxes of RAC3.
NR Box Mutations Can Impair RAC3 Interactions with Nu-
clear Receptors in Vitro-To assess the integrty of the LXL
motif in mediating the interaction between the RAC3-RID and
nuclear receptors, we used site-directed mutagenesis to switch
the leucine residues of each motif to alanines (Fig. 3A). The
mutants were made using the GST-RAC3-RID fusion as the
template and tested for their ability to interact with the VDR or
ERf3 in GST pull-down assays. The wild-type RAC3-RID was
able to pull down a significant amount of VDR in the
presence of 1 JLM vitamin D (Fig. 3B). This interaction was
specific, for GST alone pulled down much less VDR. Muta-
tions in NR boxes i or ii displayed wild-type binding. However
when NR box iii was mutated, the RID-VDR interaction was
greatly reduced to a level only slightly higher than background
binding to GST alone. GST-RAC3 342-646, which contained
only NR box i, also had minimal binding to the VDR, consistent
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FIG. 2. Peptides corresponding to the NR boxes of the RAC3-
RID can compete for VDR and ERfJ binding with the RAC3-RID.
Far Western assay using VDR to probe GST-RAC3-RID in the
presence of llLM vitamin D and given concentration of each peptide. 
the data from was quantified by Phosphorlmager and plotted as
percent GST-RAC3-RID bindig to VDR versus peptide concentra-
tion. 100% RID binding represents the density of the band in the
absence of peptide. . , peptide I; peptide ii; A, peptide iii. C, Far
Western assay demonstrating that inhbition of VDR interaction
with GST-RAC3-RID by peptide iii is specific. Peptide iii abolishes
nearly all the interaction , whereas a control , random peptide has no
effect. Far Western assay using ER/3 to probe GST-RAC3-RID in
the presence of IILM estradiol and given concentration of each peptide.
the data from was quantified by Phosphorlmager and plotted as
the percent GST-RAC3-RID bindig to ER/3 versus peptide concen-
tration. . , peptide I; peptide ii; A , peptide iii.
with the Far Westem assay (Fig. IE). Equal protein concen-
trations of each GST fusion confirmed the specificity of these
findings. Thus, these data support the above observations in
implicating NR box iii as being most critical to RAC3 interac-
tion with the VDR.
The wild-type RID was also able to pull down signficant
amounts of ERf3 in the GST pull-down assay (Fig. 3C). 
contrast to the VDR, an alanine substitution for leucine in any
of the three NR boxes weakened the interaction of the RAC3-
RID with ERf3, with the mutation of NR box ii being the most
deleterious, again supporting the results of LXL peptide
competition experiments (Fig. 2B). However, with each muta-
tion, significant binding above background between the RAC3-
RID and ERf3 was stil observed. Furthermore, the GST-
RAC3 342-646 fragment, with only NR box i, was able to
interact effciently with ERf3 (Fig. 3C) as in the Far Westem
assay (Fig. lC). These data suggest that although all three
motifs are capable of interacting with ERf3 separately, none of
them is absolutely required for the interaction. In contrast, NR
box iii of RAC3 appears to be essential for the interaction with
the VDR.
RAC3-RID Interactions with DNA-bound Nuclear Recep-
tors-The above data provide compellng evidence that the
VDR interacts specifically with RAC3 in solution via the
LXL motifs of the RAC3 RID , particularly NR box iii. To
gain further insight into the function of NR boxes in coactiva-
tor-VDR interactions on a heterodimeric complex bound to
DNA, we performed gel-shift assays with VDR/ het-
erodimers on a DR3 element in the presence of wild-type or
mutant RAC3-RID (Fig. 4). The VDR/ heterodimer bound
strongly to the 32 labeled DR3 probe and was unaffected by
the addition of GST alone (Fig. 4A lanes 1 and 2). The addition
of the RAC3-RID resulted in a ligand-dependent shift of the
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GST fusion proteins in the presence of 1 JLM estradiol. The bottom panel
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Coomassie Blue stainng. The two observed bands are due to two ERj3
products in the in vitro translation reaction.
heterodimeric complex to a slower-migrating form (arrow
lanes 3 and 4). The mutation ofNR box i had little effect on the
abilty of the RID to shift the complex (lane 5). However
mutating NR box ii diminished the formation of the RID-VDRI
RX complex, whereas mutating NR box iii nearly abolished
the formation completely (lanes 6 and 7). Consistently, GST-
RAC3 342-646 , with only NR box i, was unable to shift theVDRI complex (lane 8). These results differ slightly from
the GST pull down, in which only the NR box iii mutation
inhbited interaction with VDR alone (Fig. 3B), suggesting that
both motifs ii and iii may contribute to the interaction with
DNA-bound VDRI heterodimer.
We next analyzed the involvement of nuclear receptor AF-
domains in regulating the interaction between the RAC3-RID
and the VDRI heterodimer (Fig. 4B). Using the gel-shift
assay, we compared the ability ofthe RID to bind the wild-type
heterodimer versus the VDRl443 and VDR4021R het-
erodimers , in which the AF -2 domain of RX or VDR had been
deleted, respectively. As demonstrated above, the RID was able
to bind the DNA-bound, wild-type VDRI complex (Fig. 4B
lane 2). Deletion of the VDR AF -2 domain did not affect the
formation ofthe heterodimer-DNA complex but resulted in the
loss ofthe RID-shifted complex (lane 4). Ths suggests that the
VDR AF -2 domain is required for interaction of RAC3 with the
heterodimer and that RXAF-2 domain alone is not sufficient
for the interaction. Interestingly, deletion of the RX AF-
domai resulted in a much stronger shift of the heterodimeric
complex by the RAC3-RID (lane 6) without affecting het-
erodimer formation (lane 5), suggesting that the RX AF-
domain can inhbit the interaction between RAC3 and VDRI
RX. The strong interaction was abolished upon deletion of the
VDR AF -2 domai (lane 8), further supporting a requirement of
VDR AF-2 helix 12 for RAC3 binding to the DNA-bound
heterodimer.
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FIG. 4. Mutation ofRAC3 NR boxes inhibits RAC3-RID bindig
to DNA-bound VDR/ heterodimer. gel-shift assay of the
effects ofNR box mutations (mut) on RAC3-RID bindig to DR3-boundVDRI. 1.5 JLl of each labeled nuclear receptor was added to a
bindig reaction (see "Experimental Procedures ) containig I JLM vi-
tami D , equal amounts of the indicated GST fusion protein, and the(32PJdCTP-labeled DR3 probe. The arrow indicates the RID-receptor
complex. wild type. the RX AF -2 domai can interfere with RIDbinding to VDRI, whereas the VDR AF -2 domai is required for the
interaction. The gel-shift assay was performed as in except the
AF- trucated RX443 or VDR402 was used where indicated. * , non-
specifc band from lysate. C, the VDRl443 heterodimer has differ-
ent NR box preferences than the wild-type receptor heterodimer. The
gel-shift assay was performed as in A. , nonspecific band from lysate.
autoradiograph confrming the equal expression of the labeled
receptors used in and C.
Finally, we compared the RAC3 NR box preferences ofVDRI
RX versus VDRl443 (Fig. 4C). Intriguingly, the VDRI
RX443 heterodimer displayed different NR box preferences.
Mutation of NR box i or iii greatly reduced the shift by the
RAC3-RID (Fig. , lanes 3 and 5), whereas mutation of NR
box ii only slightly weakened the binding (lane 4). Thus dele-
tion of the RX AF -2 domain resulted in a switch in the NR box
requirements , with NR boxes i and iii being most important for
VDRl443 compared with NR boxes ii and iii for VDRI.
An autoradiograph confirmed equal expression levels of each
labeled receptor (Fig. 4D). This finding supports the hy-
pothesis that multiple LXL motifs provide RAC3 with the
flexibility to adapt to different configurations of a nuclear re-
ceptor dimer.
Effects of NR Box Mutations on RAC3 Coactivation Function
in Vivo-RAC3 has previously been shown to enhance the
transcriptional activity of the RA and progesterone receptor
(37). However, its effect on VDR and ERI3 function in vivo has
not been demonstrated. To address this, we performed tran-
sient transfection assays in HEK293 and CV-1 cells using
luciferase reporters harboring either two copies of the vitamin
D response element of the osteopontin gene for VDR studies or
a consensus ERE element for ERI3 studies (Fig. 5). Transfection
of the VDR into CV- l cells minimally activated the vitamin D
response element driven reporter (Fig. 5A). However, treating
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FIG. 5. Mutation of RAe3 NR boxes blocks coactivation ofVDR
and ERp activity in vivo. A mutation (mut) of NR box ii or iii inhbits
RAG3 enhancement ofVDR activity. GV- I cells were transfected with
expression plasmids for VDR, wild-type (wt), or mutant RAG3 and the
Sppx2-luciferase reporter and treated with 40 nM vitamin D for 24 h
where indicated. Upon harvesting cells, luciferase activity was meas-
ured and normalized to ,B-galactosidase activity. mutation of NR box
, ii, or iii inbits RAG3 enhancement ofER,B activity. GV- I cells were
transfected with expression plasmids for ER,B, wild-type , or mutant
RAG3 and the ERE-luciferase reporter and treated with 10 nM estradiol
for 24 h where indicated. Upon harvesting cells
, luciferase activity was
measured and normalized to ,B-galactosidase activity. C, deletion of theRX AF-2 domain results in enhanced coactivation ofVDR/ activ-ity by RAG3. HEK293 cells were transfected with the appropriate
nuclear receptor expression plasmids along with expression plasmids
for RAG3 and Sppx2-luciferase and treated with 10 nM vitamin D where
indicated. Upon harvesting cells, luciferase activity was measured and
normalized to ,B-galactosidase activity.
these cells with vitamin D strongly stimulated its activity.
Cotransfection of RAC3 further enhanced VDR transcriptional
activation by approximately 50% , consistent with the coactiva-
tion function of RAC3 (37).
We then analyzed the role of the NR boxes in mediating the
ability of RAC3 to potentiate VDR activity. Mutations of each
NR box of the RAC3-RID were made in the context of the
full-length RAC3 protein and tested for their ability to coacti-
vate the VDR in transient transfection assays (Fig. 5A). Muta-
tion of NR box i did not inhbit RAC3 enhancement of VDR
transactivation, consistent with its inability to block the inter-
action ofRAC3 with VDR in vitro. However, the RAC3- NR box
ii or iii mutations reduced the function of RAC3 in enhancing
VDR activity (Fig. 5A), consistent with their requirement for
RAC3 binding to the DNA-bound VDR/ heterodimer in
gel-shift assays (Fig. 4A). Taken together, it is clear that NR
boxes ii and iii are both involved in RAC3 regulation of VDR
function, whereas the role of NR box i appears minimal.
We then repeated these experiments with the ER,B (Fig. 5B).
Estradiol treatment ofCV- l cells transfected with the ER,B and
the ERE-luciferase reporter activated reporter expression ap-
proximately 8-fold. Cotransfection of wild-type RAC3 resulted
in a strong enhancement of ER,B activity. It is evident from
these data that RAC3 is a more potent coactivator for the ER,B
than for the VDR. Cotransfection ofRAC3 expression plasmids
containing mutations in NR boxes i , ii, or iii all suppressed the
ability of RAC3 to coactivate the ER,B, with the NR box ii
mutant having the greatest and NR box iii mutant having more
modest effects on RAC3 function. Thus
, these in vivo data
correlate with the in vitro data in implicating all three NR
boxes ofthe RAC3-RID as being important for RAC3 regulation
of ER,B function.
Finally, we decided to assess the functional consequences of
the antagonism of RAC3 interaction with DNA-bound VDR/
RX by the RX AF-2 domain observed in gel-shift assays (Fig.
4B). To do this, we compared the ability of RAC3 to coactivateVDR/ and VDR/443 activities by transient transfec-
tion assays (Fig. 5C). When wild-type VDR and RX were
expressed in HEK293 cells , RAC3 was able to enhance tran-
scriptional activation by approximately 50% (Fig. 
, left).
However, when VDR was coexpressed with RXR443 , RAC3
displayed a 2. fold enhancement of receptor activity (Fig. 
center). As expected, the VDR402 mutant was transcriptionally
inactive, and RAC3 could not modulate its activity(Fig. 
right). Thus , these in vivo data are consistent with the gel-shift
data in demonstrating that the RX AF-2 domain can inhibit
RAC3 modulation of the VDR/ heterodimer, whereas the
VDR AF-2 domain is absolutely required for this regulation.
DISCUSSION
In this study, we have investigated the role ofthe NR boxes
ofRAC3 in mediating the ability of this coactivator to bind and
coactivate the VDR and ER,B. We found that NR box iii is most
critical to VDR binding, whereas NR boxes i
, ii, and iii are
involved in ER,B interaction. Peptides corresponding to these
respective motifs were able to compete with the RAC3-RID for
VDR and ER,B binding. The integrity of the motifs themselves
was also important, for mutations in specific NR boxes inhib-
ited RAC3 interaction with these receptors in solution and
when bound to DNA. The AF -2 domain of VDR is required for
binding of the RAC3-RID to DNA-bound VDR/, whereas
the AF-2 domain of RX was able to antagonize this interac-
tion. Removal of this inhibitory AF-2 helix of RX enhances
ligand-dependent binding of RAC3 to the VDR/443 het-
erodimer and alters the NR box requirements. Furthermore
the mutation of NR box ii or iii blocked the ability of RAC3 to
enhance transcriptional activation by the VDR in vivo. In con-
trast, mutation ofNR boxes i, ii , or iii reduced RAC3 coactiva-
tion ofER,B. Together , these in vitro and in vivo studies suggest
a mechanistic difference in the manner by which RAC3 regu-
lates VDR and ER,B activities.
The NR boxes are highly conserved among the SRC family of
coactivators (18). Our data and that of others clearly reveal
that multiple motifs are necessary for high affnity interactions
with nuclear receptors (23 , 32 , 33). With the DNA-bound VDR/
RX heterodimer, we found that mutation ofNR boxes ii or iii
of RAC3 weakens the interaction with the RAC3-RID. In con-
trast, NR box iii of RAC3 is the only critical motif for interac-
tion with VDR in solution. Therefore, it is likely that each motif
binds to each monomer ofthe receptor heterodimer
, consistent
with the structure of a peroxisome proliferator-activated recep-
tor ')-LBD dimer co-crystallzed with a fragment of SRCI con-
taining two NR boxes (12). Our data on ER,B suggest that all
three NR boxes of the RAC3-RID are involved for a wild-type
interaction, whereas the presence oftwo motifs is suffcient for
a strong interaction, motif ii being most important. In light of
this finding, RAC3 may utilize motif ii in combination with
motif i or iii for efficient interaction with the ER,B homodimer.
The integrity of the other motif may be critical to the overall
conformation of the coactivator or potentially make an addi-
tional contact with another region of the receptor. Support for
the latter possibility can be found in recent studies detailing
the enhancement ofthe N-terminal AF-l activation function of
nuclear receptors by SRC co activators (38
, 39). The presence of
multiple NR boxes also likely provides co activators the fiexi-
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bility to interact with a broad range of nuclear receptors , re-
sulting in the different preferences that are observed between
nuclear receptors and distinct motifs , depending on the precise
structural nuances of each receptor-coactivator interface. This
is evident upon comparing the NR box requirements of the
VDR/ heterodimer versus those ofVDR/443. Deletion
ofthe AF-2 helix ofRX not only enhances RAC3-RID binding
to the heterodimer but also switches the NR box preferences
from motifs iiliii to motifs iliii. Finally, amino acids flanking the
NR boxes also likely contribute to the specificity of interaction
(15 , 32), for, despite the high homology between the RAC3 NR
boxes , peptides comprising each motif and surrounding resi-
dues displayed different affnities for VDR or ER/3 binding.
Thus , it is clear that the multiple NR boxes do not serve merely
redundant functions.
Our finding that the AF -2 domain of RX can interfere with
RAC3-RID binding to a DNA-bound VDR/ heterodimer is
consistent with studies suggesting allosteric inhibition-of coac-
tivator binding to RA by the RX AF -2 domain (36). This
inhibition may be the result of competition between the AF-
domain of RX and the LXL motif for the coactivator bind-
ing site on the other receptor (11 , 12, 36). In the antagonist-
bound ERa-LBD crystal structure , the AF-2 domain occupies
the coactivator binding groove, mimicking the hydrophobic in-
teractions of the NR box peptide with this domain in the ago-
nist-NR box peptide-receptor complex (11). Biochemical studies
with RA and SRCI support these observations , for bind-
ing of RA- and RX-specific ligands enhance SRCI interac-
tion with the receptor dimer relative to the interaction in the
presence of either ligand alone (36). Presumably, one ligand
binding recruits a single NR box to the receptor dimer, which
displaces the AF -2 domain from the coactivator binding site
and relieves allosteric inhibition, allowing the second ligand to
bind the other receptor monomer. This, in turn, enhances the
interaction with coactivator by recruiting a second NR box (36).
In the case of wild-type receptors , hormone does stimulate
RAC3-RID binding to the heterodimer, but only weakly com-
pared with the VDR/443 dimer, where a very strong, vita-
min D-dependent interaction is observed. These observations
are confirmed by in vivo studies demonstrating that RAC3 can
coactivate VDR/443 activity to a greater extent than VDR/
RX activity. Hormone binding and RID recruitment must not
be able to displace every RX AF -2 domain from the coactivator
binding site of the partnering receptor; thus , fewer RID mole-
cules are able to bind in the presence of the RX AF -2 domain.
This suggests that the AF -2 domain of RX plays a critical role
in regulating RAC3 modulation of receptor function. However
other possibilities may explain this finding, foremost being the
hypothesis that deletion ofthe AF-2 domain ofRX results in
a conformational change of the VDR/443 dimer that en-
hances its affnity for the RAC3-RID.
Our data demonstrate for the first time that RAC3 can
enhance the transcriptional activation function of the VDR and
ER/3 and that this coactivation activity depends on different
NR box requirements. Several other cofactors have been found
to stimulate VDR activity, including SRCl, GRIPlIIF2
NCoA- , and the DRIP (VDR-interacting proteins) complex
(13 , 40-42), whereas SRCI can coactivate the ER/3 (43). The
role of multiple coactivators in the function of the VDR in vivo
is unknown, but several possibilties exist that suggest that the
function of these co activators is not completely redundant.
First, the relative contribution of each coactivator may depend
on cell or tissue type and/or coactivator levels in these cells.
RAC3 is expressed at a high level in placenta, heart, and HeLa
cells relative to TIF2 and SRCI (20); thus , it may serve a more
prominent role in receptor function in these cells. Second, dif-
ferent coactivators may serve different functions that in total
result in maxmal transcriptional activation by the VDR. For
example , RAC3 can interact with CBP; thus, RAC3 may recruit
CBP to the VDR. SRCI has intrinsic histone acetylation activ-
ity, and the DRIP VDR-interacting proteins complex may re-
model nucleosomes (21 , 44), which also may contribute to the
overall function of the VDR in stimulating target gene expres-
sion. Finally, we cannot rule out the existence of a complex
containing multiple coactivators , which synergize to potentiate
VDR activity.
In summary, our data establish RAC3 as a potent coactivator
of the vitamin D receptor and estrogen receptor /3. Interest-
ingly, RAC3 modulates the function of these receptors differ-
ently via interactions that depend on specific LXL motifs in
the RAC3 receptor-interacting domain. Although the biological
role of RAC3 in nuclear receptor function remains to be ex-
plored, this study sheds light on the molecular mechanisms of
RAC3 regulation of receptors that wil hopefully lead to a better
understanding of SRC coactivator function in vivo.
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Abstract
Nuclear hormone receptors are ligand-dependent transcription factors that regulate genes critical to such biological processes
as development, reproduction, and homeostasis. Interestingly, these receptors can function as molecular switches, alternating
between states of transcriptional repression and activation, depending on the absence or presence of cognate hormone, respectively.
In the absence of hormone , several nuclear receptors actively repress transcription of target genes via interactions with the nuclear
receptor corepressors SMR T and NCoR. Upon binding of hormone, these corepressors dissociate away from the DNA-bound
receptor, which subsequently recruits a nuclear receptor coactivator (NCoA) complex. Prominent among these coactivators is the
SRC (steroid receptor coactivator) family, which consists of SRC- , TIF2/GRIPl , and RAC3/ACTR/pCIP/AIB-1. These cofactors
interact with nuclear receptors in a ligand-dependent manner and enhance transcriptional activation by the receptor via histone
acetylation/methylation and recruitment of additional cofactors such as CBP/p300. This review focuses on the mechanism of
action of SRC co activators in terms of interactions with receptors and activation of transcription. Specifically, the roles of the
highly conserved LXXLL motifs in mediating SRC function will be detailed. Additionally, potential diversity among SRC family
members, as well as several recently cloned SRC-associated cofactors, will be discussed. i! 2000 Elsevier Science B.V. All
rights reserved.
Keywords: CBP; LXXLL motif; RAC3/ACTR/pCIP/AIB- 1; Steroid receptor coactivator; TIF2/GRIP1
1. Introduction
The steroid and thyroid nuclear receptor superfamily
is a large class of ligand-dependent transcription factors
involved in the regulation of genes that play critical
roles in a wide array of biological processes , including
development, reproduction and homeostasis
(Mangelsdorf et aI. , 1995). This superfamily can be
Abbreviations: ACTR, activator of retinoic acid receptor; AF-
activation function-2 domain; AIB- I, amplified in breast cancer-
CARM1 , coactivator-associated arginine methy1transferase; GRIP1
glucocorticoid receptor-interacting protein 1; HAT, histone acety1-
transferase; LBD , ligand binding domain; NR box, nuclear receptor
interacting box; pCIP, p300/CBP cointegrator-associated protein;
RAC3 , receptor associated coactivator 3; SRA , steroid receptor RNA
activator; SRC, steroid receptor coactivator; TIF2, transcription inter-
mediary factor 2; TRAM- , thyroid receptor activator molecule 1.
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further subdivided into three classes of nuclear receptors.
Type I or steroid receptors include those for estrogens
(ER), progestins (PR), androgens (AR), glucocorticoids
(GR), and mineralcorticoids (MR). Type I receptors
are coupled to heat-shock proteins and sequestered to
the cytoplasm in the absence of ligand (Tsai and
Malley, 1994). Upon hormone binding, they dissoci-
ate from the heat-shock proteins , homodimerize , and
translocate to the nucleus, where they bind cognate
response elements consisting of palindromic repeats.
Type II receptors include those for all- trans retinoic acid
(RAR), thyroid hormone (TR), and vitamin D (VDR).
These receptors are strictly nuclear and form heterodim-
ers with the receptor for 9-cis retinoic acid (RXR). They
also bind constitutively to response elements consisting
of direct repeats. A third class of nuclear receptors is
the orphan receptors, so-called because endogenous
ligands for these proteins are currently unknown.
Most members of the nuclear receptor superfamily
share a common domain structure. The N-terminus
0378- 1119/00/$ - see front matter 2000 Elsevier Science BY All rights reserved.
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contains the variable A/B region, which also includes
the ligand-independent activation function- l (AF-
domain. The C region represents the highly conserved
DNA-binding domain (DBD) and is followed by the
hinge region (D) and the C-terminal ligand-binding
domain (LBD) (E). The LBD contains the ligand-
dependent activation function-2 (AF-2) domain and
also mediates dimerization of nuclear receptors. In the
absence of ligand, several nuclear receptors are able to
repress basal transcription via recruitment of the nuclear
receptor corepressors SMRT and NCoR (Horlein et aI.
1995; Chen and Evans , 1995). SMRT and NCoR are
found in complexes with the corepressor mSin3 and
histone deacetylases (HDACs), suggesting that tran-
scriptional repression by nuclear receptors may' involve
histone deacetylation (Nagy et aI. , 1997; Heinzel et aI.
1997; Alland et aI. , 1997). Ligand binding triggers the
release of these corepressors and subsequent recruitment
of co activators through a drastic conformational change
in the AF-2 domain of the receptor. Structural studies
have demonstrated that helix 12 within the AF-2 domain
projects away from the LBD in the unliganded structure
(Renaud et aI. , 1995; Wagner et aI. , 1995; Bourguet
et aI. , 1995; Brzozowski et aI. , 1997). This helix rotates
nearly 180 to pack tightly against the LBD upon
hormone binding in the RAR, TR, and ER crystal
structures. This conformational change, together with
ligand-induced changes in helices 3- , is believed to
facilitate interactions of the receptor with coactivators
(Shiau et aI. , 1998; Darimont et aI. , 1998; Feng et aI.
1998; Nolte et aI. , 1998). Subsequently, co activators are
able to enhance transcriptional activation by the recep-
tor via mechanisms that include recruitment of the
general coactivator CBPjp300 and histone acetylation.
Coactivators are generally defined as proteins that
can interact with DNA-bound nuclear receptors and
enhance their transcriptional activation function.
Although many nuclear receptor coactivators have been
identified (McKenna et aI., 1999), the steroid receptor
coactivator (SRC) family has been the focus of intense
study in recent years. Thus this review will focus on the
mechanisms of action of these cofactors in regulating
the function of nuclear receptors and also highlight
several of the recently cloned SRC-associated proteins.
2. The SRC family of coactivators
The first nuclear receptor coactivator , steroid receptor
coactivator- l (SRC- l), was cloned by using the PR-LBD
as bait in a yeast-two-hybrid screen of a human B-cell
cDNA library (Onate et aI. , 1995). SRC- l interacts in
a ligand-dependent manner with and enhances AF-
transcriptional activation by a broad range of nuclear
receptors, including PR, ER , TR , RXR, GR , and PPAR.
Recent data also detail the enhancement of ER (Webb
et aI. , 1998) and AR (Alen et aI. , 1999; Bevan et aI.
1999; Ma et aI. , 1999) AF- l activities by SRC- l. In
addition, SRC- l has been demonstrated to interact with
the general transcription factors TBP and TFIIB
although the functional consequences of these inter-
actions are unknown (Takeshita et aI. , 1996; Ikeda et aI.
1999). Furthermore, SRC- l is able to enhance transcrip-
tional activation mediated by NF-KB , SMAD3, and
AP- l (Lee et aI. , 1998; Yanagisawa et aI. , 1999; 
et aI., 1998), supporting a role for nuclear receptor
co activators in multiple intracellular signaling pathways.
Subsequent studies have identified two functionally dis-
tinct SRC- l isoforms , SRC- la and SRC- , which con-
tain unique C-termini, suggesting that alternative
splicing may regulate SRC-l function (Kalkhoven
et aI. , 1998).
The identification of transcription intermediary factor
2 (TIF2) and GR-interacting protein 1 (GRIPl) estab-
lished the SRC family of coactivators (Voegel et aI.
1996; Hong et aI. , 1996). TIF2 was isolated in a Far-
western screen as an ER- and RAR-interacting factor
while GRIPI was isolated using the GR-LBD as bait in
a yeast-two-hybrid screen. TIF2 and GRIPI share 94%
amino acid identity, thus represent the human and
murine orthologs , respectively. TIF2 and GRIPI associ-
ate in vivo with hormone-bound RAR , ER , and PR
and coactivate ligand-dependent transactivation. Like
SRC- , GRIPI also has been demonstrated to enhance
receptor AF- l activity in addition to that of the AF-
domain (Ma et aI. 1999). Intriguingly, the
inv(8)(pllq13) chromosomal translocation results in a
fusion between TIF2 and the MOZ gene , which contrib-
utes to the pathogenesis of acute myeloid leukemia
(AML), suggesting a role for transcriptional regulation
by nuclear receptor co activators in these leukemias
(Carapeti et aI. , 1998).
The third member of the SRC family was reported
simultaneously by several groups as an RAR-interacting
protein (RAC3), a CBP-interacting protein (pjCIP), a
hRAR -stimulatory protein (ACTR), a gene amplified
in breast cancer (AIB- l), and a TR - interacting protein
(TRAM- I) (Li et aI. , 1997; Torchia et aI. , 1997; Chen
et aI. , 1997; Anzick et aI. , 1997; Takeshita et aI. , 1997).
pjCIP represents the mouse homolog, while
RAC3/ACTRjAIB- ljTRAM are human isoforms. In
addition to coactivating many nuclear receptors , pCIP
has also been demonstrated to enhance the activity of
interferon-ex and cAMP regulatory element binding pro-
tein (CREB), suggesting that this coactivator may be
involved in multiple signaling pathways (Torchia et aI.
1997). Furthermore , RAC3/TRAM- l expression can be
upregulated by hormone treatment, which represents
another possible mechanism by which co activators may
potentiate hormone action (Li and Chen, 1998; Misiti
et aI. , 1998).
3. The LXXLL motif
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The SRC family of coactivators also shares a common
domain structure, with the most highly conserved region
being the N- terminal bHLH-PAS domain (Fig. la). The
bHLH region functions as a DNA-binding or dimeriza-
tion surface in many transcription factors, including the
MyoD family of proteins (Murre et aI. , 1989a, b). The
PAS motif is also found in several transcriptional regula-
tors , including Period (Per), Aryl hydrocarbon receptor
(AhR), and single-minded (Sim). Similar to the bHLH
domain , the PAS domain also plays a role in protein-
protein interactions and dimerization. However, the
function of the bHLH-PAS domains of SRC coactiva-
tors remains unknown, though it is likely to mediate
intra- or intermolecular interactions. This bHLH-PAS
bHLH PAS- PAS-
SRC 
domain is followed by a centrally located receptor-
interacting domain (RID) and C-terminal transcrip-
tional activation domain (AD), which will be discussed
in detail below.
The RID of SRC co activators mediates ligand-depen-
dent, direct interactions with nuclear receptors (Li and
Chen, 1998; Voegel et aI. , 1998; Onate et aI., 1998).
Intriguingly, detailed analysis of the sequence of the
RID identified a conserved motif, LXXLL, where L is
leucine and X is any amino acid , that is termed the NR
box (Heery et aI. , 1997) (Fig. Ib). Three such motifs
are found in the RID of SRC coactivators, with an
additional, non-conserved NR box also present at the
terminus of the SRC- l isoform SRC- la. Site-directed
mutagenesis and peptide competition experiments have
provided strong evidence for the requirement of these
RID
HAT
RID
ii iii iv v vi Q-rich vii
P/CAF
CARM1
CBP/p300
NR boxes
RAC3 615
TIF2
SRC1 632
RAC3 678
ii. TIF2 683
SRC1 683
RAC3 730
iii. TIF2 738
SRC1 739
RAC3
iv. TIF2
SRC1
RAC3
TIF2
SRC1
RAC3
vi. TIF2
SRC1
vii. SRC1 1424 Q T P QAQQ K S L L Q QL L T E
Fig. 1. SRC family domain structure. (A) Schematic representation of the structural domains of SRC coactivators. The N-terminus contains the
highly conserved bHLH and PAS A/B domains. The centrally located receptor-interacting (RID) and activation (AD) domains each contain three
LXXLL motifs, while 8.RC- I contains an additional , non-conserved motif at the C-terminus. The C-terminus contains a glutamine-rich domain.
The specific domains for interaction with P/CAF, CBP/p300 , and CARMI , as well as the histone acetyltransferase (HAT) domain , are indicated.(B) Sequence alignment of the SRC LXXLL motifs. The starting amino acids are in parentheses. Motifs i-iii are located in the receptor-interacting
domain and motifs iv-vi are found in the transcriptional activation domain. SRC- I contains an additional non-conserved motif at its C-terminus.
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motifs for mediating interactions between coactivators
and 1iganded nuclear receptors (Heery et aI. , 1997;
Torchia et aI. , 1997; Ding et aI. , 1998). Further support
for the role of these motifs in mediating agonist-depen-
dent interactions with nuclear receptors is found in a
study in which phage-displayed peptide libraries were
screened for peptides that interact specifically with ago-
nist or antagonist bound estrogen receptor (Norris et aI.
1999). Many peptides isolated with estradiol-bound
ERcr contained the LXXLL motif, while those isolated
with tamoxifen-bound receptor did not. These findings
suggest that the activation of the ERcr by tamoxifen
that is observed in some tissues might occur via a
different mechanism than estradiol- induced activation
such as through the recruitment ofnon-LXXLLcontain-
ing coactivators to tamoxifen-specific surfaces of the
ER. Crystallographic and protein structure prediction
analyses have indicated that these motifs form amphi-
pathic cr-helices with the leucine residues comprising a
hydrophobic surface on one face of the helix. The helix
is able to interact with the AF-2 domain of the 1iganded
receptor via a hydrophobic groove made up of residues
from receptor helices 3 , 4, 5 , and 12 that is the result of
the conformational change induced by hormone binding
(Torchia et aI. , 1997; Shiau et aI. , 1998; Nolte et aI.
1998; Darimont et aI. , 1998; Feng et aI. , 1998).
The most interesting aspect of NR box function is
the revelation that a receptor-specific code exists , where
different nuclear receptors prefer different NR boxes of
the RID for interaction with coactivators (Leers et aI.
1998; Ding et aI. , 1998; Darimont et aI. , 1998; McInerney
et aI. , 1998). For example, a 13-aa peptide encompassing
GRIP1 motif ii effciently blocked interaction between
GRIP1 and the TR LBD in vitro, while a peptide
comprising motif iii was a more potent competitor for
GR binding (Darimont et aI. , 1998). Similarly, yeast-
two-hybrid assays demonstrate that mutation of TIF2
motif ii is most deleterious to interactions with PPARcr
while a motif i mutation has the greatest effect on the
TIF2-RXR interaction (Leers et aI., 1998). In all
cases, however, mutation of a single motif does not
completely abolish coactivator interaction with nuclear
receptors , suggesting that multiple NR boxes contribute
to the overall, high-affnity binding to the receptor. It is
likely that the precise arrangement of multiple motifs
and structural nuances of each receptor determines the
relative contribution of each NR box to the interaction.
This receptor-specific code has also been analyzed in
vivo in terms of transcriptional coactivation of nuclear
receptors by SRC- 1 via site-directed mutagenesis and
antibody micro injection assays (McInerney et aI. , 1998).
The requirement of specific NR boxes for transactivation
of reporter genes by different receptors was determined
by injecting anti SRC- 1 antibodies into cells along with
rescuing p1asmids for wild-type or NR box mutants of
SRC- l. Anti-SRC- 1 IgG completely abolishes transcrip-
tiona1 activation by ER , PR , RAR , TR , and PPARy,
while coinjection of wild-type SRC- 1 rescues receptor
function. Mutation of NR box ii prevented rescue of
ER function in SRC- 1 immunodep1eted cells , while NR
boxes ii and iii were required for rescue of RAR and
TR activity and boxes i and ii for PR activity.
Furthermore, in the case of PPARy, different 1igands
elicited different NR box requirements for SRC- 1 coacti-
vation. Trog1itazone-bound PPARy preferred NR box
ii over box i, while the opposite was observed in indo-
methacin-treated cells. Together, these data support
receptor-specific LXXLL motif requirements for coacti-
vation function and receptor interactions that account
for the presence of multiple NR boxes within SRC
coactivators and imply that these motifs do not serve
merely redundant functions.
Other determinants that contribute to the specificity
of NR box selectivity by different nuclear receptors
include residues flanking each NR box. For instance , a
chimeric peptide containing the GRIP1 NR box iii motif
in the context of the flanking sequences of NR box ii
competed for TR-LBD binding with a similar potency
as the peptide comprising NR box ii (Darimont et aI.
1998). Also , using phage-displayed libraries enriched for
LXXLL-containing peptides , it was demonstrated that
several subclasses of these peptides exist which contain
different flanking residues and which vary in their abili-
ties to interact with different ER mutants and other
receptors (Chang et aI. , 1999). Furthermore, it has been
shown that the flanking N-termina1 amino acids are not
essential, while the eight residues C-termina1 to the NR
box are required for SRC- 1 mediated coactivation of
RAR , TR, and ER (McInerney et aI., 1998). These
studies also revealed additional preferences of ER and
RAR for different NR box ii C-termina1 amino acids.
Intact residues + 12 and + 13 (where L of LXXLL is
+ 1) are required for SRC-1 rescue of ER activity, while
residues at +6, + 7, + 11 , and + 13 are necessary for
rescue of RAR function. Finally, since most nuclear
receptors require two intact NR boxes of coactivator
for interaction, the spacing between the motifs also can
serve as a determinant for recognition. Deletion of 30
of the 50 amino acids between NR boxes ii and iii
abolished the ability of SRC-1 to rescue IgG-mediated
inhibition of RAR activity (McInerney et aI. , 1998). In
contrast, proper spacing between NR boxes i and ii was
required for coactivation of PPAR y, consistent with the
requirement of intact motifs i and ii for maximal PPAR 
transactivation.
4. Ray crystal structures
The biochemical studies outlined above clearly outline
the LXXLL motifs of SRC coactivators as being critical
to the interaction with and coactivation of nuclear
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receptors. Further insight into the molecular basis of
these interactions can be found in the recently solved
crystal structures of several nuclear receptor LBDs with
coactivator fragments containing NR boxes. In the
structure of TR LBD complexed with T3 and a 13-aa
peptide encompassing NR box ii of GRIP1 , the leucines
of the a-helical NR box make contacts with a hydro-
phobic groove consisting of residues from helices 3 , 4
, and 12 of TR (Darimont et aI. , 1998). single
LXXLL peptide interacts with each monomer of the
dimer. Mutagenesis confirms the importance of
these receptor residues for in vitro binding of GRIPl 
. A very similar structure is observed with agonist-
bound ERa-LBD complexed with a peptide comprising
NR box ii of GRIPl (Shiau et aI. , 1998). However, in
the antagonist-bound ERa-LBD structure, helix 12 of
the ERa is occluding the coactivator-binding site , consis-
tent with the inability of SRC co activators to bind
antagonist-bound nuclear receptors. Most strikingly, a
region of helix 12 contains an NR box-like sequence
(LXXML) and functions as an intramolecular mimic of
the LXXLL motif by making contact with the hydro-
phobic groove. This structural data supports the model
of allosteric inhibition of the RXR-RAR heterodimer
by the RXR AF-2 domain (Westin et aI. , 1998). These
observations provide a molecular basis of antagonist
function via conformational changes of helix 12 and
inhibition of coactivator binding. Finally, the structure
of the PPARy-LBD bound to rosiglitazone and an 88-aa
fragment of SRC- l containing NR boxes i and ii has
also been described (Nolte et aI. , 1998). This study
details the function of a "charge clamp" of conserved
glutamine and lysine residues of the LBD that positions
the LXXLL motif into the hydrophobic groove of the
receptor. In addition, the two NR boxes of the SRC-
fragment are observed to contact simultaneously the
PPAR y dimer, providing further support for the role of
multiple motifs in mediating coactivator-receptor
interactions.
5. Transcriptional activation by SRC coactivators
The SRC coactivators also contain an intrinsic tran-
scriptional activation function , which is evident upon
tethering coactivator to DNA via a heterologous DNA-
binding domain. All three members are able to effciently
activate transcription when fused to the Ga14 DNA-
binding domain in both yeast and mammalian cells (Li
et aI. , 1997; Ofiate et aI. , 1998; Voegel et aI. , 1996).
Detailed deletional analysis has subsequently mapped
the activation domain (AD) as being located C-terminal
to the receptor-interacting domain. Interestingly, this
AD also contains three additional LXXLL motifs repre-
senting NR boxes iv, v, and vi , that have been linked
to interaction with the general transcriptional activators
CBP/p300. CBP/p300 has been demonstrated to interact
with SRC proteins in vitro and in vivo and mutation of
one or more of the AD NR boxes markedly impairs
these interactions , as well as the activation function of
the coactivator (Voegel et aI. , 1998; McInerney et aI.
1998). Furthermore , microinjection studies have shown
that anti-CBP antibodies abolish the ability of SRC-
to coactivate RAR, suggesting that CBP/p300 is required
for the coactivation function of SRC-l (McInerney
et aI. , 1998). However, it is worth noting that additional
CBP-independent transcriptional activation domains
have also been attributed to members of the SRC family,
supporting the existence of multiple mechanisms of
transcriptional activation by co activators (Ikeda et aI.
1999; Ma et aI. , 1999; Voegel et aI. , 1998). The contribu-
tion of these multiple activation domains to overall
coactivator function is not completely clear , but several
studies suggest that co activators may preferentially uti-
lize specific ADs depending on the receptor or activation
function (AF- l vs. AF-2) that is mediating the response
to hormone (Ma et aI. , 1999). In particular, the
terminal AF- l activation domain seems to be most
critical to transcriptional activation by the androgen
receptor (AR). SRC- l and GRIPl have been demon-
strated to bind and coactivate the AF- l domain of the
AR (Alen et aI., 1999; Bevan et aI. , 1999; Ma et aI.
1999). These interactions are mediated by the
terminus of the SRC coactivator, rather than the
centrally located domain containing NR boxes ifi/iii.
Consistent with this observation, mutation of these
motifs does not inhibit the ability of the coactivator to
enhance transcriptional activation by the full-length AR
but only the isolated AF-2 domain (Alen et aI. , 1999;
Bevan et aI. , 1999). This AF- l interacting domain also
lacks the CBP-interacting domain of the coactivator
thus coactivation of AF- llikely occurs via mechanisms
other than CBP recruitment, but through additional
coactivators , such as CARMl (see below), which also
binds the C-terminus of GRIPl (Chen et aI. , 1999a).
Interestingly, the N-terminus of the AR also can interact
with the C-terminal AF-2 domain and is required for
both AF- induced transcription and SRC coactivation
of AF- activity (Alen et aI., 1999). These studies
suggest that the AF- l and AF-2 domains may synergize
for complete AR activity and that the interaction of the
two activation domains may result in recruitment of
coactivator to the AR. Finally, SRC co activators have
also been demonstrated to enhance the AF- l activity of
the ERa in the presence of both estradiol and tamoxifen
suggesting that the partial agonism of tamoxifen occurs
by coactivator recruitment to the AF- l domain (Webb
et aI. , 1998).
Another potential mechanism of transcriptional acti-
vation by SRC co activators is histone acetylation.
Hyperacetylated his tones have long been linked to tran-
scriptionally active chromatin, for acetylation leads to
an unpacking of the condensed chromatin network
thereby facilitating the access of transcription factors to
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target gene promoters. Accordingly, both CBP/p300 and
the CBP/p300-associated factor P/CAF have been
demonstrated to possess potent histone acetyltransferase
(HAT) activity (Bannister and Kouzarides, 1996;
Ogryzko et aI., 1996; Yang et aI., 1996), which 
required for transcriptional activation by CBP
(Martinez-Ba1bas et aI. , 1998). Both factors interact
with SRC coactivators , as well as with nuclear receptors
themselves , and enhance receptor transcriptional activa-
tion (Kamei et aI. , 1996; Blanco et aI. , 1998; Chakravarti
et aI. , 1996). Therefore , recruitment of HAT-containing
coactivators by the receptor may lead to a modulation
of chromatin structure, thereby facilitating the access of
either additional transcriptional activators , such as the
DRIP/TRAP complex (see below), or the assembly of
the pre-initiation complex, ultimately leading 'to tran-
scriptional activation. Interactions between co activators
and the basal transcription machinery may also playa
role in transcriptional activation, for both CBP/p300
(Kwok et aI. , 1994; Yuan et aI. , 1996) and SRC-
(Ikeda et aI. , 1999; Takeshita et aI., 1996) have been
reported to interact with TBP and TFIIB. Interestingly,
moderate HAT activity has also been attributed to
SRC- 1 and ACTR, suggesting that liganded nuclear
receptors recruit a coactivator complex containing
multiple enzymatic activities (Chen et aI. , 1997; Spencer
et aI. , 1997). The apparent redundancy of HAT activities
among the coactivator complex remains to be resolved
completely. However transcription factor-specific
differences in HAT requirements have been established
for RAR versus CREB via microinjection analysis
(Korzus et aI., 1998). Whereas P/CAF HAT activity
was required for transcriptional activation by RAR
CBP HAT activity was required for CREB function.
Additionally, cell-type and promoter-specific differences
may also account for the existence of numerous HAT-
containing coactivators. Finally, multiple HAT activities
may be required if non-histone proteins also serve as
substrates for these enzymes. In support of this , p300
has been demonstrated to acety1ate p53 , increasing its
DNA binding activity (Gu and Roeder, 1997). Also
CBP and P/CAF can acety1ate TFIIE and TFIIF in
vitro, which again links the basal transcription
machinery to transcriptional activation by nuclear recep-
tor co activators (Imhof et aI. , 1997). Furthermore, a
recent study reports that ACTR itself can be acetylated
by CBP/p300 (Chen et aI. , 1999b). In this paper , hor-
mone treatment results in enhanced histone acetylation
at ER, RAR, and VDR target gene promoters and
increased recruitment of coactivators, including ACTR
and CBP/p300. However, this effect is transient in nature
and is strongly downregu1ated after prolonged hormone
treatment. Surprisingly, acetylation of ACTR by
CBP/p300 at specific lysine residues causes the dissoci-
ation of ACTR from the DNA-bound ER homodimer.
These results suggest that the mechanism of downregula-
tion of receptor activity involves release of the coactiva-
tor complex from the receptor via acetylation of the
coactivator itself.
6. Diversity among SRC coactivators
One of the most important remaining questions to
be answered concerning the function of SRC c6activa-
tors in vivo focuses on whether or not these three
cofactors serve redundant functions. Although all three
SRC family members do possess similar properties in
terms of interactions with nuclear receptors and
enhancement of transcriptional activation several
reports suggest that their activities are not completely
overlapping and particularly outline a division between
SRC- 1 and TIF2/GRIP1 versus RAC3/ACTR/pCIP/
AIB-1 functions. For example, microinjection of expres-
sion plasmids for SRC- l or NCoA- , but not pCIP
were able to rescue RAR-dependent activation in SRC-
immunodepleted cells (Torchia et aI. , 1997). Also, the
relative contribution of each coactivator may depend
on cell or tissue type and/or coactivator levels in these
cells. RAC3/ACTR/AIB- 1 is expressed at high levels in
placenta, heart, and HeLa cells relative to TIF2 and
SRC- 1; thus it may serve a more prominent role in
lUclear receptor function in these cells (Li and Chen
1998). In addition, AIB- 1 was cloned as a gene that is
amplified in ER-positive BT-474, MCF- , and ZR75
breast cancer cell lines (Anzick et aI., 1997). AIB-
mRNA and protein levels are expected1y higher in these
cells as well. SRC- 1 and TIF2/GRIP1 are expressed at
relatively low levels in these cell lines , suggesting that
AIB- 1 is specifically involved in the pathogenesis of
these tumors. Furthermore, the viability of an SRC-
knockout mouse may, in part, be due to the observed
compensatory overexpression of GRIP1/TIF2 in certain
tissues (Xu et aI., 1998). RAC3/pCIP levels are
unchanged in these tissues compared to the wild-type
mouse, again supporting a different functional role for
this coactivator versus SRC- 1 and TIF2/GRIPl. Finally,
a recent study demonstrates that SRC- 1 does not co10-
ca1ize with ERcr in rat mammary epithelial cells, but
rather is expressed in a distinct subset of cells , suggesting
that TIF2/GRIP1 or RAC3/ACTR/AIB-1 may be more
important for ERcr function in these cells (Shim et aI.
1999).
7. Other nuclear receptor coactivators
In addition to the SRC family of co activators dis-
cussed above , many other cofactors have been identified
which stimulate the activity of nuclear receptors. For
the sake of brevity, we wil focus on those associated
with SRC coactivators.
1. SRA
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Recently, in a search for nuclear receptor cofactors
a novel steroid receptor RNA activator (SRA) was
isolated in a yeast-two-hybrid screen using the AF-
domain of the PR as the bait (Lanz et aI.
, 1999). This
coactivator is selective for the N-terminal AF- l activa-
tion domain of nuclear receptors and can reverse estro-
gen-induced squelching of PR-driven gene expression.
Interestingly, SRA is also selective for steroid receptors
versus RXR heterodimers , for it enhances only PR , GR
, and ER activities while having no effect on the
activities of the , RARy, RXRy, or PPARy.
However, maybe the most surprising characteristic of
SRA is that it apparently functions as an RNA tran-
script, which is evident from several observations. First
efforts to generate SRA-encoded protein in vitro or in
vivo were not successful. Second, several mutant con-
structs of SRA that disrupt translational start sites or
open reading frames were still able to potentiate PR
activity. Third, SRA retained coactivation activity in
the absence of protein synthesis via cyclohexamide treat-
ment. Finally, SRA transcripts were identified as compo-
nents of an SRC-l complex in vivo via whole-cell
fractionation followed by gel filtration chromatography.
SRA, detected by R T -PCR, specifically copurified with
SRC- l in the same fractions. SRA mRNA was also
effciently coimmunoprecipitated with SRC- l antibodies
further supporting the existence of a complex containing
SRA and SRC-1. This study suggests that SRA is a
novel RNA coactivator that forms a complex with
SRC- 1 in vivo and selectively enhances the activity of
steroid hormone receptors via the AF - 1 domain.
7.2. CARM1
A novel enzymatic activity was attributed to nuclear
receptor co activators with the cloning of CARM1
(coactivator-associated arginine methyl transferase 1) via
a yeast-two-hybrid screen using the C-terminal amino
acids 1121- 1462 of GRIPI (Chen et aI., 1999a). This
region represents a second, CBP-independent activation
domain of GRIP1 (Ma et aI. , 1999). CARM1 showed
extensive homology to the PRMT (protein methyl-
transferase) family of arginine-specific methyltransfer-
ases and interacted with all three members of the SRC
coactivator family in vitro. Furthermore , CARM1 con-
tained potent histone methyltransferase activity in vitro
with a preference for histone H3. In vivo , CARM1
enhanced transcription by a Ga14-DBD fusion of
GRIP1 1121- 1462 and further stimulated GRIP1 coacti-
vation of AR, TR, and ER activities. This coactivation
function was dependent upon three amino acids located
in the region critical to methyltransferase activity, sug-
gesting that this enzymatic activity is required for
CARM1' s ability to enhance receptor function. In the
absence of GRIP1 , CARM1 had no effect on receptor
function, thus SRC co activators are likely required in
order to recruit CARM1 to the receptor complex.
Overall, the cloning of CARM1 contributes to the
mechanism by which SRC coactivators activate tran-
scription through multiple domains. One activation
domain may be required in order to recruit CBP/p300
and histone acetylation activity, while the second activa-
tion domain recruits CARMI and histone methylation
activity. These multiple enzymatic functions may be
promoter specific or cooperate to remodel chromatin
and facilitate transcriptional activation.
7.3. PGC-
The cloning and characterization of PGC- l (PPAR
gamma coactivator- 1) was a critical finding to the field
of nuclear receptor coactivators , for it linked coactivator
function to the regulation of a specific physiological
process, namely adaptive thermogenesis. PGC- l was
isolated in a yeast-two-hybrid screen using PPAR y 183-
505 as the bait and was demonstrated to interact with
several members of the nuclear receptor superfamily
(Puigserver et aI. , 1998). It also possesses potent coacti-
vation function for PPAR y and TR activities at the
UCP- 1 (uncoupling protein- I) promoter, inducing the
expression of this mitochondrial protein involved in heat
generation in brown fat cells. Consistently, PGC- 1 is
also upregulated in muscle and brown fat cells upon
exposure to cold temperatures. Further studies have
demonstrated that PGC- 1 enhances mitochondrial bio-
genesis and oxygen consumption in muscle cells via the
induction ofUCP-2 and the regulation ofNRFs (nuclear
respiratory factors), which are transcription factors that
regulate genes involved in mitochondrial DNA replica-
tion and transcription (Wu et aI. , 1999). Finally, a very
recent study reports the functional association between
PGC- 1 and SRC- 1 (Puigserver et aI. , 1999). SRC- , as
well as CBP/p300 , interacts with PGC- 1 in vitro and in
vivo and enhances transcriptional activation by 
Ga14DBD fusion of PGC- 1 in transient transfection
assays. These interactions are mediated by SRC- l 782-
1139 and p300 1805-2441. Intriguingly, expression of
PPARy or NRF- 1 also enhanced Ga1-PGC- 1 activity,
while cotransfection of PPAR y increased the interaction
between PGC- 1 and SRC- 1 or CBP/p300 in vitro and
in vivo. These data support a model ofPGC- l activation
in which the interaction with a transcription factor such
as PPARy stimulates PGC- 1 activity by inducing SRC-
recruitment (Puigserver et aI. , 1999). This recruitment
likely is the result of a conformational change in PGC-
that occurs upon binding to the transcription factor.
This study also suggests the SRC coactivator function
may be essential to adaptive thermogenesis , for it may
be required for transcriptional activation by PGC-
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8. DRIP/TRAP coactivator complexes
Much effort has been made recently to isolate and
purify an entire complex of polypeptides that functions
to coactivate nuclear receptor function. To this end
several groups have identified virtually identical com-
plexes that appear distinct from the SRC coactivator
complex. Using the VDR-LBD as an affnity matrix, a
complex was purified from Namalwa cell extracts termed
DRIP (VDR-interacting proteins) that specifically
interacts with ligand-bound VDR-LBD (Rachez et aI.
1998). The same complex was also purified using affnity
chromatography from He La cells that constitutively
express Flag-tagged TR and named TRAP
(TR-associated proteins) (Fondell et aI. 1996).
Subsequently, this complex was identified as ARC (acti-
vator-recruited cofactor) (Naar et aI. , 1999) and SMCC
(Srb/Mediator coactivator complex) (Gu et aI. , 1999).
The DRIP/TRAP complex lacks CBP/p300 or SRC
proteins (Rachez et aI., 1999) and is recruited to the
receptor AF-2 domain by the DRIP205/TRAP220 sub-
unit via a single LXXLL motif (Rachez et aI. , 1999;
Yuan et aI., 1998). Unlike SRC coactivators, the
DRIPs/TRAPs have been demonstrated to be required
for transcriptional activation by nuclear receptors in
cell-free in vitro transcription assays (Rachez et aI.
1998; Fondell et aI. , 1996). The DRIPs also enhance
VDR activity on chromatin-organized templates despite
a lack of HAT activity, suggesting a potential uniden-
tified chromatin remodeling function (Rachez et aI.
1999). Furthermore , it is evident that this complex plays
a more global role in transcriptional activation rather
than being specific to nuclear receptors , for ARC was
identified as a coactivator for VP16 and p65 (Naar
et aI. , 1999), while SMCC enhances p53 activity (Gu
et aI. , 1999). What is not clear is the mechanism by
which the DRIP/TRAP and SRC complexes both con-
tribute to overall nuclear receptor function. One possi-
bility involves a two-step model in which the SRC
complex is first recruited to the nuclear receptor to open
up the chromatin network via histone acetylation
(Freedman , 1999). This would allow access for the large
DRIP/TRAP complex, which would subsequently
remodel chromatin, facilitating the organization of the
pre-initiation complex or binding of other transcription
factors. However it is also possible that the
DRIPs/TRAPs may target RNA polymerase to the
target gene promoter, for several subunits are homolo-
Model of SRC coactivator function
Histone
Acetylation Histone
Methylation
Fig. 2. Model of SRC coiictivator function. The nuclear receptor is able to recruit an SRC coactivator upon binding hormone , which subsequently
results in the recruitment of additional coactivators to the complex. SRC is able to interact with the receptor and CBP/p300 via LXXLL nuclear
receptor (NR) boxes. The histone acetylation and methylation activities of various constituents of the coactivator complex facilitate the relaxation
of the chromatin architecture at the target gene promoter, thereby enhancing transcriptional activation. It should be noted that this is only 
general model of the coactivator complex. It is likely that additional cofactors are involved and that different receptors may recruit different
components of the ,complex , thus achieving a level of specificity among receptors and coactivators. NR = nuclear receptor, SRC = steroid receptor
coactivator , SRA=steroid receptor RNA activator , CARM=coactivator associated arginine methyltransferase, CBP=CREB-binding protein
PCAF = p300/CBP-associated factor.
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gous to proteins found in Mediator
, a transcriptional
regulatory complex that associates with RNA pol 
(Kim et aI. , 1994). In support of this, RNA pol II can
be isolated with the SMCC complex at low ionic strength
(Gu et aI. , 1999). One also cannot rule out the possibility
that SRC and DRIP/TRAP functions are not integrated
at all, but rather have cell-type, promoter, or transcrip-
tion factor specificity. Specificity may also be the result
of the alteration of one or more of the subunits of the
complex, depending on the target gene. Overall, it is
clear that the DRIP/TRAP complex is likely involved
in the regulation of a broad range of signaling pathways
but whose biological role is unknown.
9. Model of SRC function
In order to integrate the wealth of data collected on
the mechanism of action of SRC co activators, we pro-
pose the following model of SRC function in the regula-
tion of nuclear receptor activity (Fig. 2). Hormone
binding triggers nuclear translocation of Type I steroid
receptors and the release of the corepressor complex
from Type II non-steroid receptors and subsequent
recruitment of an SRC coactivator to the target gene
promoter. SRC is able to interact with the AF-2 domain
of each monomer of the dimer via multiple
, ex-helical
NR boxes located in the receptor-interacting domain.
SRC is likely complexed with the RNA coactivator
SRA, which enhances AF- 1 activity. After initial SRC
docking to the receptor, it is able to recruit additional
co activators to the complex. These include CBP/p300
which uses the NR boxes of the SRC transcriptional
activation domain for interaction with coactivator, and
the CBP/p300-associated factor P/CAF. Additional
direct interactions between CBP /p300 and nuclear recep-
tors and between P/CAF and SRC have also been
reported, which may enhance complex formation.
Furthermore, SRC is also able to recruit CARM1 to
the target gene via a different domain than that required
for CBP/p300 binding. Once this complex is assembled
the histone acetylase activities of CBP/p300 , P/CAF
and possibly SRC itself, together with the histone
methyltransferase activity of CARM1 , serve to remodel
the chromatin architecture, thus facilitating the access
of additional transcription factors , co activators such as
the DRIP/TRAP complex, and/or the basal transcrip-
tion machinery to the target gene promoter to activate
transcription. Of course, caveats to this model likely
exist. For example, the coactivator complex may be
comprised of different components depending on the
specific nuclear receptor, cell type, or target gene.
Different coactivator complex components may create a
level of specificity among different receptors that answers
the questions surrounding the potential redundancy
among the members of the SRC family. Also , with the
intense focus on hormone action and plethora of recep-
tor cofactors being cloned in recent years
, it is likely
that additional members of the coactivator complex
have yet to be identified. In addition, non-histone sub-
strates for the enzymatically active cofactors may be
involved, for as described above , CBP/p300 can acetylate
non-histone proteins such as ACTR, p53, and
TFIIE/TFIIF. Finally, it is possible that the receptor is
able to recruit single, pre-formed coactivator complex
to the target gene upon hormone binding. However
though the precise details of transcriptional activation
by nuclear receptors are still not clear, it is evident that
the SRC family of coactivators is critical to receptor
function and wil continue to warrant investigation into
its role in intracellular signaling pathways.
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PML fuses with retinoic acid receptor (RA ) in the t(15;17) translocation that causes acute promyelo-
cytic leukemia (APL). In addition to localizing diffusely throughout the nucleoplasm
, PML mainly resides indiscrete nuclear structures known as PML oncogenic domains (PODs), which are disrupted in APL and
spinocellular ataxia cells. We isolated the Fas-binding protein Daxx as a PML-interacting protein in a yeast
two-hybrid screen. Biochemical and immunofluorescence analyses reveal that Dax is a nuclear protein that
interacts and colocalizes with PML in the PODs. Reporter gene assay shows that Daxx drastically represses
basal transcription, likely by recruiting histone deacetylases. PML, but not its oncogenic fusion PML-
inhibits the repressor function of Daxx. In addition, SUMO- l modification of PML is required for sequestra-
tion ofDaxx to the PODs and for effcient inhibition of Daxx-mediated transcriptional repression. Consistently,
Daxx is found at condensed chromatin in cells that lack PML. These data suggest that Daxx is a novel nuclear
protein bearing transcriptional repressor activity that may be regulated by interaction with PML.
Acute promyelocytic leukemia (APL) arises as a result of
chromosomal translocation involving the retinoic acid (RA)
receptor a (RARa) gene on chromosome 17 fused with either
the promyelocytic leukemia gene (PML) on chromosome 15
the promyelocytic leukemia zinc finger gene (PLZF) on chro-
mosome 11 , the nucleophosminIB23 (NPM) gene on chromo-
some 5, or the nuclear mitotic apparatus gene (NuMA) 
chromosome 11 (30, 39). The t(15;17) translocation between
PML and RARa accounts for nearly all APL cases. This trans-
location creates an oncogenic fusion protein, PML-RAa
which contains both the DNA-binding domain (DBD) and
ligand-binding domains of RARa and the N terminus of PML.
Transgenic mice that overexpress PML-RAa or PLZF-
RARa developed an APL-like phenotype (9 , 21 , 26), suggest-
ing that these fusion proteins are directly involved in APL
pathogenesis. Recent studies have focused on analyzing the
functional properties of PML-RAa and PLZF-RARa (20
, 25, 40) in order to understand the molecular basis of leu-
kemogenesis. Both fusion proteins fonn homodimers that bind
to RA response elements and interact with the nuclear recep-
tor corepressors SMRT (silencing mediator for retinoid and
thyroid hormone action) and N-CoR (nuclear receptor core-
pressor), which in turn recruit a histone deacetylase complex
46). Pharmacological concentrations of all-trans-(atRA) induce dissociation of the corepressors from PML-
RAa , but not PLZF-RARa, due to the presence of an ad-
ditional, RA-insensitive corepressor-interacting surface on
PLZF. This differential degree of dissociation of corepressors
induced by atRA correlates with the ability of histone deacety-
lase inhibitors and atRA to induce tenninal differentiation of
these two subtyes of APL cells. These findings indicate that
abnormalities in transcriptional repression by the oncogenic
fusion proteins may be involved in leukemogenesis.
* Corresponding author. Mailing address: Department of Pharma-
cology and Molecular Toxicology, University of Massachusetts Medi-
cal School , 55 Lake Avenue North , Worcester, MA 01655. Phone:
(508) 856-1481. Fax: (508) 856-1225. E-mail: don.chen0)umassmed
edu.
PML belongs to a family of proteins characterized by the
presence of a RING finger domain (8). RING finger proteins
are implicated in transcriptional regulation, and some mem-
bers of the RING family are associated directly with chromatin
(53). Ablation and overexpression experiments suggest an im-
portant role of PML in the regulation of cell growth , hemato-
poietic cell differentiation, tumorigenesis , apoptosis, and RA
signaling (44, 63). In normal cells, PML is concentrated within
10 to 20 nuclear structures known as nuclear domains 10(NDIO), Knppel bodies, nuclear bodies, or PML-oncogenic
domains (PODs) (2, 17, 33, 59, 65). The POD structure is
disrupted in the t(15;17) translocated APL cells (17
, 33, 65),
presumably through interaction of wild-type PML with PML-RAa. Interestingly, the POD structure reorganizes upon
treatment with atRA or arsenic trioxide (As ), a process
that correlates with differentiation of APL cells , indicating that
the POD structure might affect promyelocyte differentiation.
In addition to PML, the POD contains several other pro-
teins, including the 100-kDa nuclear protein antigen (SplOO)(2), the small ubiquitin-related modifier (SUMO- l (41), also
known as PML-interacting clone 1 (PICl) (7), ubiquitin-like 1(UBLl) (57), or sentrin (48)), and the 140-kDa protein (SpI40)(6). Sp100 is a nuclear antigen recognized by autoantibodies
from patients with primary biliary cirrhosis (62). Expression of
both PML and SplOO are upregulated by interferon (23).
SUMO- l was recently identified as a ubiquitin- like protein that
forms covalent conjugates with ML and SplOO (7, 58). In
addition, the CREB-binding protein (CBP) and the retinoblas-
toma tumor suppressor (pRB) have been found in the PODs
(35 , 61). Also, the PODs are targets of several viral proteins
which alter POD structure (11 , 14, 18). Although there i
evidence for POD' s role in transcriptional activation (15 , 35),
DNA replication (19), apoptosis (51 , 64), and viral infection
(14, 42), the precise function of PODs in these processes re-
mains unclear.
We have sought to understand the function of PODs
through identification of PML-interacting proteins that also
localize in the PODs. By using the yeast two-hybrid system , we
identified SUMO-l and the Fas-binding protein Dax (68)
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(J. D. Chen and R. M. Evans, unpublished data). Dax has
been shown to promote Fas-mediated apoptosis through acti-
vation of the Jun NH terminal kinase (JNK) and JNK kinase
kinase ASKI (apoptosis signal-regulating kinase 1) (12). Re-
cent data suggest that Dax is not suffcient for Fas-mediated
apoptosis, since a Fas mutant that selectively binds to Dax but
not the Fas-adaptor death domain-containing protein (FADD/
MORTl) failed to induce apoptosis (13). Other evidence sug-gests that Dax may interact with the centromeric protein-c
(CENP-C) and may bind to a steroidogenic factor 1 (SF-I)-like
DNA element (32, 50). Therefore, the exact mechanism by
which Dax regulates Fas-mediated apoptosis may involve nu-
clear processes.
In the present study, we have characterized both biochemi-
cal and functional interactions between Dax and PML. Dax
resides primarily in the cell nucleus, where it forms a complex
with PML. Confocal immunofluorescence data demonstrate
that Dax colocalizes with PML in the PODs, and such colo-
calization persists in NB4 APL cells (36) before and after
treatment with atRA and As
. Dax possesses strong tran-
scriptional repressor activity and appears to interact directly
with histone deacetylases. Intriguingly, overexpression of PML
inhibits Dax-mediated transcriptional repression and
, in cells
that lack PML, Dax is preferentially associated with con-
densed chromatin. Our data reveal a new role for Dax in
transcriptional repression and suggest a novel function of PML
and the POD structure in the suppression of transcriptional
repression.
MATERIS AND METHODS
Yeast two-hybrid system. The screening of PML-interacting proteins was con-
ducted by the yeast two-hybrid system by using the Y190 strain as previously
described (16). The Gal4 DBD (amino acids 1 to 147) fusion of full-length PML(29) was constructed in the yeast vector pAS1 (16). The resulting Gal4 DBD-
PML fusion protein was used as bait to screen a Gal4 activation domain (AD)-
fused human B-lymphocyte cDNA library in the pACT expression vector (16).
About 10 yeast transformants were screened on selection plates containing 50
mM 3-aminotriazole (Sigma). For ligand treatment
, the culture was incubated in
the presence of ligand or solvent (control) for 24 h before measuring the f3-ga-
lactosidase (f3-Gal) activity.
Biochemical cell fractionation. HeLa cells (2 x 106) were harvested into 500
fLl of CLB buffer (10 mM HEPES, 10 mM NaC!, 1 mM KH P04' 5 mMNaHC03 , 1 mM CaCl , 0.5 mM MgCl 5 mM EDTA-1 mM phenylmethylsul-
fonylfluoride-proteinase inhibitors. Cells were allowed to swell for 5 min on ice
Dounce homogenized 35 times, and centrifuged at 7 500 rpm for 5 min to pellet
nuclei and debris. The supernatant (cytosol plus plasma membrane) was then
spun at 25 000 rpm for 30 min to pellet the membrane. The nucleus-debris pellet
was resuspended in 1 ml of TSE buffer (10 mM Tris
, pH 7.5; 300 mM sucrose;
1 mM EDTA) and Dounce homogenized 30 times
, followed by centrifugation at
000 rpm for 5 min. The pellet was resuspended and washed twice to obtain the
final nucleus pellet. Equal amounts of protein in each fraction were analyzed
Western blotting.
Western blotting. Western blotting was conducted by using the enhanced
chemiluminescence reagents according the manufacturers
' recommendation(Amersham). The affnity purified anti-Dax polyclonal antibodies were raised
against glutathione S- transferase (GST)-Dax (amino acids 556 to 740) fusion
protein and subsequently purified with the GST-Dax protein column as de-
scribed earlier (24). Anti-GaI4-DBD antibody was purchased from Santa Cruz
and anti-HDAC1 antibody was from Upstate Biotechnology.
Co-IP. Coimmunoprecipitation (Co-IP) was conducted according to a stan-
dard procedure by using the protein A-agarose beads (Santa Cruz) (24). Nuclear
extracts were prepared as described earlier (3). HeLa and NB4 cells were lysed
in cell lysis buffer (0.4 M NaCI, 0.2 mM EGTA, 10% glycerol, 1% NP-40), and
cell extracts were precleared by incubating them with protein-A agarose beads
for 1 h at room temperature. The affnity-purified IP antibodies were conjugated
with protein A-agarose beads in cell lysis buffer for 2 h at room temperature. The
antibody-protein A-agarose was collected by brief centrifugation and incubated
with cell extracts (100 fLg) overnight at 4 C. The precipitates were collected by
centrifugation and washed five times with excess phosphate-buffered saline con-
taining 0. 1 % NP-40. The final precipitate was dissolved in sodium dodecyl sulfate
A (SDS) sample buffer and analyzed by SDS-polyacrylamide gel electrophoresis(PAGE) and Western blotting.
Immunofluorescence and confocal microscopy. Cells were grown on cover
glasses (VWR Scientific), fied in a methanol-acetic acid (1:1) mixture on dry ice
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for 2 min and processed for immunofluorescence staining as described elsewhere
(17). For NB4 cells, the cover glasses were coated with polY-L-lysine before
seeding the cells. Afer immunostaining, cell nuclei were stained with DAPI
(4' , diamidino- phenylindole dihydrochloride hydrate) (Sigma). Confocal mi-
croscopy was conducted with a Leica TCS SP spectral laser scanning confocal
microscope. Channel cross,talk was avoided by reducing the intensity of the
excitation laser beam in the absence of the other excitation laser. Standard
epifluorescence microscopy was performed on an Olympus IX-70 microscope
equipped with a back-iluminated cool charge-coupled device (CCD) camera
(Princeton Instruments), and the image was processed by using the MetaMorph
softare (Universal Imaging Corp.
Transient-transfection assay. Transient transfection was conducted using a
standard calcium phosphate precipitate method as described earlier (3). Cul-
tured cells were maintained in Dulbecco modified Eagle medium or RPMI
medium (for NB4 cells) supplemented with 10% fetal bovine serum (Gibco).
Twelve hours prior to transfection, 2 X 10 cells were plated in each well of
12-well plates. Transfected cells were refed with fresh media and harvested 36 to
48 h after transfection. Transfected cells in each well were lysed and processed
for luciferase and f3-Gal assay as described elsewhere (38). The luciferase activity
was determined with an MLX plate luminometer (Dynex) and normalized with
the cotransfected f3-Gal.
Far-Western blot. GST fusion proteins were expressed in DH5a cells and
purified by standard glutathione agarose beads according to manufacturer
recommendation (Pharmacia). The purifed proteins were separated by SDS,
PAGE and electroblotted onto a nitrocellulose filter in transfer buffer (25 mM
Tris-HCl, pH 8.3; 192 mM glycine; 0.01 % SDS). Proteins were denatured with 6
M guanidine hydrochloride (GnHCl) and renatured by stepwise dilution of
GnHCI. Filters were blocked and hybridized overnight with 35 labeled protein
as described elsewhere (38). The membrane was then washed three times with
hybridization buffer, and the bound probe was detected by autoradiography.
GST pull-down assay. The GST pull-down assay was conducted according to
a protocol as described earlier (24). Briefly, 5 fLg of glutathione agarose-proteinbeads was incubated with 5 fLI of in vitro-translated labeled protein with
moderate shaking at 4 C overnight in binding buffer (20 mM HEPES
, pH 7.7; 75
mM KCI; 0. 1 mM EDTA; 2.5 mM MgCl ; 0.05% NP-40; 1 mM dithiothreitol; 1
mg of bovine serum albumin per ml). The bound protein was washed three times
with the binding buffer, and the beads were collected by centrifugation. The
bound protein was eluted in SDS sample buffer and analyzed by SDS-PAGE and
autoradiography.
Site-directed mutagenesis. Site-directed mutagenesis was conducted by using
the Quick-Change site-directed mutagenesis kit according to manufacturer
instruction (Stratagene). A mammalian hemagglutinin (HA)-PML vector was
used as a template, and mutagenesis was conducted in three rounds consecutively
on the same template. The mutated construct was confirmed by DNA sequencing
by using dideoxyucleotide chain-termination reactions and Sequenase (U.
Biochemicals).
RESULTS
Identification of Daxx as a PML-interacting protein. In the
yeast two-hybrid screen, we identified a PML-interacting clone
that encodes the C-terminall84 amino acids of Dax (32, 50).
Yeast two-hybrid assay shows that this Dax clone interacts
with Gal4 DBD fusions of both PML and PML-RARa but not
SPI00 (Fig. lA), suggesting that Dax may be a PML-interact-
ing protein. Since atRA binds to PML-RAa in a way similar
to that of wild- type RAa (4), we determined the effect of
atRA on interaction between Dax and PML-RAa (Fig. lB).
atRA inhibits the two-hybrid interaction between Dax and
PML-RAa effciently and in a dose-dependent manner. The
inhibition of binding is slightly more sensitive with the long
form of PML-RARa than with the short form, a finding con-
sistent with the higher affnity of the long form of PML-RAafor atRA (4). This atRA-dependent inhibition of binding is
specific, for atRA has no effect on the interaction between
PML and Dax while it enhances the interaction between
PML-RAa and the coactivator RAC3 (38). Also , the thyroid
hormone triiodothyronine that does not bind PML-RAa alsohas no effect on the interaction between Dax and PML-
RARa. These data suggest that Dax is a PML-interacting
protein that may also associate with the oncoprotein PML-
RAa in the absence of atRA.
Daxx forms a complex with PML in vivo. In addition to
being diffusely distributed in the cytoplasm, PML is mainly a
nuclear protein, while Fas is a transmembrane cell surface
AD-Daxx:
DBD fusion: PML-
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FIG. 1. Interaction between Dax and PML in vivo. (A) Interaction of Dax with PML in yeast two-hybrid system. The average J3-Gal activities of three
transformants expressing the indicated combinations of Gal4 AD and DBD fusion proteins were detennined as described in Materials and Methods. The AD-Dax
fusion protein contains amino acids 556 to 740 of human Dax. The DBD fusion proteins contain full-length PML- , SP100, and PML-RAa short fonn , respectively.
The minus sign indicates empty vector alone. (B) atRA disrupts the interaction between Dax and PML-RAa. The effect of atRA on Dax-PML-RA interaction
was detennined after a 24-h incubation of the culture in the presence of the indicated concentrations of respective ligands. Columns: 1 , solvent only; 2, 1 nM; 3 , 10
nM; 4, 100 nM; and 5 , 1 000 nM. T3, 3 3' , triiodo- thyronine. (C) Subcellular fractionation of Dax. HeLa cells were fractionated into cytosolic, membrane, and
nuclear fractions , and an equal amount of protein was analyzed by Western blotting for Dax (left panel). The distribution of the cytoplasmic protein J3-tubulin and
the nuclear protein hPc2 in each fraction was also determined by immunoblotting to validate the fractionation. Two independent preparations of HeLa nuclear extracts
are shown. The right panel is a Coomassie blue-stained gel that shows the relative amount of proteins in each fraction used in the Western blot. (D) Co-IP of Dax
with PML. NB4-cell extracts were immunoprecipitated with affnity-purified anti-Dax and anti-PML antibodies, and the presence of Dax in the immunoprecipitates
was determined by immunoblotting with anti-Dax antibodies. The antibodies used for the IP and the Western blot (W. ) are indicated.
receptor. Since Dax interacts with both PML and Fas, it is
important to determine whether Dax is a nuclear or cyoplas-
mic protein. We analyzed the subcellular distribution of Dax
by using biochemical fractionation followed by Dax immuno-
blotting. In this assay, Dax cofractionates primarily with nu-
clear fraction, with a minority also present in the cytosolic and
membrane fractions (Fig. Ie). Control antibodies against the
cyoplasmic protein tubulin and the nuclear protein poly-
comb hPc2 (55) show no cross-contamination between the
cytoplasmic and nuclear fractions. All of these proteins were
detected in the membrane fraction , presumably because this
fraction also contains insoluble organelles involved in protein
synthesis and transportation. These results demonstrate that
Dax resides mainly in the cell nucleus, suggesting that Dax
may interact with PML in the nucleus.
To confrm that the interaction between Dax and PML also
occurs in mammalian cells, we performed Co- IP assays from
HeLa and NB4 cell extracts (Fig. ID). Both anti-Dax and
anti-PML antibodies, but not preimmune serum, effciently
coimmunoprecipitate endogenous Dax. These data suggest
that Dax may form a stable complex with PML in vivo. In the
immunoprecipitates of Dax and PML antibodies, we also de-
tected weak signals of the 90-kDa PML and two SUMO-
conjugated forms of PML (data not shown), confirming the
presence of PML in the IP. We also attempted to demonstrate
an interaction between Dax and PML in vitro in GST pull-
down and far-Western assays, but all experiments failed to
show a convincing interaction. We reasoned that this might be
due to the fact that PML is extensively modified by SUMO-I in
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Daxx SElO overlay
FIG. 2. Dax colocalizes with PML at the PODs. (A) Confocal immunofluorescence analysis of endogenous Dax and PML. HEp2 cells were fied and
immunostained with affnity-purifed rabbit anti-Dax polyclonal antibodies and mouse anti-PML 5E10 monoclonal antibodies as described in Materials and Methods.
The sample was analyzed by use of a confocal microscope. Panels a and b show the signals of Dax (green) and PML (red) on a single confocal section. Panel c shows
colocalization (yellow signals) of Dax and PML in the merged image. Panel d is a differential interference contrast image showing the surfaces of the cells and nuclei.
Bar, 10 fLm. (B) Three-dimensional presentation of the colocalization between Dax and PML. Total of 32 consecutive z-sections at increments of 0.08 fLm were
reconstructed into a three-dimensional image by using the Leica confocal softare. The right and left projected images were rotated 4.5 at opposite directions along
the (horizontal) axs. Yellow represents the colocalization between Dax (green) and PML (red). (C) Colocalization of Dax and PML in APL ceUs. NB4 cells were
plated on cover glasses coated with polY- lysine. The control (untreated), atRA-treated (1 fLM for 72 h), and As treated (1 fLM for 72 h) cells were fied and
immunostained with anti-Dax polyclonal and anti-PML monoclonal antibodies. Colocalization of Dax and PML was revealed by confocal laser microscopy (except
for the untreated cells).
vivo (44, 45 , 58) or that an additional factor may bridge the
interaction between PML and Dax.
Daxx colocalizes with PML in the PODs. We then wished to
determine if Dax colocalizes with PML in the PODs in order
to provide further evidence for a physiological interaction be-
tween Dax and PML. Confocal immunofluorescence micros-
copy using affnity-purified anti-Dax antibodies reveals dis-
crete nuclear structures in interphase HEp2 cells, in addition
to an evenly distributed nucleoplasmic staining (Fig. 2Aa).
Double immunostaining, together with use of anti-PML anti-
bodies, demonstrates that the Dax foci colocalize perfectly
with the PODs in cell nuclei (Fig. 2Aa to d). Such colocaliza-
tion occurs in many different cell tyes, including HeLa
HEK293, and A549 cells and normal human fibroblasts , sug-
gesting that colocalization between Dax and PML may be a
common phenomenon in different cell tyes. The colocaliza-
tion has been confrmed by using antibodies against diferent
POD antigens, including SPlOO and SUMO- , as well as under
conditions that modify the POD structure, such as with inter-
feron, As treatments, and viral infections (unpublished
data). A three-dimensional topographic analysis of the colo-
calization between Dax and PML demonstrates an extensive
colocalization between Dax and PML in the PODs (Fig. 2B).
Colocalization ofDaxx and PML in NB4 APL cells. We next
analyzed the distribution of Dax in the NB4 APL cells (Fig.
2C), in which the PODs are disrupted into "microparticulate
structures. Similar to PML, Dax is also disrupted in the NB4
cells, in which it remains colocalized with PML. The presence
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FIG. 3. Modulation of promoter activity by Dax. (A) Transcriptional repression by Gal-Dax. Recruitment of Dax to a promoter via GaI4-DBD results ininhibition of basal transcription in a dose-dependent manner. Transient transfection was conducted in HEK293 cells with increasing concentrations (nanograms) of
Gal-Dax as indicated. The relative fold repression of the basal promoter activity in the presence of Gal-Dax was compared to that of GaI4-DBD alone. The bottompanels show immunoblots with anti-GaI4-DBD antibodies of the transfected fusion protein at indicated concentrations of expression vector. (B) Dax represses basal
transcription as strong as PML-RAa. HEK293 cells were transfected with equal amounts (250 ng) of each expression vector, and the relative repression wasdetennined as described in Materials and Methods. The results show that Gal-Dax represses basal transcription as strongly as Gal-PMLRAa. (C) Requirement of bindingsites for transcriptional repression by Gal-Dax. HEK293 cells were transfected with 250 ng of Gal-Dax or Gal4-DBD alone, and the effects on the promoter activities ofGal-tk,luciferase (luc) and tk-Iuc reporters were detennined. The Gal-tk-luc reporter contains four copies of Gal4-binding sites in front of the minimal tk promoter
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of PML-RAa fusion protein in the microparticulate struc-
tures (17) supports the observed interaction between Dax and
PML-RAa (Fig. 1). Upon atRA treatment, PML-RAa 
degraded in NB4 cells (47), and these microparticulate struc-
tures reorganize into normal size of the PODs (17, 65), where
Dax and PML remain colocalized. The colocalization be-
tween Dax and PML is more evident in NB4 cells treated with
03' in which larger and fewer PODs are observed. These
results suggest that Dax and PML colocalize in APL NB4
cells, and such colocalization persists after reorganization of
the PODs induced by atRA or AS 03'
Daxx represses basal transcription. Several POD-associated
proteins, including PML, are implicated in transcriptional reg-
ulation (for reviews see references 34 and 39). Since Dax
interacts with PML and localizes at the PODs, we decided to
test whether Dax might regulate transcription. Transfection
of the GaI4-DBD full-length Dax fusion protein (Gal-Dax)
in HEK293 cells strongly inhibits basal transcription of the
GaI4-tk-Iuciferase reporter in a dose-dependent manner (Fig.
, top). Western blotting using anti-Gal4 DBD antibodies
confirms increased expression of Gal-Dax in transfected cells
in the presence of higher concentrations of DNA (Fig. 3A
bottom). Comparison of Dax-mediated transcriptional re-
pression with that of PML-RAa fusion proteins indicates
that Dax represses as strongly as the PML-RAa oncopro-
tein (Fig. 3B). Moreover, repression by Gal-Dax requires
Gal4-binding sites (Fig. 3C) and occurs .in multiple cell types
(Fig. 3D), demonstrating the specifcity of the observed Dax-
mediated transcriptional repression.
We attempted to determine the sequences in Dax that are
responsible for the repression activity by standard deletion
analysis (Fig. 3D). Progressive deletion from the C terminus to
residue 124 gradually reduces the repression activity of Dax in
a cell-tye-dependent manner. Deletions of the N terminus
and several other mutants also show a significant decrease in
repression. Equal expression of these Gal-Dax deletion pro-
teins in transfected cells is confirmed by Western blotting using
the anti-Gal4 DBD antibodies (Fig. 3E). These data suggest
that multiple regions of Dax may be important for transcrip-
tional repression in a cell-tye-dependent manner.
Dax was previously isolated in a yeast one-hybrid screen
using a reporter containing a SF- like element (32). We de-
cided to investigate whether Dax can repress transcription
from a promoter containing the SF- like element in a tran-
sient-transfection assay (Fig. 3F). As expected, overexpression
of wild-tye Dax represses basal transcription from the SFl-
tk-Iuciferase reporter that contains four copies of the SFl-like
element, while it has little effect on the tk-Iuciferase reporter
lacking the SF-l sites. These data indicate that Dax may
repress the basal transcription of natural promoters containing
SFl-like elements , a result consistent with the strong repressor
activity observed with the Gal-Dax fusion protein.
Daxx interacts with HDACs. Histone de acetylation has been
demonstrated to playa central role in transcriptional repres-
sion by inducing chromatin assembly and condensation (49
66). To determine whether histone deacetylation is required
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for Dax-mediated transcriptional repression, we analyzed the
interaction between Dax and the three available human his-
tone deacetylases (HDACs) (67). The three human HDACs
are highly conserved in structure and function. All of them
repress basal transcription in the GaI4-DBD fusion assay, and
all display histone deacetylase activity (67). Far-Western anal-
yses demonstrate interactions between Dax and all three
GST-HDAC fusion proteins, but not GST alone, while PML
and SPI00 show no interaction with any of these GST-HDACs
under the assay conditions (Fig. 4A and B and data not
shown). A positive control shows that PML interacts effciently
with GST-PML under identical conditions (Fig. 4C). Further-
more, a Dax mutant (amino acids 400 to 657) that possesses
weak repression activity also does not interact with HDACI
(Fig. 4C). These data support a role for HDAC interaction in
Dax-mediated transcriptional repression. The interaction be-
tween Dax and HDACI is further confirmed in a GST pull-
down assay (Fig. 4D), in which GST-HDACl , but not GST
alone, precipitates about 20% of input labeled Dax.
Moreover, an interaction between Dax and HDACI in vivo 
also observed by Co-IP of HeLa nuclear extracts (Fig. 4E), in
which HDACI coimmunoprecipitates with Dax antibodies
but not with the preimune serum. Together, these experi-
ments provide strong evidence that Dax and HDACs interact
in vitro and in vivo.
HDAC inhibitor reverses Daxx-mediated repression. The
physical interaction observed between Dax and HDAC sug-
gests that Dax may recruit a HDAC corepressor complex to
repress basal transcription via histone deacetylation and chro-
matin condensation. To provide more evidence for this possi-
bility, we assayed the effect of a histone deacetylase inhibitor
trichostatin A (TSA), on the repressor activity of Gal-Dax in
a transient-transfection assay (Fig. 4F). As expected , TSA re-
verses transcriptional repression by Gal-Dax in a dose-depen-
dent manner, while it has little effect on GaI4-DBD alone
under identical conditions. These data indicate that histone
deacetylation is involved in transcriptional repression by Dax.
Inhibition of Daxx-mediated transcriptional repression by
PML. Since Dax was identified as a PML-interacting protein
and subsequently demonstrated to possess strong transcrip-
tional repression activity, we decided to investigate the role of
PML in the regulation of transcriptional repression by Dax.
To do this, Gal-Dax was cotransfected with increasing
amounts of full-length PML into HEK293 cells and the activity
of the luciferase reporter was measured (Fig. SA). As observed
above, Gal-Dax represses reporter expression strongly when
compared to the GaI4-DBD alone (Fig. SA, compare lanes 1
and 6). Interestingly, coexpression of increasing amounts of
PML inhibits this repression in a dose-dependent manner
abolishing nearly all of the repressor function of Gal-Dax
(lanes 2 to 5). This effect is specific to Gal-Dax, for cotrans-
fection of PML with the GaI4-DBD alone has little effect on
reporter activity (lanes 7 and 8). These data suggest that PML
may inhibit Dax-mediated transcriptional repression.
Similar experiments were then performed to determine 
PML-RAa might also regulate the function of Gal-Dax.
while the tk-Iuc lacks the binding sites. (D) Mapping of the Dax sequences required for repression. Schematic presentation of Gal-Dax deletion mutants and their
effects on promoter activity in HEK293, HeLa, and CV - 1 cells are summarized. The two acidic regions are indicated by black bars, and the two potential nuclear
localization signals are marked with diamonds. The bottom graph shows a column presentation of the repression activity of various Gal-Dax deletion mutants in
HEK293 cells. (E) Expression of Gal-Dax mutants in transfected cells. The transfected lysates were analyzed by immunoblotting by using mouse anti-GaI4-DBD
monoclonal antibodies. The top band in each lane represents the expected molecular weights of the Gal-Dax mutants, except for Gal-Dax (125-215), where the lower
band is the expected product. The deviation in protein expression level was compensated by normalization of luciferase activity with the coexpressed f3-Gal activity. (F)
Inhibition of basal transcription from a natural promoter by Dax. Wild-type Dax was transfected into HEK293 cells together with either the SFl-tk-luciferase or
tk-luciferase reporter. The fold repression of the Juciferase activity at increasing concentrations (micrograms) of Daxx is presented.
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When either the short or long forms of PML-RAa were
cotransfected with Gal-Dax, the repression activity of Gal-
Dax was unchanged (Fig. 5B). Thus, despite the observation
that both PML and PML-RAa interact with Dax, only PML
can inhibit the abilty of Dax to repress transcription, suggest-
ing a differential role of PML and its oncogenic fusion protein
in regulation of Dax function.
25-
FIG. 4. Interaction of Dax with HDACs. (A) 3S 1abeled protein probes used in the far-Western assays. In vitro-translated ( S)methionine-label d Dax, PML
and SPIOO were analyzed by SDS-PAGE and detected by autoradiography. (B) Far-Western analysis of interaction between Dax and HDACs. The top panel shows
the Coomassie blue-stained proteins used in the far-Western assay. The middle panel shows the far-Western blot of GST-HDACs with the 
labeled Dax probe. The
bottom panel shows the far-Western blot with tlie labeled PML probe. (C) PML interacts with GST-PML in the far-Western assay. A positive control showing that
PML interacts with GST-PML in the far-Western assay was conducted under conditions identical to those for panel B. A far-Western blot showing that the 
Dax mutant
(400-657) fails to interact with GST-HDACI fusion protein. (D) GST pull-down assay showing interaction between GST-HDACI and Dax. The input labeled Dax
contains one-third of the lysate used in the pull-down reaction, which was conducted as described in the Materials and Methods. (E) Co-IP of HDACI and Dax. HeLa
nuclear extracts were incubated with affnity-purified anti-Dax antibody or an equal concentration of the preimmune serum. The immunoprecipitates were resolved
by SDS-PAGE and analyzed by Western blot by using anti-HDACI polyclonal antibodies. (F) TSA reverses transcriptional repression by Gal-Dax. HEK293 cells were
transfected with 250 ng of Gal4,DBD or Gal-Dax mammalian expression vector together with a Gal4-dependent luciferase reporter. The fold repression by Gal-
Dax
at different concentrations of TSA was determined relative to that for the GaI4-DBD alone.
PML recruits Daxx to the POD. To elucidate the mechanism
by which PML blocks Dax-mediated transcriptional repres-
sion, immunofluorescence microscopy was used to investigate
the subcellular localization of Gal-Dax upon coexpression of
PML. In these experiments, HEp2 cells were transiently trans-
fected with Gal-Dax in the absence or presence of HA-PML
and subsequently stained with the mouse anti-GaI4-DBD and
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FIG. 5. Inhibition of Dax-mediated transcriptional repression by PML. (A)
PML inhibits Dax-mediated transcriptional repression. HEK293 cells were tran-
siently transfected with 100 ng of the GaI4-DBD or Gal-Dax mammalian ex-
pression vectors in the absence or presence of the indicated amounts of PML
expression vector together with a Gal4-dependent luciferase reporter. Data are
presented as the percentage of maximum repression, where Gal-Dax activity is
represented as 100% repression. (B) PML-RAcr has no effect on Dax-medi-
ated transcriptional repression. HEK293 cells were transiently transfected with
100 ng of the GaI4-DBD or Gal-Dax mammalian expression vectors in the
absence or presence of expression vectors for PML, PML-RAcr (short form), or
PML-RAcr (long form), together with a Gal4-dependent luciferase reporter.
Data are presented as the percentage of maximum repression, where Gal-Dax
activity is represented as 100% repression.
rabbit anti-HA antibodies (Fig. 6A). When Gal-Daxwas over-
expressed alone in HEp2 cells, a fairly diffse, evenly distrib-
uted staining pattern is observed in the nucleus (Fig. 6A, pan-
els a and b). Cotransfection of PML drastically alters the
.-c
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distribution of Gal-Dax, for nearly all of the Gal-Dax protein
is recruited to the PODs, even at very high levels of Gal-Dax
expression (Fig. 6A, panels c to f). Examination of the local-
ization of these enlarged PODs indicates that they occupy the
loose chromatin regions (Fig. 6Ae and f), similar to the local-
ization of PODs in the absence of PML overexpression. On the
contrary, cotransfection of PML does not recruit a Dax mu-
tant (Gal-Dax 1-502) lacking the PML-interacting domain to
the PODs (Fig. 6A, panels g to j), suggesting the specificity of
the assay. The abilities of PML to reverse Dax-mediated re-
pression and to recruit Dax to the PODs support the hypoth-
esis that PML may inhibit Dax repressor function by seques-
tration of Dax to the PODs.
PML recruits endogenous Daxx to the PODs. To address
whether recruitment of Dax to the PODs also occurs at the
endogenous levels of Dax, HA-PML was transfected into
HEp2 cells alone , and the localization of endogenous Dax was
analyzed by immunofluorescence staining by using anti-Dax
antibodies (Fig. 6B). Double immunostaining with anti-PML
antibodies reveals that overexpression of PML leads to accu-
mulation of endogenous Dax to the PODs, resulting in re-
duced nucleoplasmic staining (Fig. 6B, panels a to c). Recruit-
ment of endogenous Dax to the PODs is confirmed with
anti-HA antibodies that detect only the transfected HA-PML
(Fig. panels d to f). These data indicate that PML is able
to recruit endogenous nucleoplasmic Dax to the PODs.
PML does not recruit HDACl to the PODs. So far we have
shown that Dax interacts with HDACs (Fig. 4) and that PML
recruits Dax to the PODs (Fig. 6). Accordingly, we wished to
determine the localization of HDAC and other corepressors
such as SMRT, after PML overexpression. We find that over-
expression of PML does not alter the distribution of HDACI
or SMRT (Fig. panels g to 1), suggesting that PML may
segregate Dax away from the corepressor complex. These
observations are consistent with a speculative mechanism by
which PML may inhbit transcriptional repression of Dax via
sequestrating Dax to the PODs.
SUMO- l modification ofPML is required for recruitment of
Daxx to the PODs. To determine if SUMO-l modification of
PML may playa role in Dax interaction, we generated a PML
mutant with all three SUMO-l modifcation lysine residues
replaced with arginines by site-directed mutagenesis, based on
a prior study that mapped the modification sites (31). Upon
mutation of the three lysine residues of PML, we no longer
observe SUMO-I-conjugated forms of PML, even after treat-
ment of the transfected cells with As and coexpression with
SUMO- l (Fig. 7A). This PML SUMO mutant behaves sim-
ilarly to the wild-tye protein in localizing to the PODs and in
enlarging the POD structure (Fig. panels a, d, and g).
Interestingly, while this SUMO- deficient mutant is capable
of localizing to PODs (panels band c and panels d and e),
overaccumulation of the mutant protein in the PODs fails 
recruit nucleoplasmic Dax (Fig. panels g to i). In contrast
many of the enlarged PODs show reduced staining of Dax
(Fig. panels g to i), suggesting that accumulation of the
unmodified form of PML in the PODs may lead to the disap-
pearance of Dax in PODs. These data suggest SUMO- l mod-
ification as being the underlying mechanism for the observed
interaction and colocalization between Dax and PML in vivo.
SUMO- l modification of PML is required for effcient inhi-
bition of Daxx-mediated repression. If our hypothesis that
recruitment of Dax to the POD is inhibitory to its transcrip-
tional repression activity, one would predict that the PML
SUMO mutant that fails to recruit Dax to the PODs will be
defective in reversing transcriptional repression by Dax. 
expected, we found that the PML SUMO mutant is less
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FIG. 6. Recruitment of Dax to POD domains by overexpression of PML.
(A) Overexpression of PML recruits transfected Gal-Dax into the PODs. Gal-Dax or Gal-Dax (1-502) were transiently transfected into HEp2 cells in the
absence or presence of HA-tagged PML and subsequently stained with the
mouse anti-GaI4-DBD and rabbit anti-HA antibodies. Primary antibodies were
detected with rhodamine-conjugated anti-mouse immunoglobulin G and fluo-
rescein isothiocyanate-conjugated anti-rabbit immunoglobulin G secondary an-
tibodies and analyzed by immunofluorescence microscopy. Panels a and b show
diffse nuclear staining of Gal-Dax in the absence of PML. Panels c to f show
Gal-Dax and HA-PML colocalization at the PODs. Panels g to j show that
HA-PML cannot recruit a Gal-Dax (1-502) mutant lacking the PML-interacting
domain to the PODs. (B) Recruitment of endogenous Dax but not HDACI and
SMRT to the PODs. HA-PML was transfected into HEp2 cells, and the local-
ization of endogenous Dax, HDACl , and SMRT was analyzed by immunoflu-
orescence microscopy. Panels a to c show colocalization of transfected and
endogenous PML with endogenous Daxx by using anti-PML monoclonal 5ElO
and anti-Dax rabbit polyclonal antibodies. Panels d to f show HA-PML andDax colocalization by using the anti-HA monoclonal and anti-Daxx polyclonal
antibodies. Panels g to I demonstrate that HA-PML does not recruit HDACI or
SMRT to the PODs by using anti- , anti-HDACl , or anti-SMRT antibodies.
Yellow signals in the overlayimages indicate colocalization.
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effective in reversing transcriptional repression by Dax in
transient transfection (Fig. 7C). Furthermore, we found that
the wild-type PML is incapable of reversing transcriptional
repression by Gal-HDAC1 and Gal-SMRTe (Fig. 7C). These
data correlate with immunofluorescence studies demonstrating
PML recruitment of Dax, but not HDAC or SMRT, to the
POD, where it presumably is unable to repress transcription.
Daxx is associated with condensed chromatin in the absence
of PML. To provide further evidence that the demonstrated
functional interactions between Dax and PML may be phys-
iologically relevant, we screened several cell lines to find a cell
type that may display abnormal localization of Dax and/or
PML. We identified the embryonic carcinoma NT2 cell line;
upon staining with the anti-PML antibody, it is evident that
only a subset of these cells express PML and thus contain
PODs (Fig. 7D). In these cells, PML and Dax colocalize in the
PODs (panels a to d). However, in cells lacking detectable
PODs, Dax forms aggregates around the condensed chroma-
tin (Fig. 7D , panels e to h). Therefore, the localization and thus
the function of Dax may depend on the level of PML in the
cell. At low PML levels, Dax is concentrated at condensed
chromatin, where it may repress transcription. When PML
levels are higher, it is able to recruit Dax away from con-
densed chromatin to the PODs, where Dax no longer re-
presses basal transcription.
DISCUSSION
In the present study, we have identified Dax as a PML-
interacting protein and characterized the functional interac-
tion between Dax and PML. We find a majority of Dax in the
nucleus of HeLa and HEp2 cells where it colocalizes with PML
in the PODs. In the NB4 APL cell line, Dax is distributed in
the microparticulate structures that contain the PML-RAa
oncoprotein (17). The repressor function of Dax is observed
upon tethering it to a reporter gene via a heterologous DNA
binding domain, as well as from a reporter containing a natural
SF1-like promoter element. The mechanism by which Dax
represses basal transcription is found as involving histone
deacetylation, for Dax interacts with HDACs in vitro and in
vivo and tbe histone deacetylase inhibitor, TSA, blocks the
repressor activity. Coexpression of PML reverses the transcrip-
tional repression by Dax, which, in turn, correlates with the
recruitment of Dax to the PODs. In addition, we show that
SUMO-1 modification of PML is required for both recruit-
ment of Dax to the PODs and effcient inhibition of Dax-
mediated repression. The physiological role of Dax in tran-
scriptional repression is further supported by the observation
that Dax associates with condensed chromatin in cells that
lack PML. Together, these data establish novel roles for Dax
as a transcriptional repressor, and for PML, as a protein that
can potentially regulate the repressor function of Dax.
Consistent with our findings, Dax has recently been iden-
tified as an inhibitor of transcriptional activation by Pax3
, a
member of the homeodomain family of transcription factors
(28). Thus, Dax not only is able to repress basal transcription
as suggested from our data, but can also inhibit transcriptional
activation via interactions with DNA-binding transcription fac-
tors. While the exact mechanism of the inhibition of Pax3
transactivation by Dax is unclear, our data elucidate the
mechanism of Dax-mediated repression of basal transcription
as involving histone deacetylation. We observe Dax localiza-
tion to condensed chromatin in NT2 cells that lack detectable
PML. Condensed chromatin is considered as a site of tran-
scriptional repression that also includes transcriptionally silent
centromeric heterochromatin. Other POD-associated pro-
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FIG. 7. SUMO-1 modifcation of PML is required for sequestration of Dax to the POD and inhibition of Dax-mediated transcriptional repression. (A) The PML
IlSUMO (l1SU) mutant lacks SUMO-1 modification. This mutant was created by replacing all three lysines at residues 160, and 490 with arginines. The wild-type
(WT) PML and the IlSUMO mutant were transfected into HEK293 cells alone or in combination with a SUMO-1 expression vector. Cells were treated with 1fLM
arsenic trioxide (As ) for 6 h where indicated. The total celllysates were analyzed by Western blotting by using anti-HA monoclonal antibodies. The upper bands
in the wild-type proteins represent SUMO-1 conjugated forms of PML. (B) The PML IlSUMO mutant localizes to the PODs but fails to recruit Dax. The HA-PML
l1SUMO mutant was transfected into HEp2 cells and analyzed by immunofluorescence microscopy to detect localization of the transfected mutant protein and the
distribution of endogenous Dax. Panels a to c show localization of the transfected HA-PML l1SUMO mutant protein (detected by a HA antibody) in the PODs that
were revealed by a PML polyclonal antibody (1-14). Panels d to f show that the enlarged PODs in the HA-PML l1SUMO mutant transfected cells do not result in
prominent recruitment of Dax to the PODs. Panels g to i show that many enlarged PODs containing PML-l1SUMO mutant have little or no Dax protein. The SE10
antibodies also detect PODs in untransfected cells that show smaller structures colocalized with Dax foci. (C) The PML l1SUMO mutant is deficient in reversing
transcriptional repression by Dax. The transfection was conducted in HEK293 cells, and the initial fold repression mediated by the GaI4-DBD fusion proteins is as
indicated at the bottom. The axs indicates the fold reversal of repression. The wild-type PML does not reverse transcriptional repression mediated by HDAC1 or
SMRTe. (D) Association of Dax with condensed chromatin in cells that lack PODs. The human neuronal NT stem cells were analyzed by double immunofluorescence
staining with anti-Dai polyclonal and anti-PML SElO monoclonal antibodies. The NTI cells display heterogeneous staining for PML. In cells that contain normal PML
nuclear bodies (panels a to d), Dax appears normal and shows complete colocalization with PML. In contrast, cells that contain only two or fewer PML nuclear dots
show aggregated Dax surrounding the condensed chromatin areas stained with DAPI (panels e to h).
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teins, such as SP100, have been demonstrated to interact with
heterochromatin protein 1 (HP1) and also colocalize with cen-
tromeric chromatin (10, 54). Consistent with this idea, Dax
has been shown to interact with CENP-C in a yeast two-hybrid
assay and partially to colocalize with interphase centromeres
(50). Also, Dax has been shown to interact with DNA meth-
yltransferase 1 , which plays a role in gene silencing (43).
Previous studies have implicated the PODs as sites of tran-
scriptional activation. For example, PML has been demon-
strated to interact with the transcription coactivator CBP and
recruit CBP to the PODs (15 , 35). Furthermore, PML can
enhance the transactivation functions of both CBP and mem-
bers of the nuclear receptor superfamily (15). PML also in-
duces enes of the major histocompatibility complex, while
PML - - mice display reduced transactivation responses to
atRA (64, 69). Finally, the transcriptional activator Sp140 (5
6) and nascent RNA (35) have been found in at least a subset
of PODs. Our fidings that Dax represses basal transcription
and PML inhibits such repressor activity suggest a new role for
the POD structure in gene regulation. The POD may enhance
transcription of target genes not only through recruitment of
activators but also through the inactivation of repressors such
as Dax via recruitment by PML. Because other transcriptional
repressors, such as PLZF, pRB, and Sp100, have also been
found in the PODs, it wil be interesting to determine if PML
can regulate the repressor activities of these proteins as well.
Our observations that PML-RAa can interact with Dax
but not inhibit transcriptional repression by Dax suggest a
potential role for Dax in acute promyelocytic leukemia. Sup-
port for this hypothesis is evident in our finding that Dax
PML-RAa, and PML colocalize at difsely distributed mi-
croparticulate structures in nucleus of the APL NB1 cells. The
PML-RAa fusion protein disrupts the POD structure in
these cells and, through its interaction with Dax, may direct
Dax to the microparticulate structures, where it is capable of
repressing gene expression. PML-RAa itself is a potent tran-
scriptional repressor, which acts via the recruitment of the
corepressors SMRT, N-CoR, and HDAC1 (40). The POD
structure is reorganized upon treatment of these cells with
atRA or arsenic trioxide, leading to the degradation of the
PML-RAa fusion protein and colocalization of Dax and
PML in the PODs (47). Therefore, Dax inactivation through
localization to the PODs may be critical to the differentiation
of normal hematopoietic cells. Since expression of the PML-
RAa fusion protein disrupts the integrity of the PODs, Dax
may act as a constitutive repressor in the APL cells , which
along with the repressor function of PML-RAa, may block
expression of specific genes that are critical for cell diferenti-
ation and culminate in the subsequent APL pathology.
Dax was initially identified as a Fas-binding protein that
promoted Fas-mediated apoptosis via activation of the JNK
kinase cascade pathway (12, 68). Interestingly, PML has also
been found to be involved in apoptosis triggered by Fas, tumor
necrosis factor alpha, and tye I and II interferons , possibly by
recruitment of the death effector Bax and cdk inhibitor p21
(37, 51 , 64). In contrast , expression of PML-RAa prevents
apoptosis in response to these signals (51). Our findings
, to-
gether with these reports, suggest that the regulation of Dax
repressor function by PML may also be important in pro-
grammed cell death. Consistent with this possibility, several
transcriptional repressors are known to playa role in apopto-
sis. For example, the adenovirus E1B and the cellular Bcl-
oncoprotein block p53-mediated apoptosis by inhibiting tran-
scriptional repression by p53, suggesting that p53 induces ap-
optosis via transcriptional repression (52, 56). In the case of
Dax, PML may recruit it to the PODs, where it is inactivated
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thus allowing the expression of certain genes required for ap-
optosis. Conversely, PML-RAa might inhibit apoptosis in
APL cells through disruption of the PODs, thereby promoting
enhanced or constitutive repression of these target genes by
Dax and the PML-RAa fusion protein itself, which leads to
the APL phenotye. Retinoic acid treatment would stimulate
degradation of PML-RARa and restoration of the POD struc-
ture (17, 47, 65). This would allow Dax to be inactivated
through sequestration to the PODs and allow apoptosis to
proceed and would eventually lead to remission of the APL
phenotye. Because PML can shuttle between the nucleus and
cytoplasm (59, 60), it is possible that Dax may be brought
along with PML to regulate cytoplasmic events relevant to
Fas-mediated apoptosis. However, a recent study reports that
the loss of Dax leads to extensive apoptosis in early mouse
development (43), a result seemingly opposite to other findings
concerning the function of Dax in apoptosis (12, 13, 68).
Therefore , the precise role of Dax in apoptosis remains to be
further elucidated.
Our data provide strong evidence for the roles of PML and
the PODs in regulating the function of Dax as a transcrip-
tional repressor. Dax and PML interact in vivo and colocalize
in the PODs. Overexpression of PML recruits Dax to the
PODs, which correlates with a complete inhibition of tran-
scriptional repression by Dax. Although the detailed mecha-
nism of this inhibition of Dax by PML remains to be deter-
mined, our data provide several possibilities. First, PML might
inactivate Dax by transporting it to the PODs and separating
it from HDAC and putative target genes. In response to cer-
tain stimuli such as interferon, PML levels increase in the
PODs , which, via competition for Dax binding or conforma-
tional change of Dax upon PML binding, might result in the
dissociation of Dax from HDAC and recruitment of Dax, but
not HDAC, to the PODs. Confinement of Dax in the PODs
would thus block access to target genes, whose expression level
would then increase to at least the basal level in the absence of
Dax repression. Our findings that PML overexpression results
in increased Dax levels in the PODs , while having no effect on
HDAC1 distribution or repression by HDAC1 , support this
possibility. Alternatively, the increased PML levels may disso-
ciate HDAC from Dax and recruit both Dax and its putative
target genes, but not HDAC, to the PODs. Because Dax
requires HDAC and histone deacetylation for its repressor
activity, the target genes may be expressed in the absence of
HDAC. The presence of transcriptional activators in the PODs
would facilitate transcription of target genes. With either pos-
sibility, it is evident that the POD is involved in maintaining the
balance of Dax function, depending on the PML level. At
normal, physiological levels of PML, Dax might repress tran-
scription at areas of condensed chromatin. However, with in-
creased PML expression, more Dax is recruited to the PODs
thus reducing its overall repression activity. Although the pre-
cise mechanism of the inhibition of Dax repression by the
PODs awaits further investigation, our data clearly reveal a
novel connection between Dax and PML in regulating tran-
scriptional repression that may playa critical role in acute
promyelocytic leukemia and apoptosis.
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SMRT (silencing mediator of retinoic acid and thy-
roid hormone receptor) and N-CoR (nuclear recep-
tor corepressor) are two related transcriptional
corepressors that contain separable domains ca-
pable of interacting with unliganded nuclear recep-
tors and repressing basal transcription. To deci-
pher the mechanisms of receptor interaction and
transcriptional repression by SMRTIN-CoR, we
have characterized protein-protein interacting sur-
faces between SMRT and nuclear receptors and
defined transcriptional repression domains of both
SMRT and N-CoR. Deletional analysis reveals two
individual nuclear receptor domains necessary for
stable association with SMRT and a C-terminal
helix essential for corepressor dissociation. Coor-
dinately, two SMRT domains are found to interact
independently with the receptors. Functional anal-
ysis reveals that SMRT contains two distinct re-
pression domains, and the corresponding regions
in N-CoR also repress basal transcription. Both
repression domains in SMRT and N-CoR interact
weakly with mSin3A, which in turn associates with
a histone deacetylase HDAC1 in a mammalian two-
hybrid assay. Far-Western analysis demonstrates
a direct protein-protein interaction between two
CoR repression domains with mSin3A. Finally
we demonstrate that overexpression of full-length
SMRT further represses basal transcription from
natural promoters. Together, these results support
a role of SMRT/N-CoR in corepression through the
utilzation of multiple mechanisms for receptor in-
teractions and transcriptional repression. (Molec-
ular Endocrinology 11: 2025-2037 1997)
' i I ,
INTRODUCTION
Transcriptional regulation by steroid/thyroid hormones
and retinoids is a critical component in controlling
many aspects of animal development , reproduction,
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and metabolism (1-4). The functiom; of these hor-
mones are mediated by intracellular n ceptors, which
comprise a large superfamily of "ligand-dependent
transcription factors (1). It has been established that
both retinoic acid receptors (RARs) and thyroid hor-
mone receptors (TRs) function via formation of het-
erodimeric complexes with retinoid X receptors (RXRs)
(5. 6). Once bound to a DNA response element, the
heterodimer responds to ligand through the C-terminal
ligand-binding domain (LSD), which is known to me-
diate not only hormone binding but also receptor
dimerization, transcriptional activation, and repression
(7, 8).
Both TR and RAR can function as transcriptional
repressors in the absence of ligands and potent acti-
vators upon binding of ligands (7). DNA-binding as-
says and functional analysis have demonstrated that
the repressor activities of unliganded receptors de-
pend on DNA response elements, as well as on the
intact LSD of the receptors (7 , 9, 10). In vivo, the
TR/RXR heterodimer binds to DNA in the context 
chromatin , and nucteosome assembly enhances the
transcriptional silencing effect (11). Importantly, the
oncogenic activity of v-erbA, a mutated form of TR , is
directly linked to transcriptional repression (12, 13). In
addition, deletion of the activation domain of RAR
converts it into a potent transc iptional repressor, and
this mutation was shown to.cause defects in cellular
differentiation and development (14-16). Therefore
transcriptional repression by unliganded nuclear re-
ceptors appears to play an important role in regulating
cell growth and differentiation.
Hormone binding is thought to induce conforma-
tional changes that lead to ligand-dependent transfor-
mation of the receptors from repressors to activators
(1). The C terminus of TR, about 20 amino acids,
constitutes the 12th amphipathic helix (helix 12) of the
LSD (17-19), which functions as a ligand-dependent
activation core domain known as the AF2-AD, '!, or
T4 domain (8 , 20-22). Comparison of the LSD struc-
tures of the unliganded (19) and liganded receptors
(17, 18) reveals a striking difference in the relative
position of the helix 12/AF2-AD domain. This posi-
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tional shift is thought to play an important role in
receptor activation , allowing the liganded receptors to
displace corepressors (8 , 23-25) and to interact with
coactivators (see reviews in Refs. 26-28).
SMRT (silencing mediator of retinoic acid and thy-
roid hormone receptor) and N-CoR (nuclear receptor
corepressor) are two related transcriptional corepres-
sors (24 , 25) that are distinct from other proteins (29).
They were shown to utilize the C-terminal domain for
interaction with unliganded receptors (30-33), and the
terminal domain for transcriptional repression (25,
30). In this study, we investigate mechanisms of pro-
tein-protein interactions between SMRT and nuclear
receptors and analyze the modes of repression medi-
ated by SMRT/N-CoR. To do this, we define the inter-
acting surfaces between SMRT and nuclear receptors
i'1 binding and functional assays. Next, we compare
transcriptional repression mediated by SMRT and N-
CoR using transient transfection assays in mammalian
cells. Evidence is presented that SMRT and N-CoR
interact with additional corepressors , and that histone
deacetylation plays a role in SMRT/N-CoR- mediated
repression.
! ,.,.. 
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RESULTS
"",
Two Receptor Domains Are Essential for
Interaction with SMRT
. .
io..
Deletion mutants in the carboxyl and amino termini of
TR and RAR. were used to analyze the contribution 
different regions in the receptors for protein-protein
interaction with SMRT. Figure 1A shows the domain
structure of TR and the relative position of individual
helices in the LBO as determined by x-ray crystallog-
raphy (17 , 18). The sequence at the C terminus region
around helices 11 and 12 is also shown for both TR
and RAR. ( S)Methionine- labeled TR or RAR deletion
mutants were hybridized to glutathione S-transferase
(GST)-SMRT and GST-RXR in far-Western analyses
in the absence of hormone (Fig. 1 B). The relative
strengths of these interactions are summarized in
Fig. 1C.
Full- length TR (1-456) associates well with both
SMRT and RXR , and the interaction with SMRT can be
drastically reduced upon hormone treatment. A resid-
ual weak interaction was observed in the presence of
ligand, consistent with previous observations (24 , 30).
Carboxyl-terminal truncation at residue 441 , which de-
letes helix 12 , results in a mutant that interacts nor-
mally with RXR but that exhibits enhanced interaction
with SMRT. Further truncation at residue 423, which
rembves part of helix 11 , reduces the interaction
with SMRT back toa level similar to that of wild type
TR. In contrast, this deletion markedly reduces in-
teraction with RXR. Further deletions that remove
- '
additional helices (helices 8, 9, and 10) result in
barely detectable interaction with SMRT and no in-
teraction with RXR. These results suggest that helix
, ,
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12 inhibits SMRT association while helix 11 might
promote the association.
Amino-terminal truncation of TR at residue 173
which removes the DNA-binding domain (DBD), does
not affect the interaction with either SMRT or RXR.
Fu, ther N-terminal deletion to residue 260 , which re-
moves the first and second helices of the TR LBO
markedly impairs SMRT association. No interaction
with RXR by this mutant was detectable. Similarly,
terminal deletion of helix 12 from RAR (1-403) also
increases interaction with SMRT as compared with
that of wild type RAR (1-462). Further deletion to res-
idue 395 , which removes part of helix 11 , diminishes
the enhanced interaction to a level comparable with
that of full-ength RAR , and ligand has little effect on
the interaction. Together, these results identify two
distinct :nteracting domains at the N-terminal hinge
and C-terminal helix 11 regions of the receptor LBO
that might act synergisticall)( to promote interaction
with SMRT. We find that the other two RAR isoforms,
(3 and 'Y, also interact with SMRT in a ligand-reversible
manner, although the interactions observed are
weaker compared with that with RARa (Fig. 1 D). The
interactions of both RAR(3 and RAR'Y with RXR were
not affected by ligand treatment.
Interaction of Helix 121AF2-AD Deletion Mutants
with SMRT in Yeast
To further understand the role of helix 12/AF2-AD in
interaction with SMRT, we analyzed interactions be-
tween AF2-AD deletion mutants of RAR and RXR with
terminal receptor- interacting domain of SMRT in a
yeast two-hybrid system (Fig. 2). The RAR LBO alone
is sufficient to interact with SMRT in a ligand-revers-
ible manner (Fig. 2A, column 3), but the resulting ac-
tivity is much weaker compared with that of full-ength
RAR (column 9). Similar to the far-Western results
SMRT and full-ength RAR retain some interaction,
even after treatment of the yeast cells with a saturating
amount of ligand. It is unclear whether this obervation
reflects an association between liganded receptors
and SMRT or the existence of a small percent of
unliganded receptors aftr ligand treatment. Deletion
of the AF2-AD domain results in a RAR mutant that
stimulates gene expression in response to hormone
treatment in yeast (columns 4 and 10), as opposed to
the dominant negative activity of this mutant observed
in mammalian cells (14). The ligand-dependent activa-
tion of RAR403 is more obvious in the context 
full- length receptor (column 10). A similar effect has
been shown in v-erbA, which normally acts as a con-
stitutive repressor in mammalian cells , but as a ligand-
dependent activator in yeast (34). Cotransformation of
the RAR403 mutants with a Gal4 activation domain-
SMRT fusion (Ga14 AD-SMRT) strongly induces (3-
galactosidase expression , even in the absence of hor-
mone (columns 5 and 11). Furthermore, in contrast to
the hormone-dependent dissociation seen with full-
length RAR , hormone treatment does not interrpt
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Fig. 1. Two Receptor Domains Interact with SMRT
. Domain structure of human TRf3 and the sequences of the C-terminal helix 11 and 12 (AF2-t-.D) region of TR and RAR. The
relative positions of individual helices determined by x-ray crystallography (18) are also indicated. B, Protein-protein interactions
between receptors and SMRT or RXR in far-Western analyses. The full- length TR and RAR and their deletion derivatives were
translated in vitro and labeled by ( S)methionine. All these deletion mutants expressed similar amounts of proteins as analyzed
by SDS-PAGE and autoradiography (not shown). The position of GST- SMRT (SMR1) and GST-RXR (RXR) fusion proteins are
as indicated (arrows). Please note that GST-RXR appeared as a doublet in our extract. C, Summary of relative levels of interactions
between receptor mutants a.nd SMRT or RXR. The relative levels of interactions were scored from background level (-) to strong
(+ + +). nd , Not done. D , Human RARf3 and RARy interact with SMRT in a ligand-reversible manner in far-Western blots. - , vehicle
only; RA, 1 ILM of all-trans-retinoic acid.
these interactions. Similarly, the Gal4 DBD-SMRT fu-
sion interacts strongly with the Gal4 AD-RAR403 mu-
tants in a ligand-insensitive manner (columns 6 and
- 12). These results are consistent with the enhanced
interaction observed in vitro and indicate that the
AF2-AD domain may act as a negative regulatory el-
ement, controllng hormone-sensitive interaction be-
tween SMRT and nuclear receptors.
The effect of AF2-AD deletion in RXR on association
with SMRT was also analyzed in the two-hybrid sys-
, '"'.... ., ,.. ", )'\ j. ;'\'\ , ." :
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Gal4 DBD fusion: I.RAR I.RAR 1.403 1.403 SMRT - f.RAR f.RAR f.403 f.403 SMRT SMRT
Gal4 AD fusion: - SMRT SMRT - SMRT 1.403 f.403 SMRT - SMRT 1.403 1.403
Gal4 DBD fusion: I.RXR I.RXR 1.443 1.443 SMRT SMRT I.VDR I.VDR
Gal4 AD fusion: - SMRT - SMRT 1.443 - SMRT SMRT
Fig. 2. Two-hybrid Interactions between SMRT and Helix 12/AF2-AD Deletion Mutants of Nuclear Receptors
, Interaction between RAR403 and C- terminal domain of SMRT in yeast two-hybrid system. The indicated Gal4 AD and Gal4
DBD fusion constructs were cotransformed into yeast Y190 cells, and the resulting l3-galactosidase activities were determined
from three independent colonies. The l3-galactosidase activities were determined in the absence (open bars) or presence (closed
bars) of 1 /-M of all- trans-RA. I, Ligand binding domain; f , full length; 403, RAR403 mutant with C-terminal truncation at residue
403. B , Interaction of SMRT with RXR443 and VDR in the absence of hormone (open bars) or presence (closed bars) of 1 /-M
9-cis-RA (for RXR) or 100 nM 1 25 dihydroxyvitamin D3 (for VDR). 443 , RXR443 mutant with C-terminal truncation at residue 443.
tem (Fig. 2B). Ligand treatment weakly activates the
Gal4 OBO-RXR LBO fusion (column 1), while cotrans-
formation with Gal4 AO-SMRT enhances reporter
gene expression (column 2), suggesting that SMRT
can interact with RXR in either absence or presence of
ligand. Truncation at residue 443 enhances the asso-
ciation between RXR and SMRT , and treatment with
ligand does not alter this interaction (columns 4 and 5).
These results suggest that SMRT can interact with
RXR and that the AF AO domain of RXR also acts
negatively in SMRT association. Furthermore, we ob-
served a significant interaction between vitamin 0
receptor (VOR) and SMRT in the absence of hormone,
and treatment with ligand reduces the interaction (col-
umn 8). This result is consistent with the recent finding
that VOR also contains intrinsic transcriptional repres-
sion activity (35), suggesting that SMRT might mediate
transcriptional repression by VOR.
Two SMRT Domains Mediate Differential
Interactions with Nuclear Receptors
The finding that two regions of TR are essential for
protein-protein interaction with SMRT suggests that
SMRT might also contain duplicated receptor-inter-
acting domains. Several deletion mutants of SMRT
were used to test this possibilty in a far-Western blot
and the results are summarized in Fig. 3A. The GST
fusions of these SMRT mutants were overexpressed
and the purified proteins (Fig. 3B, lanes 1 and 2) 
crude extracts (lanes 3, 4, and 5) were analyzed for
interaction with labeled RAR and TA. SMRT(981-
).'
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RAR TR(+T3)
1. GST-SMRT (982- 1495
+++ +++ +/-
2. GST-SMRT (982- 1291)
3. GST-SMRT (982- 1086)
4. GST-SMRT (1086- 1291)
5. GST-SMRT (1260- 1495l1)
Commassie stain hRARa
kDa
205-
106-
80.
49.
RID- RID-
hTR 35S-hTR + T3
Fig. 3. Two SMRT Domains Interact with the Receptors
A, Summary of SMRT deletion mutants used in this experiment and their relative levels of interaction with nuclear receptors
in far-Western analyses shown in panel B. The amino acids encoded by the SMRT mutants are shown in 
parentheses. Bound-RAR
and TR were detected by autoradiography, and the relative levels of interaction were scored from background level (-) to strong
(+ + +). The column numbers in each panel correspond to constructs shown in panel A. Partially purified GST fusion proteins were
used in lanes 1 and 2 and total cell extracts were used in lanes 3, 4 , and 5. RID, Receptor interacting uomain. + T3' Plus 
1 ILM
T 3; Q, glutamine-rich domain; H , putative helical region; j" an internal deletion between amino acids 1330 and 1375 resulting fromalternative splicing. 
1495.1) interacts equally well with both RAR and TR in
the absence of ligands. RAR, but not TR, also interacts
with degradation products of SMRT(981-1495.1). Sim-
ilarly, several fast migrating products of SMRT(1 086-
1291) also interact well with RAR, but not with TR (lane
4). These results indicate that RAR and TR may interact
differently with SMRT. Consistent with this speculation
we find that SMRT(982-1291) (lane 2) as well as
SMRT(1 086-1291) interact more strongly with RAR than
with TR. In contrast, the C-terminal fragment
(126o-1495 ) interacts better with TR than wth RAR
(lanes 5). All these interactions were found to be sensitive
to hormone treatment (Fig. 38 and data not shown).
Together, these results identify two independent recep-
tor interacting domains (RID-1 and RID-2) of SMRT that
appear to display different affinities to TR and RAR.
Two SMRT Repression Domains
In addition to the C-terminal receptor interacting do-
mains, SMRT/N-CoR proteins also contain strong
transcriptional repression activity at their N-terminal
regions. To define the minimal region needed for re-
pression by SMRT , serial SMRT deletion mutants were
generated, and their repression activities were ana-
lyzed using transient transfectiQn (Fig. 4A). Consistent
with previous observations, ' full-Iength as well as N-
SMRT (amino acids 1-981) repress basal transcription
strongly and in a dose-dependent fashion (rows 2 and
3), while C-SMRT (amino acids 982-1495Ll) exhibits
minimal repression (row 4) compared with Gal4 D8D
alone (row 1). Further deletion from the C terminus of
SMRT reveals that amino acids 743 to 981 are not
necessary for repression (row 5), while deletion to
idue 475 reduces the repression effect about 2-fold
(row 6). These results suggest that amino acids 475 to
981 may contribute in part to SMRT repression. Fur-
ther C-terminal deletion to residue 337 drastically in-
terferes with repression (row 7), indicating that the
terminal boundary of this SMRT repression do-
ma;n-1 (SRD-1) is located between amino acids 337 
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Fig. 4. Multiple Transcriptional Repression Domains
A, Deletion mapping of the repression domains of SMRT. The transcriptional repression activities were analyzed by transient
transfection in CV- 1 cells. The relative levels of repression were determined from an average of three independent transfections
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Functional Domains of the Corepressor SMRT
and 475. Truncation from the N terminus reveals that
amino acids 1-134 are dispensable for repression by
SRD- 1 (row 8), while further deletion to residue 337
abolishes repression (row 9), indicating that the C-
terminal boundary of the SRD-1 is within amino acids
134-337. When the SMRT fragment between amino
acids 475 and 981 was tested for repression , we found
that this fragment also strongly repressed basal tran-
scription (row 10). Together with the observation that
amino acids 743-981 are not important for repression
these results may define amino acids 475-743 as
a second, independent SMRT repression domain
(SRD-2).
Sequence comparison between SMRT and N-CoR
reveals that they share about 45% identity within both
SRD-1 and SRD- , 3uggesting potential functional
conservation. Therefore , we tested whether the two
SRD corresponding reflions of N-CoR also contain
repression activities. Consistent with a previous ob-
servation (25), amino a,:;ids 1-312 and 752-1016 of
CoR exhibit strong repression activities (Fig. 4B
rows 2 and 3), and the two N-CoR domains corre-
sponding to SRD-1 and SRD-2 also yield 10- to 30-
fold repression (rows 4 and 5), similar to the repression
effects observed by SRD-1 and SRD-2. These two
additional N-CoR repression domains are termed N-
CoR repression domain 3 and 4 (NRD-3 and NRD-4),
and the two N-terminal repression domains are called
NRD-1 and NRD-2. Together, these results indicate
that both SMRT and N-CoR contain multiple , indepen-
dent transcriptional repression domains.
To confirm that lack of repression in some of these
SMRT/N-CoR deletion mutants is not due to lack of
appropriate protein expression , we analyzed the expres-
sion of these constructs by both in vitro translation and
Western blot analysis after transient transfection. We find
that all constructs used in this experiment express ap-
proximately equal amounts of Gal4 DBD fusion proteins
in vitro (Fig. 4C) and that the repression-defective mu-
tants express well in vivo (Fig. 40). These results indicate
that lack of repression by certain SMRT/N-CoR deletion
mutants are not due to lack of protein expression.
Multiple Mechanisms of Transcriptional
Repression by SMRT/N-CoR
The mechanism of transcriptional activation by nuclear
receptors has been shown to require recruitment of
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coactivators including histone acetyltransferases
such as CBP/p300 (36-39). The opposite of histone
acetylation , histone deacetylation , has recently been
implicated in transcriptional repression by unliganded
receptors and the associated core pressors. Several
reports have described a corepressor complex con-
taining a Mad-dependent corepressor mSin3A, a his-
tone deacetylase HDAC1 or mRPD3 , and the nuclear
receptor corepressor SMRT/N-CoR (40-48). These re-
sults suggest that histone deacetylation may be a
mechanism of transcriptional repression by un ligan-
ded receptors.
To confirm the interaction between mSin3A and the
defined repression domains of SMRT and N-CoR , we
tested the interactions between mSin3A and the individ-
ual repression domains of SMRT/N-CoR in a mammalian
two-hybrid system. Coexpression of a VP16 AD-mSin3A
fusion with all Gal4 DBD-SMRT/N-CoR repression do-
main fusions results in weak reductiQf of the repression
activities (Fig. 5A). Coexpression of VP16 AD-mSin3A
with a Gal4 DBD-HDAC1 fusion also results in parial
release of repression mediated by Gal4 DBD-HDAC1
fusion. However, no activation above the background
level was observed even though a VP16 activation do-
main was present. Since the weak interaction between
SMRT/N-CoR repression domain with mSin3A in the
two-hybrid system may reflect a dominant effect of re-
pression over activation , we tested the interaction be-
tween mSin3A and individual SMRT/N-CoR repression
domains in vitro by far-Westem analysis. Full-length
mSin3A was translated and labeled in vitro and used as
a probe for GST fusions of various SRD and NRD do-
mains. We find that mSin3A interacts specifically and
consistently with NRD-1 and NRD-4 in this assay (Fig.
5B). In one experiment, we also detected interaction
between SRD-2 and mSin3A (data not shown). No inter-
action is observed between SRD- , NRD- , and NRD-
Therefore, these results suggest that different SMRT and
CoR repression domains may repress transcription in
a mSin3A-dependent or -independent manner.
SMRT Represses Basal Transcription from
Natural Promoters
The hypothesis that SMRT/N-CoR proteins are tran-
scriptional corepressors that faciltate repression by
unliganded receptors is supported by protein-protein
using 0. 1 /1g (open bars), 2 /1g (hatched bars), or 0. 5 /1g (closed bars) of plasmid Dt\IAs. The starting and ending amino acids
in each deletion construct are shown beneath each domain. SRDs , SMRT repression domains. B , Deletion mapping of the N-CoR
repression domains (NRDs). The N-CoR domains are aligned with those of SMRT in panel A. The relative levels of repression were
determined using 0.5 /1g plasmid DNA and comparing the result to the Gal4 DBD alone. Two new transcriptional repression
domains in N-CoR were found in addition to NRD-1 and NRD-2, which were identified previously (25). C, SDS-PAGE analysis of
in vitro translated products of SMRT IN-CoR deletion constructs used in panels A and B. Two microliters of the in vitro translated
products were analyzed in a 12.5% acrylamide gel, which was exposed overnight. Note that most of these constructs appear to
produce doublet bands, perhaps due to secondary structure of the DNA used in the translation reaction. D , Western blot analysis
of the repression-defective m.Jtants of SMRT after transient transfection into 293 cells by using anti-Gal4 DBD monoclonal
antibody (0.02 /1g/ml) and detected by ECl kit. The gel on the left was resolved in a 12.5% acrylamide gel while the gel on the
right was resolved in a 10% gel.
Fig. 5. Multiple Mechanisms of Transcriptional Repression by SMRT and N-CoR
. Two-hybrid interactions of mSin3A with SMRT an(j N-CoR repression domains and HDAC1. The indicated Gal4 DBD fusion
of SMRT and N-CoR repression domains and HDAC1 were transiently transfected into CV-1 cells together with either Gal4 AD
alone or Gal4 AD-mSin3A fusion as indicated. The relative levels of repression are expressed as the means of three independent
experiments relative to the Gal4 DBD alone. B In vitro protein-protein interactions between rfSin3A and SMRT/N-CoR repression
domains. The GST fusions of various SRD and NRD domains were expressed in Escherichia coli and partially purified. The GST
fusic.n proteins were analyzed by SDS- PAGE (right bottom pane and examined for their abilities to interact with labeled
mSin3A in a far-Western blot (left upper pane mSin3A appears to interact preferentially with intact GST -NRD- 1 and GST -NRD-
domains.
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interactions and transient transfections using the Gal4
fusion system. To provide further evidence that SMRT
may be physiologically relevant in transcriptional reg-
ulation , we tested the effect of SMRT overexpression
on transcriptional activity of receptor-responsive pro-
moters. Overexpression of full-ength SMRT (Fig. 6,
lane 2), but not that of C-SMRT lacking the repression
domains (lane 3), repressed basal expression from a
mouse RAR132 promoter approximately 2-fold in com-
fl0 t;t:
;:, : ,: "~~~
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parison to the empty vector (lane 1). The same result is
evident with two minimal response elements in the
context of a thymidine kinase promoter in the absence
of hormone (Fig. 5A). As expected, hormone treatment
enhanced transcription from these promoters , while
overexpression of full- length SMRT reduced slightly
this ligand-dependent activation. C-SMRT enhances
the ligand-dependent activation from these promoters
(Fig. 58). These results suggest that SMRT may, at
J' .
.).
No hormone
fJ 
c. 1.
o 1.
mRAR Luc
M atRA
Fig. 6. SMRT Represses Basal Transcription from RAR- and TR-Responsive Promoters .
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least u der certain circumstances, faciltate transcrip-
tional-repr.ession of natural promoters.
Transcriptional repression has been recognized as a
critical. component of TR and RAR function and is
, thought to be mediated by asociation of unliganded
receptors with silencing mediators (corepresors)
uch as SMRT and N-CoR. To understand the function
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possibly redundant receptor interaction and transcrip-
tional repression domains in SMRT and N-CoR. One
might expect that this multiplicity wil ensure a reliable
targeting of the corepressors and appropriate repres-
sion of target genes before activation.
The hinge region of TR was originally shown to
interact directly with the RID-2 region of N CoR (25).
Our results indicate that TR requires an additional
terminal region for efficient association with SMRT.
Nested deletion analyses suggest that helix 11 of the
TR LBD plays an important role in stabilzing SMRT
association , presumably by. cooperating with the N-
terminal helix 1-2 region. The interaction of SMRT with
either the N terminus or C terminus of the LBO alone is
very weak but detectable, suggesting that these two
potential interacting surfaces may act synergistically
to promote protein-protein interactions and to ensure
appropriate recruitment of the corepressors. Simifarly,
two independent regions in the receptor have been
shown to act synergistically for interaction with N-CoR
(32 , 49, 50). It has recently been shown that a receptor
dimer is required for interaction with SMRT/N-CoR
and that SMRT/N-CoR may contribute to receptor-
specific transcriptional repression (51). Furthermore,
an antagonist of the transcriptional activation by RXR
homodimer was shown to promote association with
the corepressor SMRT (52). Together, these studies
suggest that SMRT and N-CoR may utilze similar but
distinct mechanisms for interaction with nuclear
receptors.
We cannot exclude the possibility that the tight as-
sociation with SMRT by the AF2-AD deletion mutants
may weaken hormone binding to the receptor, but the
ability of RAR403 to respond to ligand treatment in
yeast cells indicates that this mutation does not-::;,
-;-
inate the receptor s hormone-binding capabilty, con-
sistent with previous observations (14, 53). Therefr:re
the inability of hormone. to dissociate corepressors is
likely due to the lack of certain conformational
changes that would normally take place in the pres-
ence of the AF2-AD. It is possible that the assumed
shift of AF2-AD upon hormone binding is a prerequi-
site for additional structural changes that are impor-
tant for corepressor dissociation. Alternatively, the
shift of helix 12 may mask or compete with certain
interacting surfaces required for binding corepressors.
The fact that the AF2-AD deletion creates a mutant
that binds tighter to the corepressors fav rs this
moq J, We suspect that helix 11 could constitute such
an interacting surface, since disruption, of this helix
eliminates the enhanced interaction resulting from de-
letion of AF2-AO. Our results suggest that AF2-
may act to balance the association between nuclear
r,eceptors and the corepressol', by preventing over-
association of unliganded receptors with corepres-
sors, thereby faciltating ligand':dependent dissocia-
tion of corepressors. 
Nested deletion anfilysis reveals two distinct sub-
domains in SMR"" t at are capable of independent
interaction with nuc ar recptors. Th'* tworecp",
;\- .'.
tor- interacting domains, RID-1 and RID ih(
differently with TR and RAR. The N-terminal
region interacts more strongly with RAR, and
tains a glutamine-rich domain , whife the C tij
RID-2 region interacts better with TR a:ndc()fI
putative helical domain analogous to thatk(. .
previously in N-CoR (25). The different recPtd':
acting properties of these t
yvod9r.!'if1
' 
SMRT may utilze distinct mechal"lsl) J9(j.
with different receptors. The RID':? r
has been shown to interact dir(iIY
:'L
region of TR (25), and therefor jt is:reS$o'
edictthat the tel1i aIRID-1r, l.f'"with theC-termlnal region ofthewq;:l,
Functional analysis of t trahsCripti6",
activities o SMRT andN CoR rrX
~~~
R,Jdent domains that are capableoft pre$Sl
- .
transcription. Together, there appea(to' be; flJr;1
pendent repression . dO!Tains
' J\ 90n,SMRT. These repression domains C6uI9 C!i?.
dently, and some repress basal frii (iptlori
ciently as the full-length protein, sug' &lmdomains might act redul)dantly andW'sibly;,
;;"' .'?-
different mechanisms. Sequence companspn
repression domains gives little clue- to;pb"
mechanisms . of ression. However, h,in
$;
and the corresponding NRD- , four potert1a(re
motifs sharing a consensus sequence of (3$lJgq
have been identified (32). In addition, ,two ot e('
tial repeats with a consensus seql!en
KGHVI8YEG are noted. These motifs areW
served between SMRT and N-CoR, suggesting\
they might contribute to repression. 
- ' .  '
Recently, sever,al papers reported that mSin3A8r
the histone deacetylase HDAC1 form a temarycorr1'
plex with SMRT and N-CoR (42 , 46). These resl,!
indicate that "SMRT and N-CoR , wh ile interactil1g with
unliganded receptors , can also interact with additional
corepressors such as mSin3A and mSin,3B (54), as,
well as the histone deacetylases HDAO1(55)8;rl9:
mRPD3 (56). The recruitment of histone deacetylase:to j1;;
ti'rget promoters by unliganded recej:to . through
SMRT, N-CoR, and mSin-,suggests that deacetylation;J'
of histones or other foctors may playa role in tran-
scriptional repression , perhaps by establishing n un- :i,,
;:,
favorable chromatin structure for transcriptional acti-
vation (41). Our results suggest weak two-hybrid
interactions between SMRT/N-CoR and mSin3A, or '
' '
between mSin3A and HDA91 , even though a Vf'1
'fWi
activation domain was prasent. Altematively,' these)
~~~: , . , :.,
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MATERIALS AND METHODS
Plasm ids
The GST fusions of C-SMRT (GST-SMRT) and RXR (GST-
RXR) were described previously (24, 30). Serial C-tenninal
and N-tenninal deletion mutants of human TR(: and human
RARa were generated by appropriate restriction enzyme di-
gestion and/or PCR amplification from the parental expres-
sion construct pCMX-hTR(: and pCMX-hRARa (57). The
GST-SMRT deletion constructs were generated by enzyme
digestion at indicated residues from the parental construct
GST-SMRT. The Gal4 DBD fusions of individual repression
domains of SMRT and N-CoR were generated by PCR am-
plification and were subsequently transferred to pGEX vector
for expression of GST fusion proteins. The VP16 AD-mSin3A
construct was created by subcloning the Seal (at residue 56)
to 8g11 fragment of mSin3A (58) into the pCMX-VP16 vector.
Detailed infonnation regarding these plasmids is available
upon request.
Far-Western Analysis
GST fusion proteins were separated by denaturing protein
gels (SDS-PAGE) and electroblotted onto nitrocellulose filters
in transfer buffer (25 mM Tris-HCI , pH 8.3; 192 mM glycine;
01 % SDS). After denaturation in 6 M guanidine hydrochlo-
ride (GnHCI), the proteins were renatured by stepwise dilution
of GnHCI to 0.187 M in HB buffer (25 mM HEPES, pH 7.7; 25
mM NaCI; 5 mM MgCI2; 1 mM dithiothreitol). The filter were
then saturated in blocking buffer (5% nonfat milk, then 1 
milk in HB buffer plus 0.05% NP40) at 4 C overnight or at 37
C for 1 h. In vitro translated labeled proteins were diluted
into hybridization buffer (20 mM HEPES, pH 7.7; 75 mM KCI;
1 mM EDTA; 2.5 mM MgCI ; 0.05% NP40; 1% milk; 1 
dithiothreitol), and the fiters were allowed to hybridize over-
night at 4 C. After three washes (5 min each) with the hybrid-
\zation buffer, the bound proteins were detected by
autoradiography.
Yeast Two-Hybrid Assay
The yeast two-hybrid assay was carred out in the Y190 yeast
strain (59). The Gal4 DBD fusion constructs were generated in
either the pAS or pGBT vector (CLONTECH , Palo Alto, CA),
and the Gal4 AD fusion constructs were in the pGAD or pACT
vector (CLONTECH). The (:-galactosidase activities were de-
termined with the O-nitrophenyl (:-o-galactopyranoside (Sig-
, St. Louis, MO) liquid assay as previously described (30).
Cell Culture and Transient Transfection
African green monkey kidney CV-1 cells were grown in
OM EM supplemented with 10% resin-charcoal stripped FBS,
50 U/ml penicilin G, and 50 ILglml streptomycin sulfate at 37
C in 5% CO , One day before transfection , cells were plated
in a 24-';ell culture dish at a density of 50, 000 cells per well.
Transfection was perfonned by standard calcium phosphate
precipitation - (57). All transfection experiments were per-
fonneq in triplicate and were replicated at least once. Twelve
hours fter transfection , cells were washed with PBS and,
refed fresh medium containing indicated amounts of ligands.
After 30 h, cells were harested for (:-galactosidase and
luciferase assay as described previously (30). The relative
luciferas activities are arbitrary light units nonnalized to the
l3-galactosidase activities.
. In Vitro Translation and Western Blot
In vitro transcription/trnslation reactions were carred out in
rBfbit reticulocyte Iysates using the TN T7 Quickpoupled
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